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Chapter 1
Introduction
Adapted from: The mononuclear phagocyte system and its cytokine inflammatory 
networks in schizophrenia and bipolar disorder.
Drexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen L, 
Beumer W, Versnel MA, Drexhage HA.
Expert Rev Neurother. 2010 Jan;10(1):59-76
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General Introduction
This thesis deals with immune aspects of bipolar disorder, schizophrenia, autoimmune 
thyroid disease and type 1 diabetes mellitus and therefore we give a short introduction to 
each disease. 
Bipolar disorder
Definition. Bipolar disorder is one of the major psychiatric disorders. The term “bipolar 
disorder” replaced the older term “manic-depressive illness” that was introduced by Emil 
Kraepelin (1856-1926) in the late 19th century [1].Standardized classification systems as 
DSM-IV [2] and ICD-10 [3] are used to describe the psychiatric disorders. According to 
the DSM-IV classification bipolar disorder is a chronic disorder with manic and depressive 
episodes and usually a full recovery between episodes. A manic episode is characterized 
by an elevated, expansive or irritable mood, whereas a depressed episode is characterized 
by a depressed mood together with the possible following symptoms: sleep disturbances, 
psychomotor retardation or agitation, fatigue, feelings of worthlessness or guilt, impaired 
thinking or concentration, change of appetite or weight and suicidal thoughts. Patients 
have to suffer from at least one manic episode to be diagnosed with bipolar disorder, 
but most if not all patients also have depressive episodes. In this aspect bipolar disorder 
differs from unipolar depression since in that disorder patients do not experience manic 
episodes but only depressive episodes.
Subtypes. Within bipolar disorder the DSM-IV distinguishes various forms based on the 
type and severity of mood episodes experienced. Bipolar disorder I is the classic and most 
severe form, characterized by one or more manic episodes or mixed episodes (in which 
standards are met for both depression and mania). Bipolar disorder II is characterized by 
one or more major depressive episodes accompanied by at least one hypomanic episode, 
i.e an episode with manic symptoms but without associated functional impairment. The 
key difference between bipolar disorder I and bipolar disorder II is thus that subtype II 
comprises hypomanic but not manic episodes. The third form of bipolar disorder is 
Cyclothymic Disorder. This disorder involves more or less chronic alternating hypomanic 
and minor depressive episodes. The mood cycles between highs and lows, but never 
reaches the full criteria of mania or major depression. Finally, the term bipolar disorder 
Not Otherwise Specified (NOS) is used for patients who clearly have certain symptoms 
of bipolar disorder but do not meet the criteria for one of the subtypes described above. 
Epidemiology. Bipolar disorder is a major global health problem. The life time prevalence 
of bipolar disorder (classified according to DSM-III) is estimated at 1.0 -2.0% in the general 
population across ten European countries [4]. In the United States the life time prevalence 
for bipolar disorder I is 1.0% and for bipolar disorder II 1.1% [5].The Netherlands Mental 
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Health Survey and Incidence Study, a prospective epidemiological survey in the Dutch 
general population, calculated a lifetime prevalence for the total bipolar spectrum of 
5.2% (CI 2.2-8.1), including 2% (CI:0.1-4.1) for bipolar disorder I [6]. Together with unipolar 
depression bipolar disorder belongs to the ten leading causes of disability worldwide [7]. 
It is associated with high suicide rates [8]. Approximately 25 percent of patients attempt 
suicide at some time during their lives, and around 5 percent of patients die by suicide [8] 
making bipolar disorder the third leading cause of death among adolescents [9]. 
Treatment. To achieve stabilisation of their mood episodes, bipolar patients are treated 
with mood stabilizers. Lithium is the oldest among these mood stabilizers and still 
considered (one of the first choices) because of its proven effectiveness [10] [11]. Other 
known mood stabilizers are the anti-epileptics valproate, carbamazepine and lamotrigine. 
Often other medications are needed as well, especially to treat episodes of mania (with e.g. 
atypical antipsychotics) or depression (with antidepressants, lamotrigine or the atypical 
antipsychotic quetiapine).
Schizophrenia
Definition. Schizophrenia is one of the other major psychiatric disorders. It was first 
described as Dementia Preacox by Emil Kraepelin. Emil Kraepelin made a differentiation 
between Dementia Praecox and Manic Depressive Illness based on the duration of the 
disease (usually longer in Dementia Praecox) and the course of the disease (intermittent 
in Manic Depressive Illness) [1, 12]. A few years after the original description of Dementia 
Praecox by Emil Kraepelin, Eugen Bleuler suggested rephrasing the disorder into 
schizophrenia (“fragmented mind”) [13].
According to the DSM-IV schizophrenia is a mixture of positive and negative psychiatric 
signs and symptoms [2] Positive symptoms reflect an excess or distortion of normal 
perceptive function such as delusions and hallucinations. Negative symptoms reflect a 
diminution or loss of normal function such as affective flattening and lack of initiative. 
Subtypes. The DSM-IV describes in total five subtypes of schizophrenia: paranoid type, 
disorganized type, catatonic type, undifferentiated type and residual type. The paranoid 
type has as essential feature the presence of prominent delusions or auditory hallucinations. 
The disorganized type has as essential feature disorganized speech or behaviour. For 
the catatonic type the essential feature is a marked psychomotor disturbance. In the 
undifferentiated type the clinical picture of the patient does not fit into one of the other 
subtypes. In the residual type there is no evidence for the features of the first three 
subtypes but negative symptoms are present. 
Epidemiology. Schizophrenia is present worldwide and the prevalence is in the range of 
0.5%-1.5%. There are geographic differences in prevalence, it is e.g. seen that the incidence 
is higher in urban areas [14]. Also migrant groups have a  higher incidence: 1st and especially 
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2nd generation immigrants from Morocco and Surinam in the Netherlands have a 5.8 times 
and 2.8 higher chance respectively for the development of schizophrenia [15].
Treatment. Patients with schizophrenia are usually treated with antipsychotic medication 
for the positive symptoms such as psychosis and delusions [14]. There is so far no 
medication for the negative symptoms such as alterations in drive and lack of initiative. In 
general the effect of medication is not totally satisfactory and there are numerous serious 
side effects, such as agranulocytosis (a well-known complication of clozapine) [16]. 
Autoimmune thyroid disease
An archetype of organ specific endocrine autoimmune disease is autoimmune 
thyroid disease (AITD). AITD encompasses a diverse range of clinical entities including 
Hashimoto’s thyroiditis, Graves’s hyperthyroidism and goiter, atrophic autoimmune 
thyroiditis, postpartum thyroiditis, sporadic painless thyroiditis and thyroid associated 
opthalmopathy.  The main clinical entities are Hashimoto’s thyroiditis (HT) and Graves 
hyperthyroidism and goiter. These two forms differ in clinical phenotype (hypothyroidism 
versus hyperthyroidism), but resemble each other in the histological features of thyroid 
lymphocytic infiltration, be it that in HT this infiltration is generally more severe than in Graves 
hyperthyroidism and goiter. Furthermore, the natural course of Graves hyperthyroidism 
and goiter is without surgical or iodine ablation not uncommonly hypothyroidism [17]. 
Also, both HT and Graves hyperthyroidism and goiter run in the same families, implying a 
shared genetic background of both diseases [18]. 
Hashimoto’s thyroiditis is the catabolic form of AITD and characterised by a gradual 
destruction of the thyroid gland by a T cell-mediated autoimmune process leading to 
low levels of thyroid hormone (hypothyroidism). HT is serologically characterized by 
the presence of autoantibodies against thyroid peroxidase (TPO) [19]. The other main 
autoantigen is thyroglobulin (Tg). 
Graves’ disease is the anabolic form of AITD. Here, antibodies directed against the TSH 
receptor of the thyroid stimulate the thyroid to grow and to produce more thyroid 
hormone leading to hyperthyroidism [19]. 
AITD is a multifactorial disease and thus the result of an inherited susceptibility and 
encountered environmental factors (GD: concordance rate MZ twins= 22%, DZ twins = 0% 
(range or CI not available) [20], HT: concordance rate MZ twins= 55% (95% CI=23%-83%), 
DZ twins= 0% (95%CI= 0%-25%)[20]). The low concordance rate shows that environmental 
factors play a role.
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Type 1 diabetes
Type 1 diabetes is another typical organ specific endocrine autoimmune disease in which 
the insulin producing β cells of the islets of Langerhans in the pancreas are destroyed 
by an autoimmune process. Because of this β cell destruction, the production of insulin 
diminishes and finally comes to an end. This will lead to hyperglycaemia. Insulin shortage 
can cause keto-acidoses which is, when untreated, a fatal outcome of T1D. Chronic 
hyperglycemia has its own set of problems such as cardiovascular disease, chronic renal 
failure, and retinal and nerve damage. Several autoantigens have been reported to play 
a role in T1D, including insulin, GAD65 (65 kDA glutamic acid decarboxylase), the protein 
tyrosine phosphatase-like antigen IA2 and ICA 69 (69 kDa islet cell antigen) [21]. Of these 
autoantigens insulin is probably the most important one [21]. Firstly because GAD65 and 
ICA69 were shown to be dispensable for diabetes development in GAD65 and ICA69 
knock-out mouse models [22, 23]. Secondly, because insulin deficiencies were found to 
abrogate the development of T1D [24, 25]. Thirdly, insulin reactive CD4 T cells and CD8 T 
cells isolated from the pancreas could adoptively transfer disease to syngeneic recipients 
[26] . Fourthly, in humans a relatively high frequency of insulin A-chain-reactive CD4+ T 
cells was observed in the pancreas associated lymph nodes [27]. And last but not least, 
a polymorphic variable number tandem repeats (VNTR) located upstream of the insulin 
gene leads to susceptibility or resistance to T1D in patients by influencing the level of 
expression of pro-insulin in the thymus [28]. 
Antibodies against the above mentioned autoantigens are frequently present in T1D, not 
only in patients but also in their 1st  degree relatives [29].  However, these autoantibodies 
do not have an active role in the pathogenesis of diabetes but are thought to be a parallel 
product as a result of β cell destruction caused mainly by CD8+ T cells and macrophages 
[30]. They are nevertheless helpful in the prediction of progression of the disease. 
The pathogenesis of T1D is again multifactorial. The involvement of genes is shown by the 
higher concordance rate of T1D in MZ twins (53%, 95%CI= 33%-73%) as compared to DZ 
twins (13%, 95%CI=  5%-21%) [31], the involvement of environmental factors is suggested 
by the fact that the MZ concordance rate never reaches a 100%.   
AITD and T1D are frequently associated 
AITD and T1D co-occur more frequently within patients and families than normal. The co-
occurrence of these two organ specific autoimmune diseases is described as subtype 3A 
of a syndrome called Autoimmune Polyendocrine Syndrome (APS)[32]. This syndrome was 
initially defined as a multiple endocrine gland insufficiency associated to an autoimmune 
disease in a patient. These associations were noted not to be at random but in particular 
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combinations. Therefore, the syndrome was classified after careful clinical observations by 
Neufeld and Blizzard into four main subtypes [33]. With regard to the pathogenesis of both 
AITD and T1D several similarities can be seen. In both diseases there is a destruction of 
target tissue by CD8 T cells and macrophages, the presence of autoantibodies to antigens 
in the target gland and common genes such as MHC II, CTLA4 and PTPN22 have been 
suggested as actors in both diseases.
A higher prevalence of mood disorders in AITD and T1D patients 
Subjects positive for TPO-antibodies were shown to have a higher risk to develop mood 
disorders independent from the thyroid function and this was not the consequence 
of eachother [34, 35]. Hypothyroidism (often a consequence of AITD) is commonly 
accompanied by depressive symptoms and this is in part certainly due to a lack of thyroid 
hormone needed for brain cells to function optimally.
In a systemic literature review of T1D patients  a prevalence of depression of 12% was 
found in controlled studies and in the healthy controls 3.2%, whereas in the uncontrolled 
studies the weighted mean overall prevalence rate was 13.4% [36] and considered higher 
than in the general population. In a recent Dutch study there was a prevalence of 8% 
of patients suffering from a depressive disorder based on a CIDI interview. Furthermore, 
depressive effect was associated with poor glycaemic control and proliferative retinopathy 
in this study sample [37]. The same was shown in a study from the USA [38]. Moreover, a 
meta-analysis showed that depression is associated with diabetes complications [39].
With regard to studies  using patients with T1D and T2D, a meta-analysis done by Gavard 
et al. reported a prevalence of depression of 14 % (range 9%-27%) [40]. Another meta-
analysis reported an odds risk twice as high to develop depression in diabetes then in 
healthy controls [41]. In these meta-analyses controlled studies were used.
A higher prevalence of AITD in patients with a major mood disorder
Major depressive disorder is associated with changes in the hypothalamus-pituitary-
thyroid-axis and there have been various reports on aberrancies of the thyroid in patients 
with a major depressive disorder [42].
In bipolar disorder we have shown in recent years that patients were found to be more 
prone to develop thyroid autoimmunity and this was not related to the use of lithium 
[43]. Moreover, bipolar patients had also a higher prevalence to the other organ-specific 
autoantibodies  H/K adenosine triphosphatase and glutamic acid decarboxylase-65 [44]. 
For a further discussion on the relationship major mood disorder-endocrine autoimmunity 
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it is important that we previously described that also children of bipolar patients have a 
higher risk for endocrine autoimmunity [45]. In this research, 11 of the 126 bipolar offspring 
studied were found positive for TPO-antibodies (versus 4/129 healthy controls) and 3 had 
developed T1D (i.e. 2% versus 0.4% general population). In addition, a twin study was 
performed which demonstrated that healthy co-twins of bipolar index twins show a similar 
high incidence of TPO-antibody positivity [46]. In both TPO-antibody positive offspring and 
co-twins thyroid autoimmunity was raised irrespective of mood symptoms. Thus family 
members of bipolar patients are more vulnerable to develop thyroid autoimmunity (and 
possibly also T1D), but these endocrine autoimmune diseases do develop independently 
from the vulnerability to develop mood disorders. These findings refute the concept 
that mood disorders and endocrine autoimmunity are cause or consequence of each 
other. This is further strengthened by the observation that treatment of hypothyroid 
patients with thyroid hormones does not always lead to an improvement of their mood 
disturbances. Taken together this might imply a shared common immune pathogenesis 
of mood disorders, thyroid autoimmunity and possibly also T1D. For the latter it is difficult 
to find a relation between depression and the development of type 1 diabetes, because 
type 1 diabetes usually develops in younger age than depression. 
A higher prevalence of autoimmune disease in patients with schizophrenia 
In schizophrenia there are also reports of a higher prevalence of autoimmune disease. 
In a large Danish national study patients with schizophrenia had a 45% higher chance of 
developing an autoimmune disease, amongst which thyrotoxicosis and interstitial cystitis 
[47]. Moreover, these autoimmune diseases were also more prevalent in the parents of 
patients with schizophrenia, also showing that family members have a higher chance 
of developing such autoimmune disease (again indicating a putative shared immune 
pathogenesis of psychiatric disorder and autoimmunity). A limitation of the Danish 
study was that the incidence of autoimmune disease was reported until the onset of 
schizophrenia, autoimmune diseases developed after the diagnosis of schizophrenia 
were not included in the study. Schizophrenia usually develops in early adulthood while 
autoimmune diseases develop usually later in life, so it could be that the higher risk for 
autoimmunity in schizophrenia is even higher than the already higher chance of 45%. 
Although thus autoimmune diseases, such as thyrotoxicosis and interstitial cystitis are 
described with a higher prevalence in patients with schizophrenia, there are numerous 
reports of a negative co-occurrence of schizophrenia and rheumatoid arthritis, and it is 
unknown what the underlying immune mechanism is so far [48].
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A putative shared immune pathogenesis of major psychiatric disorders 
and autoimmune thyroid disease and autoimmune diabetes
There is mounting evidence that monocytes and their descendent cells, i.e. the 
macrophages and dendritic cells (collectively also called cells of the mononuclear 
phagocyte system, MPS), of patients with autoimmune diabetes and autoimmune thyroid 
disease are in a pro-inflammatory state and abnormal in their adhesion and migration 
(vide infra in more detail). These abnormal set points of the cells most likely play a role in 
breaking T cell tolerance and inducing the aberrant autoimmune response towards β cells 
and thyrocytes. In addition a hyperactivated state of effector T cells play a role.  
Precisely such activated state of the MPS and T cell system is presently thought to underlie 
major mental disorders, and this concept is generally referred to as the “Macrophage-T cell 
Theory” of Major Mental Disorders. 
Macrophage-T cell Theory of depression and schizophrenia
Although there are reports of an involvement of the immune system in major mental 
illnesses already in the first decennia of the 20th century, it took till the last decennia of 
the 20th century before detailed studies on an involvement of the immune system in 
major mental disorders became more numerous. These studies reported aberrant levels 
of pro-inflammatory cytokines in the serum, plasma and cerebrospinal fluid of patients 
with schizophrenia and major mood disorders [49-52]. On the basis of these reports 
it was hypothesized that a pro-inflammatory state of the cytokine network induces 
psychopathologic symptoms and is involved in the pathogenesis and pathophysiology of 
these major mental illnesses.  
Pro-inflammatory cytokines are primarily produced by activated cells of the immune 
system; such as activated endothelial cells, cells of the MPS and T-cells. The realization 
that such cells must be involved led to the “Macrophage-T-cell theory of depression 
and schizophrenia”, which was proposed in 1992 and adapted in 1995 [53, 54]. In this 
theory chronically activated macrophages (and their related cells in the brain, i.e. the 
microglia) and T-cells produce cytokines and inflammatory compounds, which impact 
brain developments and destabilize the brain functionally in such a way that other 
genetic and environmental influences are able to precipitate the signs and symptoms of 
schizophrenia and mania/depression [55]. Indeed, receptors for inflammatory cytokines 
are present in various brain nuclei [56] and via their triggering deregulations of important 
neurotransmitter and neuro-developmental systems are introduced, facilitating the 
development of psychiatric signs and symptoms.  
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In the following section we give more detail on monocytes, macrophages and dendritic 
cells, how these cells traffic from the tissues to the lymphoid system and behave under 
steady state conditions, how they interact with various T cell subsets, and how they are 
involved in the inflammatory immune response under “danger” conditions and in case of 
autoimmunity. 
Cells of the mononuclear phagocyte system (mps) and their 
interaction with various t cell susbsets
The immune system is divided in the innate immune system and the adaptive immune 
system (Figure 1). 
Innate immunity
The innate immune system is the first line of defence against pathogens and provides a 
fast response with a limited specificity. The key players are: 1) barriers, such as tears, saliva 
and skin; 2) defence cells, which comprise neutrophils, cell of the MPS (monocytes and 
macrophages), natural killer cells and mast cells; and 3) soluble factors, of which various 
cytokines and chemokines are examples. If the innate system fails to resolve the infection, 
the adaptive system will get triggered by the cells of the innate immune system. This is 
seen as the inter phase between innate and adaptive immunity.
Inter phase
The cells responsible for the activation of the adaptive immune system and thus the 
key players of the inter phase are the various antigen presenting cells (APC). Accessory 
macrophages are an example of these APC but the most specialized APC are the dendritic 
cells (DC), which are also part of the MPS and in many instances derived from monocytes. 
DC pick up antigen at the site of infection, travel through lymphatics to the lymph node 
and present the collected antigen to cells of the adaptive immune system. With the 
presence of MCH class II molecules and their various co-stimulatory molecules, DC are 
well equipped to stimulate the naïve cells of the adaptive immune system, which will 
subsequently proliferate and be activated to play their role in the combat against the 
invading pathogens. 
Adaptive immunity
The adaptive immune system is antigen specific, provides a memory and is typically 
activated a few days later than the innate system. The main contributors are the T cells 
and B cells. B cells, which transform into plasma cells, are responsible for the production 
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Figure 1. The innate and adaptive immune systems. 
Depicted in this figure are the important players of the innate and adaptive immune system. Their 
roles are described in the text.
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of antibodies. Antibodies neutralize extra-cellular bacteria, viruses and toxins, activate 
complement and facilitate pathogen phagocytosis. T cells are responsible for the so called 
cell-mediated immunity.  T cells form a heterogeneous group of cells comprising effector 
cells, regulatory cells and memory cells and are typically divided into CD4+ and CD8+ 
T cells. The effector CD8+ T cells are cytotoxic and important in killing other body cells 
infected with virus, intra-cellular bacteria, or are otherwise damaged or dysfunctional. 
The effector CD4+ T cells are important in providing help to other immune cells and are 
therefore called helper T cells (Th).  A naïve T helper cell (a cell which has not encountered 
an antigen yet in the presence of an APC) can upon stimulation by an APC differentiate 
into three Th subtypes, namely Th1, Th2 and Th17 cells. Th1 cells are capable of activating 
macrophages via Interferon γ (IFN γ), and are in this way essential in the elimination of 
intracellular pathogens. Th2 cells play a central role in the transformation of B cells into 
plasma cells. The third member of Th cells, the Th17 cell, has just recently been identified. 
The function of Th17 cells is not yet completely understood but is suggested to be in host 
defence against mainly extra-cellular pathogens which have not been cleared efficiently 
by the other Th cells [57]. Next to these effector and helper T cells, there are also T cells 
with regulatory functions as the immune system needs to be tightly regulated since it is 
well equipped to lethally damage the host cells if it loses control. The best known natural T 
regulatory cell population are the CD4+CD25high T cells. Naturally occurring CD4+CD25high 
Treg cells are defined by the constitutive high expression of CD25 (IL-2 is indeed required 
for triggering their suppressive function) and of the transcription factor FOXP3 (Forkhead 
Box P3). A feature of CD4+CD25+FOXP3+ T cells is that the cells themselves are “anergic” 
to mitogenic stimuli, but are capable to suppress the proliferation of CD4+CD25neg T cells 
when cultured together. Such suppression can be abrogated by the addition of IL-2, IL-
15 or stimulation with anti-CD28 antibodies. The precise mechanisms of suppression 
by CD4+CD25+FOXP3+ T cells are not clarified yet, but cytokines like IL-10 and TGF-β 
are thought to play a role [58]. Next to CD25 and FOXP3 expression these Tregs are 
characterized by high surface expression of CTLA-4 and GITR. Other known regulatory 
T cells are the Tr1 cells (defined by a high production of the anti-inflammatory cytokine 
IL-10) and the Th3 cells (defined by a high production of the anti-inflammatory cytokine 
TGF-β) [59] .
Monocytes, macrophages and dendritic cells in more detail
Since these cells are of prime importance in this thesis, they are described in a little more 
detail. Monocytes are closely related to macrophages and dendritic cells and collectively 
these cells are often referred to as the “Mononuclear Phagocyte System (MPS)”. This group 
of hematopoietic cells has diverse characteristics and origins. In general the cells originate 
in the bone marrow and migrate as monocytes through the blood to peripheral tissues. 
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Figure 2. The mononuclear phagocyte system. 
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By cell division of monoblasts (inner ring), promonocytes are formed (second ring), which form 
monocyte by division (shaded ring). Monocytes differentiate into the various macrophages and 
dendritic cells with their different names and functions (outer ring)
S: Hematopoietic stem cell.
The main descendents of these circulating monocytes, the macrophages and DC, occur 
in virtually all organs (Figure 2). Each organ contains multiple different macrophage and 
DC subpopulations. Local myeloid precursors for macrophages and DC are also present in 
various organs, including the brain [60]. 
The best-known functions ascribed to macrophages – clearance by phagocytosis and 
digestion - and to DC – primary activation of the adaptive immune system – have long 
been the leading principle in distinguishing these cell types. However, the biologic reality 
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is much more complex. The cells of the MPS comprise a large family of functionally and/
or developmentally related cells that form a continuum in which the cells recognized as 
prototypical ‘macrophages’ and ‘DC’ form the extremes of a spectrum (Figure 2). Both DC 
and macrophages are involved in the regulation of the immune response and both DC 
and macrophages are capable of up and downregulating immune responses. In ‘danger’ 
situations the cells of the MPS become pro-inflammatory by perceiving danger signals, 
and then guide an effective T cell response to eliminate the danger-evoking signal. In 
normal situations without any danger the MPS cells stay in their “tolerogenic steady state”, 
yet are active and do interact with T cells, but in such a way that tolerance to auto-antigens 
is induced and upheld.
In sum, the MPS comprises a large family of functionally and/or developmentally related cells 
essential for both inducing tolerance towards auto-antigens and for inducing an effective 
immune response towards dangerous intruders.
Trafficking and role of cells of the MPS and T cells under steady state conditions
Under normal physiological conditions there is a low but continuous trafficking of 
immune cells, in particular of monocytes and the monocyte-derived macrophages and 
dendritic cells (DC), from the peripheral tissues, such as from the skin (the DC is known 
here as Langerhans cell), the mucosa, the endocrine organs and the brain to the draining 
lymph nodes (known there as veiled cells [61]). Part of the cells enter the tissues from the 
bloodstream transversing the endothelial cells, although there are also indications that a 
proportion stems from local organ-dwelled precursors. 
Influx of monocytes under steady state conditions. 
Intercellular adhesion molecule (ICAM) is one of the adhesion molecules involved in 
the transmigration of leukocytes through endothelium (Figure 3) and is constitutively 
present on the surface of endothelial cells [62]. Monocytes in peripheral blood carrying 
the LFA-1 receptor (CD54) bind to ICAM-1 on endothelial cells to transmigrate into the 
tissues. The presence of ICAM on the surface of endothelial cells is increased by pro-
inflammatory cytokines, causing more monocytes to migrate into the tissue. Soluble (s)
ICAM is the soluble form of ICAM and shed by endothelium. In normal conditions it is 
present in human serum in concentrations of 100-450 ng/ml, and when endothelium is 
activated levels are increased. Then also levels of endothelin-1 are increased [63]. Early 
tissue-infiltrating monocytes produce the chemokine (C-C motif ) ligand 2 (CCL2). CCL2 
promotes further migration of monocytes into the tissue. The cell surface receptors on 
monocytes that bind CCL2 are CCR2 and CCR4. Normal serum levels of CCL2 are 100-225 
pg/ml [49, 64].
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Figure 3. Traffic: Steady state situation. 
ICAM
CD54
CCL2 Steady state
M
M
M
CCL2
s-ICAM
endothelin
IL-1
IL-6
IL-1
IL-6
IL-2
Ag Mø
E
N reg
vascular endotheliumTISSUES
LYMPH NODE
reg
reg
F iDC
iDC
Treg
Treg
Treg
IL-2
IL-2R
sIL-2R
Under normal conditions, some circulating monocytes diapedese through the vascular endothelium 
entering the tissues. ICAM, CD45 and CCL2 are instrumental in this diapedesis. In the tissues the 
monocyte-descendent cells, the macrophages and immature DCs play a role in the physiological 
regulation of the growth and functioning of neighbouring parenchymal cells, for example, endocrine 
cells, neurons and fat cells; in this regulation IL-1 and IL-6 play a role. The macrophages and iDC also 
take up autoantigens of these cells and travel with these to the draining lymph nodes, where they 
stimulate, in particular, natural T regulator cells. In the proliferation of T regulator cells IL-2 and the 
shed IL-2R are produced. E: Endocrine cell; F: Fat cell; iDC: Immature dendritic cell; M: Monocyte; MØ: 
Macrophage; N: Neuron. 
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Neuro-endocrine regulatory role of tissue macrophages and DC under steady state 
conditions. 
Infiltrated monocytes or local precursors differentiate under steady state conditions into 
tissue macrophages (the histiocytes) and immature DC (iDC). Such cells are primarily 
involved in functions of tissue homoeostasis and growth- and function-regulation of 
neighboring parenchyma and not in functions of defense (since there are no dangerous 
microbes or compounds around). To give a few examples: iDC in the anterior pituitary are 
known as folliculo-stellate cells and involved in the architecture of the anterior pituitary and 
the regulation of the secretion of e.g. FSH, LH, GH and TSH by gonadotrophs, somatotrophs 
and thyrotrophs [65]. iDC and macrophages in the thyroid, the islets of Langerhans and the 
ovaries are involved in the regulation of endocrine cell proliferation (e.g. follicle and islet 
formation) and in the dampening of the secretion of thyroid hormones and insulin [66-68]. 
Interleukin-1 (IL-1) and IL-6 produced by these steady state iDC and tissue macrophages 
play important roles in these neuro-endocrine regulatory processes. 
Tissue macrophages and iDC in the brain are known as microglia and have the same 
regulatory functions as in other peripheral tissues. Animal studies have shown that 
microglia arise from primitive myeloid progenitors and not from circulating monocytes 
and are thus a distinct population in the MPS [60]. Microglia are in particular important 
for synaptogenesis, synaptic functioning and neuronal sprouting [55]. Under steady 
state conditions microglia promotes neurogenesis by the production of neurotrophic 
factors such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) 
that support the survival of neurons [69]. Also during brain development microglia 
expresses thrombospondins [70], a family of extracellular matrix proteins, able to induce 
synaptogenesis [71]. Microglial dysfunction impacts synaptogenesis, synaptic functioning 
and neuronal sprouting: The absence of thrombospondins induces a dramatic reduction 
in the number of synapses formed during postnatal stages [71], whereas a mutation in 
KARAP/DAP12, which switches microglia from a steady state to a pro-inflammatory set 
point, impacts synaptic functions and neuronal sprouting in the hippocampus [72]. 
Efflux of iDC from tissues under steady state conditions and their role in tolerance induction 
preventing autoimmunity. 
Under steady state conditions iDC also take up – due to their strong endocytic capability 
- the compounds present in their vicinity, such as insulin when in the islets, thyroglobulin 
when in the thyroid, etc. etc., thus in fact “auto-antigens”. The iDC, maturing partly under 
the influence of local cytokines (such as TNF) to semi-mature DC, thereafter travel via 
the lymphatics (known there as veiled cells, [61] to the draining lymph nodes (known as 
interdigitating cells) carrying the auto-antigens along. In the draining lymph nodes the 
superb antigen-presenting cell (APC) capability of the DC becomes evident and they start 
to trigger and expand in particular subsets of naturally occurring T regulatory cells[58].
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Apart from playing a role in positive and negative selection shaping the T cell repertoire, 
the thymus also creates naturally occurring T regulatory cells preventing autoimmunity. 
This is essential since negative selection is imperfect and autoreactive T effector cells have 
escaped to the periphery. 
In triggering this population of T cells DC build up a strong non-reactivity (=tolerance) 
towards self under steady state conditions. The expansion and proliferation of the T 
regulator cells is heavily dependent on the activity of Interleukin-2 (IL-2), a cytokine 
expressed and produced by Treg cells when triggered by the iDC. Secreted IL-2 activates 
the Treg cells to proliferate and differentiate via the IL-2 receptor (IL-2R, CD25) in an 
autocrine fashion. Activated Treg cells shed the IL-2R (CD25) from their cell surface and 
the natural activity of such shed sIL-2R is to bind IL-2 inactivating it and so fine-tuning the 
immune response. sIL-2R (sCD25) produced by activated Treg cells is spilled over in the 
peripheral blood and circulating levels of sIL2R are under normal conditions 300-550 U/ml. 
In sum, under steady state conditions the normal low level of trafficking of cells of the MPS 
(monocytes, macrophages and iDC) serves a neuro-endocrine regulatory role and promotes 
tolerance via the stimulation of natural T regulatory cells preventing autoimmunity towards 
neuro-endocrine tissues. 
Trafficking and role of cells of the MPS and T cells under inflammatory (“danger”) 
conditions
When microbes infiltrate the tissues or when the tissue is necrotic (due to e.g. ischemia) 
the disturbance in tissue homoeostasis is perceived as a “danger” signal, putting a program 
of inflammation into motion. To perceive such danger signals the tissue macrophages and 
iDC are equipped with pathogen sensors, recognizing signals such as lipo-polysaccharides 
(LPS), lipotichoic acid (LTA), poly-IC, oxidative radicals and necrotic debris. There are 3 
families of pathogen sensors: Toll-like receptors (recognize bacteria, fungi, viruses and 
protozoa); NOD-like receptors (recognize bacteria); and RIG-I-like receptors (recognize 
viruses) [73]. When triggered via such receptors the tissue macrophages and iDC change 
into inflammatory macrophages and mature (m) DC (Figure 4).
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Figure 4. Traffic: Danger situation. 
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Under situations of danger (here a microbial infection) there is an increased influx of monocytes, 
which develop in the tissues into stimulated macrophages and mature DCs. Stimulated macrophages 
have increased phagocytic and lytic potential to kill the microbes, but are often also more toxic to the 
parenchyma. Mature DCs have an altered regulatory function for neighboring parenchymal cells and 
upon arrival in the draining lymph node do not stimulate Treg cells, but effector T cells to build up an 
adaptive immune response. †: Requiescat in pace – macrophages and dendritic cells kill neighbouring cells; 
Ab: Antibody; Ag: Antigen; B: B cell; DC: Dendritic cell; E: Endocrine cell; F: Fat cell; iDC: Immature dendritic 
cell; M: Monocyte; mDC: Mature dendritic cell; MØ: Macrophage; N: Neuron; P: Plasma cell. 
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Inflammatory macrophages.
Inflammatory macrophages produce large quantities of the pro-inflammatory cytokines 
IL-1β, TNFα and IL-6 and of CCL2. CCL2 attracts more monocytes and macrophages. The 
function of IL-1β is to activate the macrophages to an enhanced phagocytosis and killing, 
to increase the expression of adhesion molecules, including ICAM, on the surface of 
endothelial cells to attract more immune cells and to increase inflammatory compound 
production. The receptor for IL-1 is the IL-1R, which can be shed. IL-1 receptor antagonist 
(IL-1RA) – also produced by inflammatory macrophages - is opposing the effects of IL-1. 
The shed IL-1R as well as IL-1RA fine-tune the IL-1 inflammatory cascade. The functions 
of TNFα and IL-6 are similar and they also have similar regulatory cascades of soluble 
receptors and inactivating compounds. 
Mature DC and the stimulation of the effector T cell response. 
Mature (m) DC are in particular meant to and equipped to stimulate the adaptive immune 
response towards the dangerous microbes or noxes, i.e. the antigen-specific effector T cell 
response and B cell response. They have upregulated particular cytokines (IL-1, IL-6, IL-12, 
IL-4 and IL-23) and co-stimulatory molecules (CD80/86) and travel to the draining lymph 
node carrying along the microbial or otherwise “dangerous” antigens. In the lymph node 
the function of IL-1 and IL-6 produced by the mDC is the stimulation of the T effector 
lymphocytes to proliferate, whereas IL-6 has an additional function in the differentiation of 
B-lymphocytes. IL-2 produced by the DC-triggered effector T cells again acts here (under 
“danger” conditions) as the autocrine proliferation factor for the T effector cells. Thus: High 
levels of serum IL-2 or sIL-2R indicate T cell proliferation of either the Treg or T effector 
compartment. 
The IL-12 produced by the mDC drives naive T cells in the direction of a Th1 development. 
Th1 cells are capable of secreting IFN-γ, which activates inflammatory macrophages to 
an even higher phagocytic and killing capacity, it also strongly activates cytotoxic T cells 
and natural killer cells, thus hyper-activating the inflammatory response towards the 
dangerous noxe.
The IL-23 produced by the mDC drives naïve T cells in the direction of a Th17 development, 
i.e. T cells capable of secreting IL-17, of which the function is not entirely known, but 
probably has similar functions as IFN-γ.
IL-4 produced by the mDC drives naïve T cells in the direction of a Th2 development. Th2 
cells secrete the cytokine IL-4 too, which primes B cells and stimulates class switching, IL-4 
is thus instrumental in the production of IgG antibodies towards the dangerous noxe. 
IL-4 secretion by T cells provides a positive feedback by encouraging the growth of more 
Th2 cells, however IL-4 also inhibits through a negative feedback the development of Th1 
cells. On its turn IFN-γ inhibits the Th2 response through a negative feedback, and thus 
TH1 and Th2 development are reciprocal phenomena.
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In sum, under conditions of danger tissue macrophages develop a program of hyper-secretion 
of pro-inflammatory compounds promoting local inflammation, while matured DC are 
capable of stimulating Th1, Th2 and Th17 effector mechanisms, of which IFN-γ, IL-4 and Il-17 
are indicators.
Abnormalities of monocytes, dendritic cells, t cells and macrophages 
in endocrine autoimmunity
Any abnormality of monocytes and DC switching the cells into a “danger” mode and 
leading to malfunctioning of the tolerogenic steady state processes  could in principle 
lead to a loss of tolerance by an escape of autoreactive T cells from control and/or an 
imbalance (either in number or in function) between T effector and T regulatory cells 
[74-76]. Such a signal which switches steady state APC towards a danger mode when 
carrying along autoantigens to the draining lymph nodes is e.g. the introduction of a 
strong danger signal during immunization with e.g. thyroglobulin by adding heat-killed M 
tuberculosis together with oil (i.e. “Freund’s complete adjuvans”). This protocol is followed 
in the induction of Experimental Allergic Thyroiditis (EAT) and also in other Experimental 
Allergic models using the appropriate autoantigens, such as Basic Myelin Protein to induce 
Experimental Allergic Encephalitis (EAE). 
However, an aberrant “danger” set point of steady state monocytes and DC can also be 
due to an “inborn” aberrant set point of the cells leading to spontaneous organ specific 
autoimmunity. Indeed, such an inborn aberrancy has extensively been described in 
the NOD mouse and the BB-DP rat, both excellent animal models of thyroid and islet 
autoimmunity [32, 77-81]. In these animal models an aberrant “danger” set point of steady 
state monocytes and DC is already detectable before the actual autoimmunization phase, 
i.e. the enhanced DC accumulation in the target gland-to-be at around 5-8 weeks of age 
and the immune reaction in the draining lymph node and the production of autoantibodies 
from week 8-10 onwards. It is thus tempting to speculate that these “inborn” aberrancies 
of the steady state monocytes and DC are causal in the break of tolerance and indeed 
corrections of the abnormal monocytes and DC have led to prevention of disease in these 
models [82, 83].
It can also be envisaged that, next to aberrancies of the steady state monocytes and DC, 
intrinsic defects in the function of T cells are a reason for a poor tolerance to autoantigens. 
Again these defects have extensively been described in the NOD mouse and the BB-DP 
rat preceding the autoimmune process and corrections have prevented or even cured the 
starting disease. 
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Interestingly the defects in monocytes, dendritic cells and T cells are similar, but not 
identical in the NOD and BB-DP rat model and are also linked to different genes in both 
models. This notion points to a concept that different molecular immune pathogenic 
mechanisms lead to a comparable functional defect in DC-T cell interaction resulting in a 
similar endpoint, i.e. autoimmunity and a final destruction of target cells. It is possible, that 
similar diverse immune molecular pathogenic pathways exist for human T1D and AITD, 
and that these diseases are in fact composed of various syndromes with diverse molecular 
mechanisms. 
Based on extensive research in our group over the last 10-15 years and based on the 
literature the aberrancies of the monocyte, macrophage, DC and T cell compartments in 
the NOD mouse, the BB-DP rat and in T1D and AITD patients can be summarized as follows 
(Figure 5):
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Collectively the various aberrancies in endocrine cell, monocyte, DC and T cell functions in both 
the NOD mouse and the BB-DP rat (models of spontaneous endocrine autoimmunity) are highly 
suggestive for a basic underlying inborn defect in growth and development of myeloid and 
lymphoid precursors in the bone marrow and thymus and of epithelial and mesenchymal cell 
precursors in the target glands. 
A. The myeloid precursors of the bone marrow show a reduced proliferation and a reduced apoptosis 
resistance, but an accelerated and deviant maturation. This results in 
1) A mature (partly inflammatory) set point of circulating monocytes with an enhanced 
adhesiveness to ECM (as shown in the NOD mouse)
2) An accelerated maturation of DC from these monocytes/precursors with an intrinsic high 
inflammatory set point, but with a poor T cell stimulatory T cell capacity (depending on the 
availability of growth factors). Such “inflammatory” DC are poor stimulators of AITCD and natural T 
regulator cells (both shown in the NOD and BB-DP rat)
B. The growth disturbances of the parenchyma and connective tissue in the target gland prior to 
the autoimmune process lead to an abnormal structure of the extra-cellular matrix (ECM) with a 
high fibronectin (FN) content (as shown in the NOD mouse). The “inflammatory” DC generated in 
the tissues from infiltrated sticky monocytes will acquire an even higher pro-inflammatory state due 
to an abnormal interaction with the abnormal ECM (high FN content). Indeed the DC in the tissues 
are pro-inflammatory (high NFκB) and have a disturbed IL-12/IL-10 ratio (as shown both in the NOD 
mouse and the BB-DP rat) and they will thus primarily stimulate Th1 pathways, tipping the already 
disturbed T cell balance from tolerance to auto-immunization. 
C. The disturbances in the growth and development of lymphoid precursors in the thymus lead to 
1. A lymphopenia and in particular a strongly reduced number of natural T regulator cells due to 
an enhanced apoptosis of recent thymic emigrants (RTE) as shown in the BB-DP rat, 
2. Various T cell apoptosis defects leading to abnormal positive and negative selection in the 
thymus  (BB-DP rat) and a defective AITCD (NOD mouse)
3. A fitness defect of T regulator cells in the NOD mouse (due to a lack of growth stimuli, e.g. IL-2)
These imbalances between the various T cell tolerogenic and autoimmunization differentiation 
routes will aggravate the antigen presenting disturbances of the autoimmune DC. 
D. In endocrine autoimmune patients similar aberrancies as in the NOD mouse and BB-DP rat have 
been found, i.e. there are signs of
1. An abnormal adhesive state of circulating monocytes (gene cluster 2 upregulated, more 
adhesiveness to FN and endothelial cells) leading to an over production of pro-inflammatory factors 
(CCL2 and S100A)
2. A defective generation of veiled cells and dendritic antigen presenting cells (APC) from monocytes 
resulting in APC with a poor capability of stimulating tolerogenic T cells or to induce AITCD
3. A resistance of T cells to undergo apoptosis in AITCD
4. A defective function of natural T regulator cells, and
5. A reduced number of T regulator cells in individuals at risk for endocrine autoimmunity.
1. A reduced proliferation and enhanced apoptosis of myeloid precursors 
Serreze et al. [84] were the first to describe that hematopoietic precursors in the bone 
marrow of NOD mice proliferated poorly to CSF-1 (M-CSF) stimulation resulting in a 
quantitative inability to generate typical and functional macrophages. They proposed 
that this defect in macrophage differentiation yielded antigen presenting cells that were 
unable to activate tolerogenic mechanisms, but remained capable of activating low level 
effector responses. 
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From our group Nikolic et al. [85] later also found a model that in the NOD mouse in 
a GM-CSF-driven bone marrow culture (to yield DC) the precursor cells had a reduced 
proliferation and a higher rate of apoptosis in comparison to 3 control strains; this resulted 
in a reduced yield of dendritic cells at the end of the culture. 
Sommandas et al. [86] did a similar observation in the BB-DP rat system: In a GM-CSF/IL-4 
driven bone marrow culture the rate of apoptosis of precursors was higher in the BB-DP 
rat as compared to the BB-DR rat, a line of BB rats without islet and thyroid autoimmunity 
because this line lacks the mutation in an important IDD gene, the lymphopenia (lyp) 
gene. This gene is responsible for the severe lymphopenia of the rat (see later); apparently 
this gene is also directly or indirectly (via lymphocyte cytokines) important for a normal 
myeloid precursor growth and apoptosis.
2. An activated state of circulating monocytes
The abnormal differentiation of myeloid precursors is not without consequences for the 
final maturation stage reached by the progeny. 
NOD mouse. Nikolic et al. [85] showed in the GM-CSF-driven NOD mouse bone marrow 
culture system that the precursors for DC did not follow the sequence of normal 
development to DC via three successive stages (i.e. earliest precursors – pro-monocytes 
- monocytes to finally yield immature DC), but showed an accelerated maturation, 
characterized by an almost immediate transition of the earliest precursors into DC, which 
had not an immature, but a mature, macrophage-like phenotype. A reflection of such 
similar maturation acceleration and deviation can be observed in the circulation of the 
NOD mouse, where there is an overrepresentation of mature (Ly-6Clow) monocytes over 
that of immature (Ly-6Chigh) monocytes. Interestingly, recent not yet published experiments 
of our group (Beumer et al., to be published) show an upregulation of a number of pro-
inflammatory genes, amongst which IL-1β, PTGS2, THBS and PAI-2, in the expanded mature 
Ly-6Clow circulating monocytes in the NOD mouse.
Also the macrophages of the NOD mouse have a pro-inflammatory phenotype. A high 
PTGS2 expression level has been reported in NOD peritoneal and bone-marrow derived 
macrophages [87] as well as a high production of the pro-inflammatory cytokines IL-1β 
and TNF-α [88, 89]  and of oxidative radicals [90]. 
BB-DP rat. Unfortunately studies on the pro-inflammatory state of circulating monocytes 
are lacking in the BB-DP rat model. However there are reports on a pro-inflammatory state 
of the peritoneal macrophages in the BB-DP rat producing high quantities of TNF-α [91] 
and oxidative radicals [90]. 
Patients: In AITD and T1D patients pro-inflammatory abnormalities of circulating 
monocytes (e.g. increased IL-1β, ROS and PTGS2 production) [92-94]  similar to those 
observed in the NOD mouse have been reported, although these findings have also been 
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doubted [95, 96]. In a recently reported study we found a pro-inflammatory monocyte 
gene expression pattern consisting of a coherent set of inflammation related genes (a.o. 
IL-1 β, IL-6, TNF, PTGS2, so-called cluster 1 genes) and a coherent set of motility-adhesion-
chemotaxis genes (a.o. CDC42, EMP1, CCL2, so-called cluster 2 genes) in the majority 
of LADA patients (60%) and to a limited extent in adult-onset T1D patients (28%). In 
monocytes of childhood-onset T1D cases only the motility-adhesion-chemotaxis cluster 2 
gene set was upregulated in 43% of patients [97]. These data firstly suggest heterogeneity 
of the pro-inflammatory activation set points of circulating monocytes in different forms 
of T1D. Secondly they show that an upregulation of a set of motility-adhesion-chemotaxis 
genes is characteristic for at least proportions of LADA, adult and childhood onset T1D 
patients. 
Monocyte gene expression data for AITD patients are lacking; Chapter 6 addresses this 
issue.
3. An increased fibronectin adhesiveness of monocytes and dendritic cells 
This increased adhesiveness leads to a pro-inflammatory state of the cells and there is a 
link with a pre-existent abnormal morphogenesis of islets and thyroid tissue.  
NOD mouse. From our group Bouma et al.. [98] showed an increased adhesiveness of NOD 
monocytes (in particular of the expanded mature (=Ly6C
low
) population) to fibronectin (FN). 
These mature monocytes are in particular the precursors of the steady state macrophages 
and DC in the tissues [99] and indeed Wildenberg et al.. [100] showed that the circulating 
mature NOD monocytes primarily produce the DC in the peripheral tissues of the NOD 
mouse. Wildenberg et al.. [101] were also able to show that such tissue DC also lacked 
the expression of CCR5 in the NOD mouse model and that this reduced CCR5 expression 
leads to an over production of IL-12, a cytokine capable of skewing the T cell response in 
a damaging Th1 direction.  
Acharya et al.. [102] took these observations further and showed that adhesion of NOD 
DC to adhesive substrates, such as FN, collagen and vitronectin, indeed modulate the 
activation and stimulatory capacity of the cells; specifically NOD-DC cultured on FN 
acquired a pro-inflammatory state, i.e. they were Th1 skewers and induced the highest 
expression of IFN-γ in T cells. 
The increased adherence of NOD monocytes and DC to FN and its consequences for the 
inflammatory state is relevant, since increased amounts of FN are present in the NOD 
pancreas particularly at the islet edges in the early postnatal period, where it is associated 
with an enhanced accumulation of monocytes and DC at these sites [103]. The increased 
amounts of FN at the islet edges is part of a general abnormal morphogenesis of the NOD 
islets prior to the onset of the autoimmune reaction: The islets are irregularly shaped, later 
becoming mega-islets, which are in particular the target of the early infiltration of DC and 
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later infiltration with macrophages and T cells [104]. The islets also show an increased ratio 
of α over β cells [105]. It is relevant to recall here that DC have the capacity to influence the 
growth and function of islet cells and perhaps their early enhanced infiltration is linked to 
this function.
BB-DP rat. Studies on the adhesive capacity of monocytes and DC to FN are lacking in 
the BB-DP rat model. However an abnormal morphogenesis of the BB rat thyroid prior 
to the autoimmune process has been described: There is a reduced thyroid growth in 
the stage preceding thyroid infiltration with DC, macrophages and T cells and isolated 
thyroid follicles isolated at that time (before 9 weeks of age) show a reduced spontaneous 
and TSH-Induced proliferation [67]. We also noted in these tissue digestion experiments 
that the thyroid tissue of BB-DP rats has other digestion kinetics as compared to control 
strains, suggesting a defiant ECM composition (not published results). Strikingly similar 
observations have been done in another model of spontaneous autoimmune thyroiditis, 
the Obese Strain (OS) chicken: A decreased in vitro growth rate of thyroid cells in the 
pre-autoimmune stage, which was suggested to be an inborn abnormality since it could 
already be detected in OS fetuses [106].
Patients. An interesting parallel exists between the NOD mouse and T1D and AITD patients 
regarding the aberrant adhesiveness of monocytes to FN. In general it is known that 
human monocytes are “activated” after adherence to FN (so-called P-monocytes) and have 
acquired an enhanced capability to produce inflammatory cytokines and chemokines 
[107, 108]. 
Monocytes of T1D patients display an increased adherence to FN (and to endothelial 
cells) and express higher surface levels of the integrin CD11b/CD18 as compared to 
monocytes of healthy controls and T2D patients [109, 110]. Interestingly, adherence to FN 
of monocytes of T1D patients induced an even higher pro-inflammatory state over that 
of healthy controls with a stronger increased production of MRP8/14 (a pro-inflammatory 
compound of the S100 family), of the pro-inflammatory chemokines CCL2 and CCL3 [111], 
but with a reduced production of IL-10 [110].
Monocytes of AITD patients also show an altered interaction with FN. The cells have, 
after adherence to FN, a strongly reduced motility response to chemo-attractants [108]. 
Recent not yet published experiments (Burgerhout et al.., to be published) show that this 
reduced motility response is linked to a pro-inflammatory state of monocytes (in particular 
to an overexpression of the genes for PTGS2, IL-1β, PTX3), suggesting that also in AITD 
monocytes might be strongly pro-inflammatory activated after FN adherence.
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4. A defective capability of dendritic cells to support tolerogenic mechanisms 
NOD mouse. As stated before Nikolic et al.. [85] showed a poor generation of DC from 
bone marrow precursors. The generated DC are not only macrophage-like, but also had 
a reduced capability to stimulate T cells. Peng et al.. [112] showed that the maturation 
defect of NOD DC was linked to the IDD10/17/18 region on chromosome 3 of the NOD 
mouse. Also in other studies in vitro generation of DC from NOD BM precursors appeared 
to be defective [112, 113], and there are indications that this reduced generation and 
deviant differentiation of NOD DC contributes significantly to imbalances in the T cell 
system in such a way that autoimmunity prevails. First of all, transfers of properly terminally 
differentiated DC prevent diabetes development in the NOD mouse [82] and Dahlen et 
al.. [83] suggested that such transfers worked due to the correction of the low level of 
co-stimulation given by defective NOD DC: The transferred maturated DC would give a 
full activation of auto-reactive T cells and would consequently induce Activated Immune 
T cell Death (AITCD) and/or the upregulation of CTLA-4, an important switch-off signal 
for activated T cells. Other mechanisms might play a role as well: properly terminally 
differentiated DC are also better equipped to expand CD4+CD25+ regulatory T cells [114]. 
Interestingly, correcting the IDD10/17/18 locus in NOD mice results in significantly more 
tolerogenic DC in the pancreas draining lymph nodes [112].
It is important to again highlight that we found that the “proliferation defective” DC had a 
macrophage-like inflammatory phenotype, despite their defect in proliferation capability 
for T cells [85]. Other investigators have also found the pro-inflammatory state of NOD DC 
cultured from bone-marrow precursors: DC over expressed various IFN-induced genes and 
this abnormality was linked to the IDD5 region [115]. In another report NOD DC showed 
high levels of NFκB and an increased IL-12p70 production; not further identified non-MHC 
IDD genes of the NOD were involved in this pro-inflammatory set point [116]. In contrast 
to our results these latter authors did not find a reduced generation of DC and a reduced 
capability of these DC to stimulate T cells to proliferate, but found an increased generation 
of NOD DC and a superb T cell proliferative capability of the cells. It must be noted that in 
their experiments NOD BM precursors were cultured in GM-SCF in combination with IL-4, 
in contrast to our studies where we used GM-CSF alone. When we cultured BM precursors 
of the NOD mouse also in GM-SCF in combination with IL-4 (instead of in the absence of 
IL-4, see before) we found that the DC differentiation defects had largely disappeared 
(Nikolic et al.., unpublished results). We interpret these findings that NOD BM precursors 
need specific growth factors, such as IL-4, to develop into fully T cell stimulatory DC, which 
is not necessary for other mouse strains. 
Thus the defective DC generation and poor T cell stimulatory capacity of DC can only 
be seen in the NOD mouse system under sub-optimal culture conditions of precursor 
cells. These suboptimal conditions probably do not normally occur in the living animal, 
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since we were not able to trace back the above-described in vitro poor T cell stimulatory 
capacities of NOD DC in ex vivo isolated DC populations. DC isolated from the NOD spleen 
and lymph nodes were excellent T cell stimulatory DC [117]. It is however important to 
note that the ex vivo and in vivo spleen, lymph node and tissue NOD are – despite their 
normal proliferative capacity - nevertheless abnormal in their inflammatory state: The cells 
are in vivo CCR5 defective and high IL-12 producers [101].
BB-DP rat. In the BB rat model the DC developmental defects are much clearer as 
compared to the situation in the NOD mouse. With regard to the BB rat model we already 
reported in the 1990’s that ex vivo preparations of thyroid DC and of spleen DC displayed 
abnormalities. Firstly, the DC preparation of the thyroid gland of the BB-DP rat contained 
more monocyte-like precursors and fewer cells with the typical characteristics of DC [66]. 
Secondly, the ex vivo spleen DC of the BB-DP rat showed a lower MHC class II expression, 
had a lower capability to form homotypic and T cell aggregations and had a reduced 
capability to stimulate T cells in syngeneic (syn)-MLR [118], in particular the ART2+ T 
regulatory cell population of the BB-rat was poorly stimulated by the BB-DP DC. We took 
these abnormalities in both the thyroid and spleen DC population as signs of defects 
in the differentiation and maturation of BB-DP DC [86, 119], which had in particular an 
impact on the development of natural regulatory T cells. 
In later studies we found similar differentiation defects with regard to DC cultured from 
bone-marrow precursors (see also above): i.e. a reduced MHC class II cell surface expression 
and a poor capability to differentiate into fully mature DC, capable of fully stimulating T 
cells [86, 119]. Various genes of the BB-DP rat are involved in these functional defects, 
including genes of the MHC complex (IDD1) and the lyp gene (IDD2) [119]. Similar to the 
NOD mouse model, bone marrow precursor derived DC of the BB-DP rat are in a pro-
inflammatory state before the onset of autoimmune disease: The DC produce however 
not more of the pro-inflammatory IL-12 (as in the NOD mouse model), but reduced 
quantities of the anti-inflammatory cytokine IL-10 [119]. 
Patients. In AITD, T1D patients and high-risk first-degree relatives there are conflicting 
data with regard to the defects in DC differentiation from precursors, DC function and the 
pro-inflammatory state of DC. This might be related to the existence of heterogeneous 
pathogenic mechanisms for different forms of T1D (e.g. for LADA, juvenile onset and adult 
onset T1D, see before), however other factors (technical differences between the assays, 
influence of environmental factors) cannot be ruled out.
We [120] were the first (1995) to describe that in a group of established T1D individuals (of all 
ages) a veiled/dendritic APC population generated from monocytes had a poor capability 
of clustering with T cells and a poor capability of stimulating T cells. We hypothesized 
that such defect would impact tolerance induction more than the induction of effector 
immune forces (as is the case in the NOD mouse and BB-DP rat). Veiled/dendritic APC can 
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be generated from monocytes when cultured for 24 hrs. under non-adherent conditions 
and in the presence of anti-oxidants [61]. These veiled APC are strongly positive for MHC-
II, share some markers with monocyte-derived DC (e.g. CD1a, CD83) and are excellent 
stimulators of T cells, yet lack markers known of classical GM-CSF/IL-4 induced monocyte-
derived DC (e.g. DC-SIGN). Veiled APC are stronger IL-10 producers than IL-12 producers 
(certainly in comparison to classical DC) and skew T cell immune responses generated in 
their presence away from Th1 responses [61]. The defect in veiled/dendritic APC found in 
1995 could thus indeed be instrumental in the break of T cell tolerance.
T cell stimulatory functions of monocyte-derived classical DC. Takahashi et al.. [121] extended 
our early observations of 1995 and showed that also GM-CSF/IL-4 induced monocyte-
derived classical DC were like veiled/dendritic APC defective and had a reduced expression 
of CD1a, MHC-II, CD80 and CD86 and a reduced T cell stimulatory function in at risk first 
degree relatives of juvenile onset T1D patients as well as in the patients themselves. It 
must be noted that these authors cultured their DC on an ECM matrix, namely collagen (a 
not-common procedure).
Also Skarsvik et al.. [122] were able to show monocyte-derived DC differentiation defects 
in a juvenile onset T1D cohort as well as in healthy children with an HLA-risk genotype 
for T1D. In addition they found a decreased production of IL-12 and TNF-α from these 
defective DC.
We also studied in the period 2000 to 2003 the generation and function of classical 
monocyte-derived GM-CSF/IL4 induced DC in relatively large series of T1D and AITD 
patients [110]. Although we did find a lower expression of maturity markers on patient 
DC, differences in expression levels did barely reach statistical significance (and only in T1D 
patients and not in AITD patients). In these studies we did however find a reduced CD54 
expression on T1D monocytes. In addition the studies showed that CD54 stimulation of 
monocytes of healthy individuals resulted in an accelerated differentiation of DC from 
these monocytes. It can thus be envisaged that DC differentiation might be defective 
in T1D when cells are cultured in the presence of ligands for CD54, such as an ECM 
matrix, as done by Takahashi et al.. (see before), but this needs further experimentation. 
The observations nevertheless highlight again the importance of the ECM matrix and its 
proteins, like FN, in the unveiling of myeloid defects in endocrine autoimmune diseases.
Vuckovic and Hart [123] did not study in vitro differentiation defects of DC from monocytes, 
but measured the number of myeloid DC (mDC) in the circulation and found reduced 
numbers particularly in young patients with juvenile onset T1D; they found however the 
expression of MHC-II, CD40 and CD86 normal on these circulating mDC.
In support of a view that mDC in T1D patients have an altered inflammatory set point 
Mollah et al.. [124] recently showed that monocytes and monocyte-derived DC of T1D 
patients (all ages) had an abnormal inflammatory signaling response, i.e. an altered NFκB 
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metabolism set point (high levels of Rel-A, Rel-B and SHP-1), making their response to LPS 
abnormal. A similar finding was done by Meyers et al.. [125] who found that TLR4 activation 
of PBMC of newly diagnosed T1D patients induced a higher frequency of IL-1β expressing 
monocytes, but a reduction in the percentage of IL-6 expressing monocyte-derived mDC.
These reports which all found a defective generation and/or (T cell stimulatory) function 
of VC/DC are in contrast with a report finding a normal DC generation/function in T1D 
individuals: Zacher et al.. [96] found no gross differences in the generation of DC from 
monocytes (apart from a slightly and transient downregulation of CD1a and a slight 
reduction of CD80 and CD83 marker expression on mature DCs); the T cell stimulatory 
capability of these DC was normal. 
Peng et al.. [126] found an increase in the number of circulating MHC-II positive DC in T1D 
patients, but this appeared due to an increase in plasmacytoid DC (pDC) and not to an 
increase in mDC. In accord with these findings the mixed mDC/pDC population of the T1D 
patients was found to secrete higher amounts of IFN-α. 
5. Defects in natural regulatory T cells
The interest in CD4+CD25+FOXP3+ T cells as a specific sub-population of naturally occurring 
thymus-derived regulatory T cells (Treg cells) has a historical association with the day-
3-mouse thymectomy model. Day 3 neonatal thymectomy-induced organ-specific 
autoimmune disease (including T1D and AITD) is due to a lack of CD4+CD25+FOXP3+ T 
cell migration into the periphery. These regulatory T cells typically migrate out of the 
thymus in this early period. Injection of purified CD4+CD25+FOXP3+ T cells into neonatally 
thymectomized mice prevents the development of endocrine autoimmunity [127, 128].  
NOD mouse.  Several lines of evidence show that Treg cells are functionally active in 
pre-diabetic NOD mice. Although NOD mice harbour Treg cells capable of preventing 
disease progression early in life pathogenic effector T cells (Teff cells) proceed to 
immune mediated destruction of the β-islet cells. Controversial data exist as to whether 
a progressive resistance of autoreactive Teff cells to Treg cell-mediated suppression is 
due to defective Treg cell functions or to an accelerated decline in Treg cell frequency. 
Taken together present data suggest that Treg cells of NOD mice increasingly acquire a 
generalized fitness defect due to a lack of DC support (see before) and/or a defect in the 
availability of IL-2 which is required for sustaining homoiostasis and competitive fitness of 
Treg cells in vivo at inflammatory sites, including the peri-insulitis of the NOD. This relative 
IL-2 deficiency occurs at the time when the initial non-destructive peri-insulitis changes 
into an aggressive insulitis and is thought to be linked to a reduced production of IL-2 by 
the Teff cells in the insulitis. Consistently, low dose administration of IL-2 in pre-diabetic 
female mice resulted in enhanced frequency of Treg cells and this regimen resulted in T1D 
protection [129].
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BB-DP rat. ART2+ T cells (formerly known as RT6+ T cells) are known for quite some time 
as an important thymus-derived Treg cell population in the rat. ART2+ Treg cells are 
important in the prevention of autoimmune diabetes/thyroiditis in the BB rat model, 
and BB-DP rats lack these ART2+ cells. The ART2+Treg cell deficiency in the BB-DP rat is 
due to a mutation in the lyp (Ian-5) gene [119]. There exists a sub-line of BB rats without 
diabetes, lacking the mutated lyp gene and having normal levels of ART2+ cells: The BB-
Diabetes Resistant (DR) rats. ART2 depletion induces diabetes in BB-Diabetes Resistant 
(DR) rats, while an adoptive transfer of ART2+ cells from BB-DR rats to BB-DP rats prevents 
diabetes. Hillebrands et al.. [130] showed that there are two distinct potent suppressive 
ART2+ Treg cell populations: the CD4+ART2+CD25+FOXP3+-CD45RC-PD-1+ and the 
CD4+ART2+CD25-FOXP3-CD45RC-PD-1+ population. The former overlaps with the 
natural occurring CD4+CD25+FOXP3+ Treg cells of the mouse. Although this population 
is normal in number in the BB-DP rat, the cells were incapable of homeostatic expansion 
and survival upon transfer to nude BB rats [131]. The lyp gene has a strong impact on 
longevity of BB-DP T cells. 
Patients: In humans in total 20 mutations in the FOXP3 gene have been described, 
which lead to the absence or malfunctioning of regulatory T cells. Patients lacking these 
regulatory T cells suffer from an overwhelming autoimmune syndrome IPEX (Immune 
dysregulation, Polyendocrinopathy, Enteropathy X-linked syndrome) [132]. This syndrome 
presents during the first months of life and is usually lethal within the first two years [133]. 
Data on Treg cell numbers and function in regular T1D and AITD patients are limited. In 
general normal numbers of Treg cells have been reported, but there are some indications 
that Treg cell function might be impaired. Co-cultures of Treg with CD4+CD25- T cells 
showed that diabetic Treg where 2-fold less able to inhibit proliferation of CD4+CD25- T 
cells as compared to Tregs from HLA-identical controls, while the cytokine profile in the 
co-cultures of T1D patients showed a pro-inflammatory profile (more IFN-gamma, less 
IL-10) [134]. Interestingly it has also been shown that there exists an enhanced apoptosis 
of Treg cells in recent-onset T1D, individuals at risk to develop T1D [135] and in AITD 
patients [136]. This enhanced apoptosis was partly due to IL-2 deprivation, which was 
shown to exist in the patients (see the analogy with the NOD mouse). We reported in a 
study on family members of AITD patients at risk to develop AITD a reduced number of 
CD4+ CD25high cells and a reduced level of sCD25 in serum and we took these data as 
suggestive for a reduction in the number of natural Treg cells [137]. In the discussion the 
question on the number of CD4+CD25+ FOXP3+ T regulatory cells in AITD will come back.
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6. Defects in T cell apoptosis (AITCD)
T cell apoptosis is an important phenomenon in both central and peripheral tolerance 
induction. In the thymus the vast majority of double positive thymocytes are deleted by 
thymus APC (dendritic cells and epithelial cells) in the process of negative selection to get 
rid of erroneously developed high-affinity autoreactive T cells. In the periphery excessive 
immune responses are terminated by activated immune T cell death (AITCD); this process 
needs highly potent APC and recently activated T cells. In both apoptotic processes Fas-
FasL interactions play an important role. Cross-linking of Fas by its natural ligand (FasL) 
leads to the recruitment of the adapter molecule, FADD and subsequently caspase-8 to the 
membrane. The association between FADD and caspase-8 (the death-inducing signaling 
complex, DISC) leads to the activation of a downstream protease cascade (caspase 10 and 
7) with final activation of caspase-3 as the last step leading to apoptosis. There also exists 
another route of apoptosis activation involving caspase -9.
NOD mouse.  In a set of experiments in which we tested the stimulatory capacity of ex 
vivo isolated NOD spleen and lymph node DC to stimulate syngeneic T cells we noted a 
prolonged response, which was accompanied by an increase in the proportion of activated 
memory T cells and a reduced rate of apoptosis in the cultures [117]. We interpreted these 
findings that AITCD was disturbed in the NOD mouse due to an intrinsic defect in T cell 
apoptosis. This decreased apoptosis of NOD T cells was similar to the then earlier observed 
resistance of NOD thymocytes and peripheral lymphocytes to the induction of apoptosis 
by other means, such as dexamethasone, γ-irradiation and cyclophosphamide [138], 
and is in accord with the observation that in vivo immune responses are enhanced and 
prolonged in NOD mice [139]. The defect in apoptosis segregates with various genetic 
loci in the NOD mouse, a.o. with genes in the region of IDD6 [140]. With regard to Fas 
expression a study described an impaired Fas expression and a reduced expression of 
caspase-8 in peripheral NOD lymphocytes displaying AITCD resistance [141]. Interestingly 
treatment with 1-25 (OH)
2
 Vitamin D3 and galectin restores the apoptosis resistance defect 
and prevent and even cures starting diabetes in the NOD mouse. 
BB-DP rat. Recent thymus lymphocyte emigrants (RTE: Thy1-ART2- lymphocytes) disappear 
within 7 days of export from spleen and lymph nodes due to apoptosis [142, 143], this 
leads to the severe peripheral lymphopenia of the BB-DP rat, particularly impacting the 
Treg cell compartment (ART2+ cells) with only very few cells finally expressing the mature 
T cell phenotype (Thy1-ART2+) [144]. The life span of RTE is extremely shortened due to 
the mutation in the lyp gene. 
We have reported that thymus branched cortical macrophages of BB-DP rats were poor 
rescuers of developing thymocytes from apoptosis including the regulatory ART2+ T cells 
[81]. Previous work has shown that transfers of thymus APC of BB-DR rats to BB-DP rats are 
partially able to restore the defects in ART2+ T cells in BB-DP rats and to prevent insulitis and 
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diabetes [145]. Thus, it is possible that the defects at the level of the thymus of the branched 
cortical macrophage APC population contribute to the faulty tolerance induction of the 
BB-DP rat due to a heightened apoptosis of primarily Treg cells.
Patients: In T1D patients there are reports on a defective Fas expression and AITCD in 
peripheral T lymphocytes [146, 147]. Later it was shown [148], that a defective expression 
and function of caspase 3 contributed to the AITCD defect. Interestingly De Franco et 
al.. showed that there were differences between juvenile onset T1D and adult onset T1D 
regarding the defects in intracellular apoptotic pathways (either via caspase  8 or 9).
With regard to AITD a proportion of pediatric patients with Hashimoto’s thyroiditis (HT) 
and Graves’ disease (GD) display a reduced apoptosis and a decreased function of Fas 
on peripheral T cells, the defect involved both caspase 8 and 9 [149]. This functional 
defect perhaps exists in the presence of a higher Fas expression on T cells, Maruoka et al.. 
[150] showed that the intensity of Fas expression on peripheral T cells was disease stage 
dependent and was not decreased but increased in severe forms of AITD. Genetic studies 
support the T cell apoptosis defect in AITD, since GWAS identified ZFAT as a candidate 
gene for AITD: ZFAT is a critical molecule in cell survival [151]. Interestingly treatment with 
statins corrects the T cell apoptosis defect in HT also improving thyroid function [152].
The group of Smith [153] has opened another interesting approach to the problem: They 
found increased numbers of IGF-1 R positive T cells in the circulation and orbit of patients 
with GD. IGF-1 enhanced proliferation and inhibited Fas-mediated apoptosis of the T cells, 
thus implicating a role for growth factors in aggravating the T cell apoptosis defect . 
Concluding hypothesis
Collectively the various aberrancies in monocyte, DC, T cell, macrophage and endocrine 
cell functions in animal models of spontaneous endocrine autoimmunity are highly 
suggestive for a basic underlying inborn defect in growth and development of myeloid, 
lymphoid, epithelial and mesenchymal cell precursors with a reduced proliferation, 
reduced apoptosis resistance, but accelerated and deviant maturation. These growth and 
developmental defects would in such view result in 
1.  Imbalances between various T cell tolerogenic and autoimmunization differentiation 
routes, i.e. 
 a)  T cell apoptosis defects leading to abnormal negative selection in the thymus,
 b)  A defective generation of natural Treg cells in the thymus (e.g. due to   
  an enhanced apoptosis of RTE), 
 c)  A fitness defect of Treg cells (due to a lack of growth stimuli, e.g. 
  IL-2) and 
 d)  A defective AITCD (apoptosis defect)
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2.  An enhanced, but deviant differentiation and maturation of myeloid cells.   
This results in 
 e)  A mature (partly inflammatory) set point of circulating monocytes with   
  an enhanced adhesiveness to ECM, 
 f )  An accelerated maturation of DC, leading to an intrinsic high inflammatory  
  set point, but with a poor T cell stimulatory capacity (depending on the   
  availability of growth factors). Such DC are poor stimulators of AITCD and  
  natural Treg cells.
3.  An abnormal parenchyma and extracellular matrix (ECM) compartment in the target 
gland prior to the autoimmune process. DC generated in the tissues from infiltrated 
monocytes will acquire an even higher pro-inflammatory state due to an abnormal 
interaction with the abnormal ECM (high FN content). 
Such pro-inflammatory DC (with a disturbed IL-12/IL10 ratio) primarily stimulate Th1 
pathways, tipping the already disturbed T cell balance to overt autosensitisation.
Abnormalities of monocytes, macrophages, dendritic cells and t cells 
in schizophrenia and bipolar disorder
There are limited data on abnormalities of monocytes, macrophages, dendritic cells and T 
cells in schizophrenia and bipolar disorder.
Numbers of peripheral monocytes and expression of surface markers
There are early reports showing that the number of circulating monocytes is aberrant in 
schizophrenia. Rothermundt et al.. [154] reported a slight increase in the mean absolute 
and relative monocyte counts. Zorrilla et al.. [155] and Falcone et al.. [156] supported these 
observations showing a monocytosis and a higher number of CD14+ cells in respectively 
non-medicated schizophrenia patients and in children with new-onset psychosis 
(psychosis NOS, schizophreniform disorder and schizo-affective disorder). Another 
study however refuted this monocytosis, be it on a small sample of patients [157]. In the 
cerebrospinal fluid of patients with schizophrenia, monocytes and macrophages show an 
accumulation during acute psychotic episodes [158]. With regard to adhesion molecule 
expression Theodoropoulou et al.. [159] showed that there is an increased percentage 
of circulating peripheral blood mononuclear cells (PBMC) expressing ICAM-1 in patients 
with schizophrenia, but the authors did not make a distinction between circulating 
lymphocytes and monocytes. Nevertheless their observation supports an activated state 
of immune cells in the circulation of patients with schizophrenia, facilitating endothelial 
transmigration of the cells.
Introduction
41
1
For bipolar disorder there are no reports on aberrant absolute or relative monocyte counts. 
We did measure CCR2 expression on monocytes of patients with bipolar disorder [50]. 
CCR2 is mainly expressed on the mature CD14+CD16+ set of monocytes (the counterpart 
of the mature Ly-6Clow monocytes of the mouse). Expression of CCR2 was not significantly 
different between monocytes of BD patients and healthy controls, nor were there 
differences between the number of mature (CD14+CD16+) and immature (CD14+CD16neg) 
circulating monocytes in BD patients.
Abnormal inflammatory gene expression
We [50] previously reported an aberrant expression of pro-inflammatory genes in 
monocytes of bipolar patients and of offspring of bipolar patients, at risk to develop 
the disease. To find the genes we performed Affymetrix analyses on pools of purified 
monocytes of bipolar patients and matched healthy controls to search for aberrantly 
expressed genes. We validated the identified molecules using quantitative real time PCR 
(RQ-PCR) on monocytes of 42 individual bipolar patients and 54 children of a bipolar 
parent, of whom 13 had and 3 developed a mood disorder within 2-3 years after blood 
collection. We detected an aberrant coherent layout of 21 genes for inflammatory (PDE4B, 
IL-1β, IL-6, TNF-α, PTGS2, PTX3, FcαR), chemokinesis/motility (CCL2, CCL7, CCL20, CXCL2, 
CCR2, CDC42), cell survival/apoptosis (A10 or TNFAIP3, BCL2A1, EMP1) and MAP kinases 
pathway (MAPK6, Pac-1 / or DUSP2, NAB2, ATF3, HePTP) molecules in the circulating 
monocytes of bipolar patients and children of a bipolar patient with or later developing a 
major mood disorder. These 21 molecules were all mutually strongly correlating forming 
a monocyte “mRNA signature”. However, careful analysis detected within this signature 2 
sub-sets of genes which in particular mutually correlated: an inflammatory  subset 1 of 13 
genes (ATF3, DUSP2, PDE4B, IL-1β, IL-6, TNF-α, PTGS2, PTX3, FCαR, CCL20, CXCL2, TNFAIP3, 
BCL2A1) and a adhesion/motility/ chemotaxis subset 2 of 9 genes (EMP1, CCL2, CCL7, 
CDC42, MAPK6, NAB2, HePTP (Figure 6).  
We also determined the contribution of genetic and environmental influences on the 
association monocyte pro-inflammatory state – bipolar disorder and carried out a signature 
study on monozygotic and dizygotic concordant and discordant twin pairs [160] From this 
study we concluded that the association of the monocyte pro-inflammatory state with BD 
is primarily the result of a common shared environment, yet for some of the sub-cluster 2 
genes a genetic influence could predominate.
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Figure 6. A hypothetical scheme of the interaction between the various fingerprint genes. 
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Numbers of peripheral T cells and T cell subsets
Numerous studies have been performed on the number of CD3+ T cells, the CD4+ and 
CD8+ subsets, the B cells and the NK cells in schizophrenia and bipolar disorder (Table I). 
In essence it has been found that these lymphocyte subsets are normal in number [50, 
154, 155, 157, 159, 161-171]; however there might be some indication that CD8+ T cells, 
particularly CD45RA cells are increased in schizophrenia [172].
The limited studies carried out on T cells positive for CD25 (low, intermediate and 
high positive; these populations are generally considered as a sign of T cell activation/
proliferation) show that these cells are probably increased in the circulation of SCZ and BD 
patients (in the latter particularly in the manic phase). However it is not known whether 
we are dealing here with an activation/proliferation of the T effector or the T regulatory 
population (Figure 7). For that, intracellular FACS staining of CD4+T cells for IFN-γ (Th1), IL-4 
(Th2) and FOXP3 (natural T regulatory cells) should be undertaken, and such studies are 
reported in Chapters 5 and 7. 
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Table I
SCHIZOPHRENIA BIPOLAR DISORDER
Monocytes - number 
- (CD14)
(↓)         ↑ ↑
↑
↓ =
n.c.
[154, 155, 161] [50, 161]
T cells CD3 ↓ ↓  = = = = =  ↑
=
= =
(=)
[154, 159, 162-166, 168] [167, 169]
CD4 ↓ ↓     = = =   ↑ ↑
=
=   ↑
n.c.
[159, 161, 162, 164-166, 168] [161, 169]
CD8 = = =      ↑(↑)
=↑
=
(=)
[159, 164, 165, 168, 171] [169]
CD45 RA ↑↑
↑
[165, 168]
CD45 RO (↓)
n.c.
[168]
CD25 =       ↑↑
n.c.
[154, 159, 168]
B cells CD19 ↓        = =
n.c.
=    ↑
n.c.
[161, 163, 165] [161, 169]
NK cells CD56 ↓           =
n.c.
= =
=
[161, 164] [161, 169]
Synopsis of the literature regarding the percentages of circulating immune cells in schizophrenia 
and bipolar disorder. References are indicated between brackets. ↓: reference indicates a 
downregulation, ↑: reference indicates an upregulation, =: reference indicates a normal level, (↓); 
downregulated but low number of included patients. The summary columns reflect our conclusions 
based on this literature; we have concluded to raised numbers of monocytes in schizophrenia 
because the cumulative index of 3 studies shows upregulation (admitted there are too few studies), 
we have concluded to normal-to-putatively raised numbers of CD8+ T cells in schizophrenia studies 
because the cumulative index of 5 studies shows some weak upregulation and to normal numbers 
of CD3 and CD4 T cell, because the cumulative index of 8 studies shows normal numbers of cells. 
n.c. means not conclusive due to low number of studies and/or clearly conflicting outcomes. 
Cytokines of the MPS and T cell system
Most of the available literature in psychiatric patients does not concentrate on the cells of 
the MPS or the T cells, but on levels of MPS- and T cell-derived cytokines. Table II gives a 
synopsis of the present literature on the serum levels of cytokines and chemokines related 
to the MPS and T cell system in SCZ and BD patients. It is however important to note that 
cytokine levels in serum or plasma are strongly confounded by a number of conditions, 
such as age, gender, lifestyle, metabolic syndrome, visceral obesity, diet, smoking and 
medication. These factors have to be taken into account when studying the effect of 
disease states, here psychiatric conditions. In doing so, the present literature indicates 
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1) That s-ICAM and endothelin-1 are reduced in 2 out of 2 studies in SCZ, suggesting a 
reduced activation of the endothelial system [173, 174]. However preliminary data of our 
group show an increased level of s-ICAM in SCZ patients (Beumer et al.. to be published), 
while there are also unpublished data on raised levels of endothelin-1 in BD patients 
(S Bahn, personal communication). Therefore further studies on endothelial factors are 
needed before firm conclusions on the state of endothelial activation in SCZ and BD can 
be drawn.
2) That studies on CCL2 levels are too few (n=1) and involve too few patients to draw any 
conclusion [49, 50, 175]. We will present in this thesis (Chapter 4), an additional CCL2 study 
on SCZ patients (n = 145). 
3) That the IL-1, IL-6 and TNF cytokine networks are activated in SCZ and BD, be it 
inconsistently since not all studies were able to find the activation [49, 50, 159, 176-200]. 
Activation was found in general (taking SCZ and BD together) in 28 out of 52 studies 
(none showed reduced levels), pointing to an inconsistent pro-inflammatory activity of 
the MPS and/or the endothelial system in SCZ and BD patients. In many of the positive 
studies various confounding factors such as medication, age, gender and life-style have 
been taken into account, which makes these observations reasonably solid.
4) That the IL-2 system is probably activated in SCZ. Increased serum levels for the IL-2 
system were found in 4 out of 10 studies (note 2 studies showed reduced levels) [159, 179-
182, 186-188, 191, 193].  Medication did not influence levels of IL-2. It is also our experience 
that the IL-2 system is activated in SCZ, but independently from the IL-1, IL-6 and TNF 
cytokine networks, suggesting that the MPS/endothelial system is activated by separate 
mechanisms than the T cell system (see Chapter 3). 
In BD there are fewer reports (n=3) on the IL-2 system, but 2 indicate an activated T cell 
system particularly in periods of mania, including our study [183, 195, 197]. In our study 
sIL-2R levels were raised in particular during a manic episode, but also (be it less) during 
euthymic and depressive episodes [169].
5) That there are too few reports and too many with contradictory results on an activation 
or non-balance of the IL-12, IFN-γ and IL-4 systems and thus insufficient indications for an 
activation of either the Th1 and Th2 effector systems in SCZ and BD [183, 186, 188, 192, 
197, 201-204]. Studies on the Th17 system are completely lacking. Chapters 5 and 7 will 
address these issues.
Introduction
45
1
Table II
SCHIZOPHRENIA BIPOLAR DISORDER
Endothelium ICAM ↓ ↓           ↑
n.c.
[173, 174]
Endothelin ↑
n.c.
Monocytes CCL2 =  ↑ 
n.c.
=   
n.c.
[49, 175] [50]
IL-1 = = = = =    ↑ ↑ ↑ ↑
↑
=  ↑
(↑)
[49, 159, 176-182] [50, 183]
IL-6 = = = = = = = = =                  
↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑
= =  ↑ ↑ ↑ ↑
↑
[49, 177-180, 182, 184-194] [50, 183, 195-198]
TNF  = = = = = =              
↑ ↑ ↑ ↑ ↑ ↑ ↑
↑
=  ↑ ↑ ↑
↑
[49, 159, 176, 178, 180, 182, 186, 
188, 191, 192, 194, 199, 200]
[183, 196-198]
T cells IL-2 ↓ ↓ = = = = ↑ ↑ ↑ ↑
(↑)
↓  ↑ ↑
n.c.
[159, 179-182, 186-188, 191, 193] [183, 195, 197]
Th1:  IL-12 =  ↑
n.c.
= 
n.c.
[203, 204] [204]
Th1:  IFNγ =  ↑
n.c.
 = ↑
n.c.
[186, 202] [197, 201]
Th2:  IL-4 ↓ ↓ = =
n.c.
         =  ↑ ↑
n.c.
[186, 188, 192, 202] [183, 197, 201]
Synopsis of the literature regarding the serum levels of indicated cytokines and their prime sources in 
schizophrenia and bipolar disorder. References are indicated between brackets. ↓: reference indicates a 
downregulation, ↑: reference indicates an upregulation, =: reference indicates a normal level. The summary 
columns reflect our conclusions based on this literature;   we have concluded to upregulation of IL-1, Il-6 
and TNF on the basis of sufficient studies of which about half show upregulation, whereas none showed a 
downregulation, we have concluded to IL-2 as putatively upregulated in schizophrenia because there are 
sufficient studies of which the cumulative index shows some upregulation, n.c. means not conclusive due 
to low number of studies and/or clearly conflicting outcomes
Conclusion
Studies on monocytes, macrophages, T cells and cytokine networks, taking into 
consideration the various confounding factors as described, indicate an activated pro-
inflammatory state of the immune system in both SCZ and BD, particularly of the MPS and 
the T cell system. Measurements of serum cytokines of the MPS and T cells system are not 
consistent and precise enough to detect this activation in an individual patient or in small 
groups of patients. Gene expression studies in immune cells and numeric determinations 
of the various sub-types of T cells hold a promise here. 
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Chapter II. Experimental questions 
Do patients with schizophrenia and AITD have a pro-inflammatory monocyte gene 
expression signature and is there a difference or overlap with the previously found 
monocyte pro-inflammatory gene expression signature in patients with bipolar 
disorder?
In a previous study Padmos et al found a pro-inflammatory gene expression signature in 
the monocytes of patients with bipolar disorder [1] and in the monocytes of T1D patients 
(in particular LADA patients). We extended these studies to patients with schizophrenia 
and AITD and first searched for “schizophrenia-related and AITD-related monocyte genes” 
via Affymetrix analysis on pools of monocytes of patients with schizophrenia and AITD. 
Genes which were more than three times higher or lower expressed and had a known 
function in inflammation or inflammation-related processes were chosen for further 
verification using Q-PCR together with the genes already found aberrant in patients with 
bipolar disorder and T1D. This verification was performed on a set of patients with bipolar 
disorder, a set of patients with an acute form of recent onset schizophrenia and on a set of 
patients with AITD. The expression levels of the different genes were compared between 
the various disorders and a cluster analysis was performed to group the various genes (See 
Chapter 3 and 6).
Do monozygotic discordant co-twins of an index twin with juvenile-onset T1D have 
the same pro-inflammatory monocyte gene expression signature?
Padmos et al previously described that monocytes of 43% of patients with juvenile onset 
T1D have monocytes lacking the gene overexpression of part of the signature (i.e. lacking 
cluster 1 containing most of the pro-inflammatory cytokines and compounds), but with 
the remaining part intact (i.e. cluster 2 containing predominantly adhesion and motility 
factors and chemokines, like CCL2 and CCL7) [2]. In the here given study we investigated 
the presence of the pro-inflammatory mRNA gene expression signature in the monocytes 
in monozygotic co-twins of index twins with a juvenile onset T1D, who were discordant for 
T1D for already for many years. We aimed at detecting putative differences in inflammatory 
gene expression between the twins explaining the discordance despite monozygosity 
(Chapter 8).
Do patients with bipolar disorder and schizophrenia have aberrancies in their Th1, 
Th2, Th17 and natural T regulator cell compartment?
As stated in the introduction, there is evidence for the involvement of the T cell system in 
the pathogenesis of schizophrenia, bipolar disorder and AITD. Therefore, we investigated 
the frequency of Th1, Th2, Th17 and natural T regulator cells in the circulation of patients 
Chapter 2
58
with schizophrenia, bipolar disorder and AITD using detailed FACS analysis. We related T 
cell outcomes to the pro-inflammatory state of the monocytes (i.e. the presence of the 
pro-inflammatory mRNA gene expression signature) and in the bipolar patients with the 
presence of TPO-antibodies in the same patients (Chapter 5 and 7).
Is an altered inflammatory setpoint of the monocytes and T cells in patients with 
bipolar disorder, schizophrenia and AITD reflected in higher serum levels of pro-
inflammatory and T cell cytokines/chemokines and how are these levels related 
in patients with chronic forms of schizophrenia to the presence of the metabolic 
syndrome, a common co-morbidity of chronic schizophrenia?
Cytokine levels were investigated in the serum of patients with bipolar disorder, recent-
onset acute schizophrenia and AITD using a cytometric bead array and serum levels of 
cytokines were correlated with the monocyte gene expression signatures and the T cell 
state in the same patients (Chapters 4, 5, 6, 7). 
The incidence of the metabolic syndrome is higher in patients with chronic schizophrenia 
and the question is whether this is due to the disease itself or due to the use of atypical 
antipsychotic medication. One of the traits of the metabolic syndrome is visceral 
obesity and the adipocytes in the white adipose tissue are able to produce several pro-
inflammatory cytokines and chemokines which play a role in insulin resistance. Moreover 
low HDL (another trait of the metabolic syndrome) negatively impacts the inflammatory 
state of the MPS. In the study reported in Chapter 4 we measured serum levels of pro-
inflammatory cytokines and chemokines in a group of 145 patients with naturalistically 
treated chronic schizophrenia and correlated the levels to the presence and traits of the 
metabolic syndrome. 
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Abstract
Accumulating evidence indicates an activated inflammatory response system as a 
vulnerability factor for schizophrenia (SZ) and bipolar disorder (BD).
We aimed to detect a specific inflammatory monocyte gene expression signature in SZ 
and compare such signature with our recently described inflammatory monocyte gene 
signature in BD. 
A quantitative-PCR case-control gene expression study was carried out on monocytes 
of 27 SZ patients and compared to outcomes collected in 56 BD patients (all patients 
naturalistically treated). For Q-PCR we used 9 “SZ specific genes” (found in whole genome 
analysis), the 19 BD signature genes (previously found by us) and 6 recently described 
autoimmune diabetes inflammatory monocyte genes.
Monocytes of SZ patients had (similar to those of BD patients) a high inflammatory set 
point composed of three sub-sets of strongly correlating genes characterized by different 
sets of transcription / MAPK regulating factors: 
1) Sub-set 1A, characterized by ATF3 and DUSP2, and sub-set 1B, characterized by EGR3 
and MXD1, were shared between BD and SZ patients (up-regulated in 67 and 51% and 
34 and 41% respectively).
2) Sub-set 2, characterized by PTPN7 and NAB2 was up-regulated in the monocytes of 
62% BD, but down-regulated in the monocytes of 48% of SZ patients.
Our approach shows that monocytes of SZ and BD patients overlap, but also differ in 
inflammatory gene expression. Our approach opens new avenues for nosological 
classifications of psychoses based on the inflammatory state of patients, enabling selection 
of those patients who might benefit from an anti-inflammatory treatment.
Key words: schizophrenia, bipolar disorder, inflammation, monocytes, Kraepelinian 
dichotomy.
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Introduction
We [1] recently described a sensitive quantitative PCR (Q-PCR) assay system to detect 
the pro-inflammatory state of circulating monocytes of naturastically treated patients 
with bipolar disorder (BD patients) and detected in the monocytes a coherent, mutually-
correlating set of 19 aberrantly expressed inflammatory genes (“a gene signature or 
fingerprint”), supporting the concept of an activated inflammatory response system (IRS) 
in mood disorders [2].
Since the concept of an activated IRS also extends to schizophrenia [2], we hypothesized 
that the same or a similar abnormal inflammatory gene fingerprint could also be found 
in monocytes of patients with schizophrenia (SZ patients) and we decided to test for 
the 19 aberrantly expressed “bipolar signature genes” in the circulating monocytes of 
naturalistically treated SZ patients. In addition, we searched for new “schizophrenia 
inflammatory genes” using Affymetrix whole genome expression profiling on monocytes 
of SZ patients and selected those genes which were markedly aberrantly expressed and 
clearly involved in inflammation (yielding 15 “new” genes, for details see Results). 
Autoimmune diabetes, thyroiditis and gastritis are about three times more prevalent in 
BD [3], whereas autoimmune thyrotoxicosis and Sjogren’s disease are more prevalent 
in SZ [4]. Given our recently reported overlap in monocyte gene expression signatures 
between BD and autoimmune diabetes, we additionally included in our analysis 6 “specific 
autoimmune diabetes signature monocyte genes [5]” to be complete. 
Thus, using Q-PCR, we validated for this report the abnormal expression of in total 34 
monocyte activation genes in 27 patients with schizophrenia (compared to monocytes 
of 32 age/gender matched healthy controls) and 56 patients with bipolar disorder (42 
patients of the reported series [1] plus 14 new cases, altogether compared to monocytes 
of 48 age/gender matched healthy controls).  
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Patients and Methods
Patients with Schizophrenia: 
Patients with schizophrenia were diagnosed according to the DSM-IV criteria and recruited 
at the department of Psychiatry of the Erasmus Medical Center in Rotterdam. All patients 
were in-patients. Patients were diagnosed with schizophrenia according to the DSM-IV 
criteria after a Comprehensive Assesment of Symptoms and History (CASH) interview [6] 
and by consensus between two senior psychiatrists who were blinded to the results. For 
patients with symptoms for less than 6 months, a final diagnosis was made after 6 months 
to comply with the DSM-IV criterium. All patients were acutely psychotic.
The SZ patients were virtually all recent onset cases and had a median duration of illness 
of only 0.3 yrs (median, range 0-3 yrs). All cases did not suffer from another severe medical 
illness (including infections and allergies), verified with a medical history assessment 
and routinely laboratory testing (Hb, Ht, leukocyte count, blood smear and kindney/liver 
function) on admission.
For Affymetrix micro array analysis (searching for aberrantly expressed genes in monocytes) 
two monocyte pools of schizophrenia patients were used. Each pool was compared 
to a monocyte pool of age- and gender-matched HC (pools were used for minimizing 
inter-individual differences in mRNA expression and to reduce costs for this expensive 
methodology): Patient pool 1 consisted of 4 male cases, ages 22, 26, 27 and 20 yrs, patient 
pool 2 consisted of three male cases, ages 17, 19 and 27 yrs. Pool 1 and 2 were compared 
to 2 healthy control pools of 2X2 males, ages between 22 and 26 yrs.
For Q-PCR (verifying the found genes) 27 additional SZ patients diagnosed according to 
the DSM-IV criteria were recruited at the department of Psychiatry of the Erasmus Medical 
Center in Rotterdam. 
All but one of the patients received antipsychotic medication at the time of blood 
withdrawal; none of the patients were drug naïve. The demographics, duration of illness 
and drug usage, of the patients used in Q-PCR are summarized in Table I. 
For the Q-PCR on SZ patients we used a control group of 32 healthy individuals (HC), 
who were age/gender matched to the SZ patients. These were recruited from enrolling 
laboratory staff, medical staff and medical students (Table I). The inclusion criteria for the 
HC were an absence of any psychiatric and autoimmune disorder and an absent history 
of these disorders in first-degree family members. HC had to be in self-proclaimed good 
health and free of any obvious medical illness for at least two weeks prior to the blood 
withdrawal, including acute infections and allergic reactions. 
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Table I. Characteristics of schizophrenia and bipolar patients and their respective healthy 
controls used for Q-PCR.
Schizophrenia Matched Healthy Controls
Group size 27 32
Age (years)1 27  (17-59) 27 (21-47)
Gender
Male 22  (81%) 25 (78%)
Female 5  (19%) 7 (22%)
Duration illness (years)1 0.3  (0-3)
Age of onset1 26  (17-58)
Medication
Typical antipsychotics 10  (37%)
Atypical antipsychotics 15  (56%)
Other 1  (4%)
None 1  (4%)
         
 
Bipolar Disorder 2,3 Matched Healthy Controls
Group Size 56 48
Dutch twin study 37
Dutch site SFBN 19
Age (years)1 42  (26-61) 42 (23-57)
Gender
Male 22 (39%) 20 (42%)
Female 34 (61%) 28 (58%)
Duration illness1 16 (3.5-40)
Age of onset1 26  (6-49)
Medication
Lithium 32
Antipsychotics 8
Antipsychotics and lithium 5
Other 11
1Mean (range)
2 The bipolar patients did not have a history of drug or alcohol dependency for at least six months; 
this was not known for the schizophrenic patients. 
3 Data on 42 of these 56 patients have been given before in Padmos et al (Padmos et al. 2008a) 
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Patients with Bipolar Disorder: 
In total, 56 outpatients with DSM-IV bipolar I or II disorder were recruited from two studies, 
i.e. the Dutch site of the former Stanley Foundation Bipolar Network (SFBN), an international 
multi-center research program described elsewhere in detail [7] (n=19 patients) and from 
an ongoing Dutch twin study on bipolar disorder described in detail in Vonk et al [8] 
(n=37). Characteristics of BD patients are given in Table I. Diagnosis was also made by 
means of the SCID. Present mood state was evaluated via the Young Mania Rating Scale 
(YMRS) and the Inventory for Depressive Symptomatology (IDS). The BD patients did not 
have another severe medical illness, verified with a medical history assessment.  
Since age and gender differed between our BD and SZ patients (Table I) we compared 
outcomes of the bipolar group to those of an extra group of 48 HC, who were age/gender 
matched to the BD patients (Table I). For inclusion criteria of the HC see above. 
The Medical Ethical Review Committee of the University Medical Center Utrecht (bipolar 
patients) and the Medical Ethical Review Committee of the ErasmusMC Rotterdam 
(schizophrenia patients) had approved the studies. Written informed consent was 
obtained from all participants after a complete description of the study had been given. 
Laboratory methods
Blood collection and preparation
Blood (drawn in the morning hours) was collected in clotting tubes for serum preparation 
(stored at -80°C) and in sodium-heparin tubes for immune cell preparation. From the 
heparinized blood, peripheral blood mononuclear cell (PBMC) suspensions were prepared 
in the afternoon by low-density gradient centrifugation, as described in detail before [9], 
within 8 hours to avoid activation of the monocytes (erythrophagy). PBMCs were frozen 
in 10% dimethylsulfoxide and stored in liquid nitrogen. This enabled us to test patient and 
control immune cells in the same series of experiments later. 
Isolation of monocytes 
CD14 positive monocytes were isolated from frozen PBMCs by magnetic cell sorting system 
(Miltenyi Biotec) The purity of monocytes was > 95% (determined by morphological 
screening after trypan blue staining and FACS). As reported elsewhere positive versus 
negative selection of immune cells did not influence gene expression profiles [10].
Affymetrix whole genome gene expression profiling
RNA was isolated from purified monocytes using RNAeasy columns as described by the 
manufacturer (Qiagen) and previously [11]. Fragmented cRNA was hybridized to U95Av2 
microarrays (Affymetrix, manufacturer’s protocol). For all experiments, the 5’ / 3’ ratios of 
GAPDH were 2 or less (usually 0.9 – 1.1). 
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Quantitative –PCR (Q-PCR)
RNA was isolated from monocytes as described above. To obtain cDNA for Q-PCR, one mg 
RNA was reversed-transcribed using the cDNA high capacity cDNA reverse Transcription 
kit (Applied Biosystems).Q-PCR was performed as previously described in detail [11] and 
in the legend of Table II. 
Statistics
Scanned micro array images were analyzed using Affymetrix Microarray Suite 4.2 software. 
Further analysis was performed using RMA software, modification de Ridder [12] and 
Ingenuity Systems (www.ingenuity.com) software. Statistical analysis was performed using 
the SPSS 15.0 package for Windows. Data were tested for normal distribution using the 
Kolmogorov-Smirnov test. Depending on the distribution pattern and the total number 
of subjects, parametric (normal distribution and ≥ 50 subjects) or non-parametric tests 
(skewed distribution or <50 subjects) were used. Bonferroni correction for multiple testing 
was used for the Affymetrix data (since this was a non-hypothesis driven approach). 
Correction for multiple testing was not used for the analysis of the Q-PCR data, because 
we focused in on the effect of specific genes found in Affymetrix analysis.. The specific 
tests used are mentioned under tables and in legends.
Table II. Q-PCR analysis of monocytes of bipolar patients (n=56, 42 from a previous study 
(Padmos et al. 2008a) plus 14 new cases) and schizophrenia patients (n=27) as compared to 
healthy control values (HC SCZ: n=32; HC BD n=48), set at 1 fold.
Schizophrenia Bipolar Disorder   
Genes selected by whole genome screening in this study in schizophrenia
EGR3 5,361  < 0,013     2,52   0,16   
MXD1 1,49   < 0,01     1,43   0,06   
MAFF 5,10   < 0,01     2,95   0,01   
F3 5,56   < 0,01     1,87   0,02   
SERPINB2 1,84 < 0,01    1,10   0,06   
THBS 4,31   < 0,01     2,02   0,05   
EREG 7,36   < 0,01     2,31   < 0,01   
CXCL3 3,99   < 0,01     3,33   < 0,01   
RGC32 0,852   0,07     2,61   < 0,01   
Genes selected in a previous study on bipolar patients (Padmos et al. 2008a)
DUSP2 5,36   < 0,01     4,96   < 0,01
ATF3 3,50   < 0,01     3,55   < 0,01
MAPK6 1,21   < 0,01     1,80   < 0,01   
PDE4B 3,91   < 0,01     3,00   < 0,01   
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Schizophrenia Bipolar Disorder   
IL6 7,89   < 0,01     5,39   < 0,01     
IL1B 9,20   < 0,01     6,45   < 0,01     
TNF 3,91   < 0,01     1,87   < 0,01     
TNFAIP3 3,22   < 0,01     2,31   < 0,01     
BCL2A1 2,39   < 0,01     3,30   < 0,01     
PTX3 2,51   < 0,01     2,63   < 0,01     
PTGS2 4,34   < 0,01     3,20   < 0,01     
CCL7 1,12   < 0,01     8,47   < 0,01     
CDC42 1,49   < 0,01     1,99   < 0,01     
CCL20 23,53   < 0,01     10,63   < 0,01   
CXCL2 3,76   < 0,01     5,31   < 0,01   
CCL2 1,60   < 0,01     3,83   < 0,01   
CCR2 0,85   0,53     0,62   0,10   
NAB2 0,76   0,21     2,58   < 0,01   
EMP1 0,97   0,88     2,19   < 0,01   
Genes selected in previous study on autoimmune diabetes (Padmos et al. 2008b)
PTPN7 0,78   0,04     2,04   < 0,01   
CD9 1,49   0,59     2,16   < 0,01   
STX-1A   0,64   0,22     3,04   < 0,01   
DHRS3 1,08   0,51     1,87   0,08   
FABP5 1,08   0,75     1,21   0,09   
HSPA1A 1,06   0,93     0,79   0,40   
Q-PCR was performed with Taqman Universal PCR mastermix (Applied Biosystems, Foster City, CA). 
All Taqman probes and consensus primers were pre-formulated and designed by Applied Biosystems 
(Assays on Demand, see supplementary Table 1). PCR conditions were 2 min at 50°C, 10 min at 95°C, 
followed by 40 cycles of 15 s at 95°C, and finally 1 min at 60°C. PCR amplification of the reference gene 
ABL was performed for each sample to allow normalization between the samples. ABL was chosen 
as a reference gene because it was previously shown that ABL was the most consistently expressed 
reference gene in haematopoietic cells (Beillard et al. 2003). The quantitative value obtained from 
Q-PCR is a cycle threshold (CT). The fold change values between different groups were determined 
from normalized CT values (CT gene- CT housekeeping gene), by the ΔΔCT method (2-ΔΔCT, User 
Bulletin 2, Applied Biosystems, Foster City, California). To correct for inter-assay variance, we set the 
mean of the studied genes found in the healthy control groups in the same assay for each gene to 
1 (∑ΔCT HC= 0, 2-0=1). The fold change values of the genes in patient monocytes were expressed 
relative to this set mean of 1.
Data are expressed relative to this HC value. HC SCZ: n = 32; HC BD: n = 48
1 Values >1: patients have a higher expression than control group. 
2 Values<1: patients have a lower expression than control group. 
3 P tested by univariate ANCOVA vs. control subjects; age and gender are included in this model.
Purity of monocytes was over 90% (as determined by morphology on each sample) and over 92% as 
determined by FACS analysis. Yield of monocytes was 28% (±10%) in the patient groups group and 
21% (±8%) for the HC group (n.s.) of the Ficoll-isolated peripheral blood mononuclear cells. 
The ΔCT values are available in the Supplementary Table I
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Results
Whole genome expression profiling of potential inflammatory biomarker genes in 
monocytes of schizophrenia patients 
Affymetrix micro array analysis was performed to search for aberrantly expressed genes 
in monocytes on two monocyte pools of naturalistically treated SZ patients. Each pool 
was compared to a monocyte pool of age- and gender-matched HC (pools were used 
for minimizing inter-individual differences in mRNA expression and to reduce costs for 
this expensive methodology): All raw data obtained by Affymetrix analysis are available as 
MIAMExpress submission (http://www.ebi.ac.uk/miamexpress/).
We analyzed the data using a modified RMA analysis [12] and considered for Ingenuity 
analysis genes which were more than 2 fold statistically differentially expressed (p < 
0.01, corrected for multiple testing) between SZ patients and HC. This resulted in 298 
discriminating genes (185 up regulated and 113 down regulated). Major pathways found 
in Ingenuity analysis were pathways involved in inflammatory and immune mediated 
disease. To select for genes which could serve as potential biomarkers for the “schizophrenia 
inflammatory condition”, we took the top genes from the up and down list, which were 
statistically more than 3.5 fold significantly differentially expressed between SZ and HC 
with the purpose of only identifying strongly discriminating genes. This resulted in 22 over 
expressed genes. None of the genes was more than 3.5 fold lower expressed (the first gene 
of the list of the lower expressed genes was CCR2, which was 2.9 fold lower expressed, 
but this gene had already been selected in our previous bipolar study [1]). Because we 
were searching for regulators and biomarkers of inflammation, out of these 22 aberrantly 
expressed genes we selected only genes clearly involved in inflammation. This resulted 
in 14 selected aberrantly expressed genes for SZ, and it is of note that five of these genes 
had previously been found over expressed in bipolar patients, i.e. PDE4B, IL1, PTGS2/COX2, 
CCL20 and CXCL2 [1], pointing to a strong overlap of inflammatory set points between 
monocytes of bipolar disorder and schizophrenia. In sum, 9 new “schizophrenia specific” 
up-regulated genes (MXD1, F3, MAFF, EGR3, THBS, SERPINB2/PAI-2, RGC32, EREG and 
CXCL3) were finally selected and we included these 9 new genes together with the 19 
aberrantly expressed “bipolar signature genes” and the 6 “autoimmune diabetes signature 
genes” in the validating Q-PCR analysis of the 27 SZ patients, 56 BD patients (42  patients 
of the previous reported study of Padmos [1] plus 14 new cases) and their 32 and 48 
matched healthy controls respectively.
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RQ-PCR analysis of monocytes of schizophrenia and bipolar patients. 
Table II (and Supplementary Table I) show that of the 34 genes tested, the mRNA expression 
levels of 25 genes were significantly different (p < 0.05 by ANCOVA, corrected for age and 
gender) in the monocytes of the 27 SZ patients as compared to HC, while in the monocytes 
of the 56 BD patients 27 genes were significantly different expressed. Data obtained in RQ-
PCR on the mRNA expression levels of the various genes in the patient groups correlated 
very strongly to those obtained in the above-described Affymetrix analysis (SZ: r = 0.708, 
BD: r = 0.663, Spearman’s Rho).
There were no differences in mRNA gene expression for the different groups of healthy 
controls (Supplementary Table I).
The aberrantly expressed genes were mostly shared between the 2 disorders but also in 
part not shared. Of the 9 “schizophrenia specific” genes, 8 were confirmed in RQ-PCR in 
schizophrenia (RGC32 appeared not to be higher expressed); while in bipolar patients 5 
of these genes were significantly higher expressed (MAFF, F3, EREG, CXCL3 and RGC32).
Of the 19 “bipolar signature genes” 16 were statistically significant up-regulated in 
schizophrenia, while for 3 genes statistical significance was not reached (CCR2, NAB2 and 
EMP1). Confirming our previous data, we found almost all 19 “bipolar signature genes” 
(apart from CCR2) statistically significant over expressed in this extended set of bipolar 
patients. 
Of the 6 “autoimmune diabetes signature genes”, 5 were not aberrantly expressed in 
schizophrenia, while PTPN7 was statistically significantly down-regulated. Interestingly, in 
the bipolar sample 3 of the 6 genes were up regulated, including PTPN7. 
Cluster analysis and identification of sub-clusters in the pro-inflammatory signature
To study their mutually interdependent state in expression, we subsequently performed 
a cluster analysis on the RQ-PCR data. The heat map and dendrograms of this analysis are 
given in Fig 1a. In sum, expression levels of virtually all genes correlated to each other, 
yet two sub-clusters of mutually very strongly correlating genes (correlation coefficient 
higher than 0.60) could clearly be identified (two major red blocks in the figure), each 
predominantly correlating to a different set of transcription/MAPK regulating factors, i.e. 
ATF3/DUSP2 and PTPN7/NAB2 respectively. These two sets of transcription factors were 
mutually, but not strongly, correlating (Fig 1b). 
The first sub-cluster correlating to ATF3 and DUSP2 consisted predominantly of various 
well-known inflammatory compounds, such as the pro-inflammatory cytokines IL-1, IL-6 
and TNF, the inflammatory compounds PTGS2/COX2 and PTX3, various inflammatory 
chemokines (CCL20, CXCL2 and CXCL3) and PDE4B (Fig 1b).
The second sub-cluster (further indicated as sub-cluster 2) correlating to PTPN7 and NAB2 
consisted predominantly of various adhesion/motility/chemotactic factors, such as EMP1, 
CDC42, CCL2 and CCL7 (Fig 1b).
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Table III 
  SCZ     BD  
CLUSTER 1A
DUSP2 5.36 < 0,01 4.96 < 0,01
ATF3 3.50 < 0,01 3.55 < 0,01
PDE4B 3.91 < 0,01 3.00 < 0,01
IL6 7.89 < 0,01 5.39 < 0,01
IL1B 9.20 < 0,01 6.45 < 0,01
TNF 3.91 < 0,01 1.87 < 0,01
TNFAIP3 3.22 < 0,01 2.31 < 0,01
BCL2A1 2.39 < 0,01 3.30 < 0,01
PTX3 2.51 < 0,01 2.63 < 0,01
PTGS2 4.34 < 0,01 3.20 < 0,01
CCL20 23.53 < 0,01 10.63 < 0,01
CXCL2 3.76 < 0,01 5.31 < 0,01
EREG 7.36 < 0,01 2.31 < 0,01
CXCL3 3.99 < 0,01 3.33 < 0,01
CLUSTER 1B
MxD 1.49 < 0,01 1.43 0.06
F3 5.56 < 0,01 1.87 0.02
MAFF 5.10 < 0,01 2.95 0.01
EGR 3 5.36 < 0,01 2.52 0.16
THBS 4.31 < 0,01 2.02 0.05
PAI-2 1.84 < 0,01 1.10 0.06
RGC32 0.85 0.07 2.61 < 0,01
CLUSTER 2
HEPTP 0.78 0.04 2.04 < 0,01
NAB2 0.76 0.21 2.58 < 0,01
MAPK6 1.21 < 0,01 1.80 < 0,01
EMP1 0.97 0.88 2.19 < 0,01
STX-1A 0.64 0.22 3.04 < 0,01
DHRS3 1.08 0.51 1.87 0.08
CCL2 1.60 < 0,01 3.83 < 0,01
CCL7 1.12 < 0,01 8.47 < 0,01
CDC42 1.49 < 0,01 1.99 < 0,01
FABP5 1.08 0.75 1.21 0.09
CD9 1.49 0.59 2.16 < 0,01
HSP 70 1.06 0.93 0.79 0.40
CCR2 0.85 0.53 0.62 0.10
The quantitative value obtained from Q-PCR is a cycle threshold (CT). The fold change values between 
different groups were determined from the normalized CT values (CT gene- CT housekeeping gene), via 
the ΔΔCT method (User Bulletin, Applied Biosystems). The fold change of the HC was set to 1.
Data are expressed relative to this HC value. HC SCZ: n = 32; HC BD: n = 48
Values >1: patients have a higher expression than control group. Red indicates significantly up regulated. 
Values<1: patients have a lower expression than control group. Green indicates significantly down 
regulated.  P tested by univariate ANCOVA vs. control subjects; age and gender are included in this model.
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In careful analysis (Fig1b and Supplementary Fig 1), sub-cluster 1 contained a further 
sub-cluster consisting of the transcription factors EGR3 and MXD1, which were mutually 
strongly correlating and strongly to the transcription factors MAFF and F3, but more 
weakly to ATF3/DUSP2 and PTPN7/NAB2 (Fig 1b, this sub-sub cluster is further indicated 
as sub-cluster 1B, the other remaining set being sub-cluster 1A). 
The expression of the three sub-clusters in schizophrenia and bipolar disorder
Table III and IV show that sub-cluster 1A is expressed in the monocytes of both SZ and BD 
patients. If one defines sub-cluster 1A positivity as positive for ATF3 and/or DUSP 2 (i.e. an 
expression level higher than the mean + one standard deviation of the healthy control 
values) 67% of BD and 52% of SZ patients are positive versus 24 and 24% of their matched 
healthy controls respectively (Table IV).
With regard to sub-cluster 1B, Table III and IV show that SZ patients and BD patients are 
positive, but in lower proportions. Using the same type of definition as for sub-cluster 1A 
(but now for EGR3 and/or MXD1), it appeared that SZ patients were significantly positive 
for 41 % versus 34% of BD patients (versus 13 and 22 % of their HC, Table IV). 
With regard to sub-cluster 2, Table III and IV show that only BD patients show an up 
regulation of these genes. Interestingly, SZ patients show a significant down regulation of 
two transcription factors belonging to this sub-cluster, i.e. PTPN7 and NAB2 (significant for 
PTPN7), while MAPK6 is up regulated (yet not to the same extent as in BD). It is noteworthy 
that the adhesion/motility factors EMP1 and STX1A are down-regulated too. If one defines 
sub-cluster 2 positivity as positive for PTPN7 and/or NAB2 (see above for definition), even 
a significantly reduced expression in SZ versus HC can be seen (7 % versus 21%), while in 
BD there is a significant increased expression (62% versus 32%) (Table IV). Vice versa, if sub-
cluster 2 is defined as a ”negative” signature (Table IV, last column) a higher proportion of 
SZ patients is positive for such reduced expression (48%).
Table IV. The prevalence of sub-clusters in bipolar patients, schizophrenia patients and 
healthy controls
Cluster 1a Cluster 1 b Cluster 2 Cluster 2
Dusp2 and/or 
ATF3 positivity
MXD1 and/or 
EGR3 positivity
PTPN7 and/or NAB2 
positivity
PTPN7 and/or 
NAB2 negative
Schizophrenia 52%  (14/27)a 41% (11/27)a 7%  (2/27)b 48% (13/27)ab
Healthy Controls 24% (7/29) 13% (4/30) 21% (6/29) 21% (6/29)
Bipolar Disorder 67% (26/39)a 34% (12/36) 62% (24/39)a   5% (2/39)a
Healthy Controls 24% (10/41) 22% (8/36) 32% (13/41) 25% (10/40)
a p < 0.05 vs. healthy controls
b p < 0.05 vs. bipolar disorder
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Positive is defined as an mRNA expression more than one SD away of the mean level 
found in the healthy controls. Signature is defined on the transcription factors positive. P 
Values are obtained from Chi-squared test
Relation of monocyte inflammatory gene expression to medication use, disease 
duration and disease activity.
Medication use. To test for the influence of lithium and antipsychotics, we turned to the 
group of BD patients, since virtually all patients with SZ were on anti-psychotics; only one 
was not, but had used an anti-psychotic in the past. Of the 56 BD patients, 32 were on 
lithium, 8 were on anti-psychotics, 5 used both and 11 were at the time of blood extraction 
not on lithium or an anti-psychotic, but had used this medication in the past (more than 6 
months ago). Table Va shows the effects of the medications in this BD group. Use of lithium 
and antipsychotics either alone or in combination resulted in a significant decrease of 
PDE4B, but not of other genes (though there was a near significant trend for a decreasing 
effect of lithium and antipsychotics on other important signature 1A genes such as IL1 
and TNF).
Table V. Correlations of aberrant gene expression 
A. With medication use in bipolar patients. 
Medication Genes p B 95% Confidence 
Interval
Lithium PDE4B 0.002 down -12.302 -4.736 to -19.867
Antipsychotics PDE4B 0.002 down -16.613 -6.555 to -26.671
Both PDE4B 0.005 down -17.142 -5.468 to -28.817
Linear regression with lithium, antipsychotics and both medications were included in the model. 
The values of patients on the indicated drug are set to 1 in the model. B=regression coefficient. 
B. With the mood status of bipolar patients 
Genes Depressive (n=9) vs Euthymic (n=40) Manic (n=7) vs Euthymic (n=40)
B 95%  CI p B  95%  CI p
CCL2 105,24 37,49 – 172,98 0,003 22,93 -44,81 – 90,68 0,500
STX1A 36,59 13,52 – 59,69 0,002 8,77 -14,30 – 31,83 0,449
DHRS 9,91 3,00 – 16,83 0,006 -0,28 -6,78 – 6,22 0,930
PTPN7 3,82 1,08 – 6,56 0,007 2,25 -0,49 – 4,99 0,106
MAPK6 2,76 0,83 – 4,69 0,006 2,29 0,36 – 4,22 0,021
EMP1 12,72 7,31 – 18,12 0,001 3,83 -1,58 – 9,24 0,161
Determination of the influence of mood on mRNA expression of molecules via ANCOVA analysis. 
The values of patients with an euthymic mood are set to 1. B = regression coefficient.
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With regard to sub-cluster 2 genes there was a near significant increasing trend of the 
use of antipsychotics in BD patients on genes such as PTPN7, NAB2 and STX1A (data not 
shown). This increasing effect of anti-psychotics on sub-cluster 2 genes was also reflected 
in the “lifetime cumulative antipsychotic drug usage in haloperidol equivalents” which 
positively and significantly correlated to important sub-cluster 2 genes as PTPN7 (r=0,55), 
HSPA1A (r=0,61) and EMP1 (r=0,62). 
Duration of illness. The patients with schizophrenia were in general recent onset cases and 
had a median duration of illness of only a couple of months (Table I). Effects of duration of 
illness were not noticeable. 
The BD patients had a median duration of illness of 16 years (range 3.5 – 40 years, Table 
I); in this latter group there was a weak, though significant correlation between disease 
duration and the expression of some of the signature genes: we found a weak positive 
correlation for IL6, PTX3, CCL2 and EMP1 (r=+ 0.30 to 0.40) and a weak negative correlation 
for HSPA1A (r= - 0.30), indicating a slightly stronger expression of part of the inflammatory 
fingerprint over years.
Disease quality and severity. In the SZ patients disease quality and severity (as expressed in 
the various PANSS scales) did not correlate to any of the various gene expression levels.
With regard to BD we previously reported [1] that the actual mood status of the patients 
tested was to some extent related to the inflammatory gene expression: During a manic 
episode, the mRNA expression of 2/19 genes were significantly increased in monocytes 
of manic versus euthymic BD patients; during depressive episodes 6/19 genes. In the 
presently extended series of 56 bipolar patients we largely confirmed this observation and 
now found 1/34 genes during mania (n = 7 patients) and 6/34 genes during depression 
(n = 9 patients) raised (in comparison to euthymic patients (n = 40 patients), Table Vb). 
Interestingly these were all cluster 2 genes. Although active disease thus is related to a 
higher expression of many of the cluster 2 signature genes (in depressive phases more 
than in manic phases), it must be noted that virtually all of the cluster 2 genes were still 
significantly higher in euthymic bipolar patients as compared to healthy controls.
Inflammatory gene expression at the protein level.
We previously reported on the IL1β, IL6, TNFα, CCL7 and CCL2 levels in the serum of 
these sets of BD and SZ patients [1, 13], and found that only IL1β was increased in BD 
(as compared to HC), while IL1β, IL6, TNFα and CCL2 were all increased in SZ patients (as 
compared to HC). 
With regard to PTX3 we were able to measure in this study serum levels and found these 
increased in BD and SZ patients (Figure 2). The figure shows that in BD and SZ PTX3 serum 
levels are significantly raised over HC levels, i.e. about 2.5 fold in BD and about 1.5 fold in 
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SZ. When we correlated serum PTX3 protein levels to monocyte gene expression levels 
we found a significant positive correlation, though weakly (r=0,184, p=0.05, Spearman’s 
correlation), indicating that factors other than monocyte gene expression also determine 
serum PTX3 levels. 
Figure 2: Serum PTx3 levels in bipolar (BP) patients, schizophrenia (SCZ) patients and healthy 
controls (HC).
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Box plots of PTX3 are given. The serum PTX3 level was determined via an in-house ELISA (M7M) 
on the serum of 58 bipolar patients, 181 schizophrenia patients and 188 healthy controls, some 
of whom were also used for Q-PCR used according to the manufacturer’s protocol (for patient 
details see [13]). The box indicates the lower and upper quartiles. The line within the box represents 
the median. The whiskers extend to the 2.5 and 97.5 percentiles. The outliers are characterized by 
the filled dots. ANCOVA was used for statistical evaluation. Age and gender were included in the 
statistical model, other confounding factors such as adiposity could however not be investigated, 
since we were not informed on the BMI in the majority of the cases tested here. The figure shows that 
in bipolar disorder and schizophrenia, PTX3 serum levels are significantly raised over healthy control 
levels, i.e. about 2.5 fold in bipolar disorder and about 1.5 fold in schizophrenia. Correlating serum 
PTX3 protein levels to monocyte gene expression levels we found a significant positive correlation, 
although it was only weakly so (r=0,184, p=0.05, Spearman’s correlation).
Discussion
The outcomes of our study show that circulating monocytes are set at a high inflammatory 
gene expression set point in both schizophrenia and bipolar disorder. On the protein level 
these high gene expression set points were (weakly, but significantly) reflected in high 
serum levels of pro-inflammatory cytokines and compounds. 
Though monocytes of BD and SZ patients clearly overlapped in signature gene expression 
sets 1A and B, they also differed with regard to signature gene expression set 2: We 
found the MAPkinase regulating factors PTPN7 and NAB2 up-regulated in monocytes of 
BD patients, but down-regulated in monocytes of SZ patients. Our immune biomarker 
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approach thus made a distinction between BD and SZ possible. Though thus supporting 
the dichotomy between BD and SZ as introduced in 1899 by Kraepelin [14], our immune 
data also lend support to the recently expressed view by geneticists [15-18] that BD and 
SZ are strongly overlapping entities sharing the same vulnerability genes, since we found 
monocytes of considerable proportions of BD and SZ patients to share an up regulated 
pro-inflammatory gene sub-cluster 1A, composed mainly of a network of well known 
pro-inflammatory cytokines and compounds such as IL1, IL6, TNF, PTGS2/COX2 and PTX3, 
many of which have previously been found up-regulated mainly at the protein level in 
mood disorders and schizophrenia [1, 13]. 
In addition, we found monocytes of particularly SZ patients  to be set at a further and higher 
inflammatory set point, due to an extra up regulation of in particular the transcription 
factors/regulators EGR3, MXD1, MAFF and F3. These transcription factors/regulators are 
mainly involved in proliferation and differentiation of monocytes, but also play a role in 
the regulation of the inflammatory set point of monocytes/macrophages [19-24]. Our 
data, which show a strong correlation of EGR3, MXD1, MAFF and F3 to the inflammatory 
cytokines and compounds to which ATF3 and DUSP2 were also correlating, supports 
such view of involvement of these transcription factors in inflammation. Interestingly, the 
expression of EGR3, MXD1, MAFF and F3 were in particular correlated to the up regulation 
of the adipogenic and vascular pathology factors THBS and SERPINB2/PAI-2, and it is here 
of note that the incidence of the metabolic syndrome is increased in BD and SZ [25]. 
Our study has limitations. Firstly, patients with schizophrenia were predominantly male and 
young in the age group of 20 years and virtually all had recent onset disease and were on 
antipsychotic medication; the BD patients were predominantly female in the age group of 
40 years, had mainly longstanding disease and many used lithium and/or antipsychotics. 
All patients were naturalistically treated and none of our patients was “treatment naïve”. It 
could be argued that age and gender simply explained the differences between SZ and 
BD and that medication is the causal factor for the high inflammatory gene expression 
level in monocytes of psychiatric patients. 
With regard to age and gender, it must be noted that we compared the patient findings with 
those of age and gender matched control groups and that the monocyte inflammatory 
state in these control groups of different age and gender did not differ (Supplementary 
Table I). 
With regard to the effects of medication it must be noted that effects of lithium and anti-
psychotics are generally anti-inflammatory in character [26-28] and the data presented 
here, as well as our previous data [1], support such an immune suppressive action and 
show that, if any, these medications do not induce but correct the abnormal inflammatory 
set point of patient monocytes (see Table Va). However we can not totally rule out an 
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important effect of elicit drugs on the induction of the specific characteristics of the 
schizophrenic monocyte signature, since our study group of SZ patients was not controlled 
for this variable (the BD patients were, see Table I). 
Another limitation is that we have made in our experimental design a selection of aberrantly 
expressed genes by selecting in whole genome analysis only highly over and under 
expressed genes (more or less than 3.5 fold), which were clearly involved in inflammation 
and inflammatory processes. Although this approach proved to be fruitful in detecting 
the three fingerprint patterns as described here (which also made a distinction between 
BD and SZ possible), we may have missed important causal genes for the inflammatory 
set points, since our assumption that the sheer expression level of genes is important for 
the inflammatory state, is naïve. Clearly, further studies of additional genes that are less 
aberrantly expressed but are critically involved in inflammation and/or have previously 
been described as aberrant in psychiatric disorders are clearly needed to see whether they 
are essential components of the inflammatory monocyte gene fingerprints. 
The criteria used in psychiatry for validating nosological categories have usually been 
restricted to clinical features, outcome and family history [29]. Kraepelin used these tools 
in formulating his ideas, leading to his dichotomous classification between schizophrenia 
and bipolar disorder. Given that the main goal of modern psychiatry is to provide effective 
treatment, the view has been expressed that the ultimate validator for a diagnostic system 
must be treatment response based on a detailed knowledge of pathogenesis [18].
Our study, using powerful new research genomic tools, precisely provides such new 
immune biological validators, which probably not only play a role in the immune 
pathogenesis of schizophrenia and bipolar disorder but are also potential treatment 
targets. There are several reports indicating that pharmacological interferences with some 
of the found up-regulated inflammatory signature genes, i.e. interference with PTGS2/COX-
2, PDE4B and TNF, may alleviate signs and symptoms of schizophrenia and depression [30-
37] and it can thus be envisaged that in particular patients positive for monocyte cluster 1 
genes would benefit from a treatment with COX-2, PDE4 and TNF inhibitors. 
In conclusion, we here describe the first steps in an immune molecular dissecting 
approach on inflammatory monocytes, which have already led to the identification of 3 
coherent sets of putative immune biomarker genes, opening new avenues for nosological 
distinctions in psychiatric disease based on inflammation. Our approach could also lead 
to putative sub-classification of patients with psychotic or bipolar disorder, who could 
possibly benefit from adjunctive anti-inflammatory treatment targeting important 
fingerprint genes. 
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Supplementary table I.  ΔCT values (mean, SD) of Q-PCR Analysis of Monocytes of Bipolar 
Patients, Schizophrenia Patients and Healthy Controls.
Gene BD HC-BD SCZ HC-SCZ p-value
PDE4B -3.32 1.40 -1.72 1.90 -2.59 1.87 -0.81 1.70 0.901
MAPK6 -3.13 1.26 -1.98 1.79 -1.13 0.98 -1.01 0.75 0.515
DUSP2 -2.55 1.65 0.08 2.25 -2.10 1.90 0.39 2.39 0.824
NAB2 0.37 2.07 2.76 1.21 2.43 1.06 1.94 1.05 0.011
PTPN7 -0.47 1.69 1.77 0.77 2.11 0.75 1.83 0.59 0.774
ATF3 -3.14 1.50 -0.70 1.78 -1.12 1.34 0.41 1.48 0.703
TNF -3.03 1.63 -1.62 1.60 -4.15 2.70 -2.05 2.39 0.938
IL1B -7.37 2.55 -3.28 2.80 -6.57 3.09 -3.45 2.95 0.561
IL-6 2.19 4.42 5.14 2.77 1.47 4.51 5.51 3.34 0.775
CCL2 -1.69 3.54 2.72 1.74 1.61 1.63 2.73 1.72 0.621
CCL7 -0.18 4.73 6.75 3.19 6.26 3.28 7.25 2.63 0.319
CXCL2 -5.60 2.65 -1.43 2.99 -3.04 2.70 -0.78 2.63 0.936
CCL20 1.39 4.28 4.55 3.77 1.32 5.08 6.05 4.64 0.428
PTX3 -1.83 2.22 -0.15 1.49 -0.75 1.69 0.44 1.26 0.856
PTGS2 -3.60 1.87 -2.13 2.01 -3.74 2.00 -1.35 2.03 0.342
TNFAIP3 -4.36 2.00 -2.78 1.87 -3.88 1.99 -2.78 1.50 0.484
BCL2A1 -5.64 2.75 -2.38 1.87 -5.19 2.20 -3.27 1.70 0.450
EMP1 -2.19 2.12 0.74 1.60 1.94 1.30 1.68 1.23 0.687
CD9 -2.20 1.67 -0.85 1.53 -0.99 1.69 -0.82 1.60 0.313
CDC42 -1.48 2.07 0.72 1.25 -0.11 1.46 1.01 1.28 0.224
STX-1A 2.11 2.94 5.77 1.48 6.53 1.29 6.16 1.11 0.902
DHRS3 -1.54 1.70 1.81 0.86 3.18 1.27 4.16 3.00 0.160
FABP5 -0.75 1.56 -1.45 0.39 -1.94 0.71 -1.96 0.26 0.195
HSPA1A -3.30 1.86 -4.71 1.58 -3.43 1.25 -4.02 1.26 0.197
RGC32 -0.05 2.14 1.74 2.02 1.41 1.69 2.13 1.59 0.908
EREG -0.94 2.50 0.17 1.96 -1.26 2.64 1.61 2.20 0.366
CXCL3 -1.62 3.45 0.91 2.82 -0.95 3.58 2.35 3.31 0.659
F3 1.08 2.20 2.05 2.25 0.99 3.13 3.85 2.61 0.317
THBS -5.69 1.80 -4.65 2.10 -5.37 2.42 -3.36 2.02 0.322
EGR3 -2.34 1.82 -2.09 2.32 -2.43 0.96 -0.36 2.77 0.287
SERPINB2 1.32 2.78 2.61 1.53 1.77 1.80 3.24 1.59 0.101
MAFF -0.38 1.55 1.01 2.11 -0.70 1.33 1.81 2.53 0.699
MXD1 -3.67 0.97 -3.65 0.97 -3.93 0.92 -3.14 0.84 0.666
Delta CT values of HC-BD (n = 48) vs HC-SCZ (n = 32). P values were tested by univariate ANCOVA 
HC-BD vs. HC-SZ; age and gender are included in this model.
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Supplementary Table II. Function of genes.
Gene Function
DUSP2 Transcription factor in the MAPKinase pathway
ATF3 Transcription factor in the MAPKinase pathway
NAB2 Transcription factor involved in repressing the MAPK-pathway
EGR3 Transcription factor involved in early growth response, 
Proliferation/differentiation monocytes
PDE4B Regulation of signal transduction
PAI-2 Adipogenesis, Vascular pathology, Inflammation 
Proliferation and differentiation of monocytes/macrophages
IL6 Inflammation
IL1B Inflammation
TNF Inflammation
PTX3 Inflammation
PTGS2 Inflammation 
TNFAIP3 Apoptosis, Inflammation
BCL2A1 Apoptosis, Cell cycle
CCL2 Chemotaxis, Motility
CCL7 Chemotaxis, Motility
CCL20 Chemotaxis, Motility
CXCL2 Chemotaxis, Motility
EREG Proliferation
CXCL3 Chemotaxis, Inflammation
MXD1 Transcriptional repressor, Proliferation/differentiation monocytes, Cell cycle, 
Apoptosis
F3 Transcription factor involved in blood coagulation, Proliferation/differentiation 
monocytes
MAFF Transcription factor involved in cellular stress response, Proliferation/differentiation 
monocytes
THBS Adipogenesis, Vascular pathology, Adhesion
EMP1 Cell-cell adhesion, Interactions with the extracellular membrane
CD9 Cell adhesion, Migration and Motility
STX-1A Membrane fusion
RGC32 Cell cycle progression, Apoptosis
PTPN7 Transcription factor involved in MAPKinase regulation, T and B cell development
MAPK6 Part of the MAPKinase pathway, Inflammation
CDC42 Signaling in the MAPK-pathway, Motility, Cytoskeletal organization of the cell, 
Chemotaxis
FABP5 Fatty acid uptake, Transport and Metabolism
DHRS3 Vitamin A metabolism, Metabolism
HSPA1A Protein folding, Cellular stress response
CCR2 Receptor for CCL2, Chemotaxis
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Dear Editors,
Serum levels of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α are raised in 
schizophrenia [1]. However, apart from these pro-inflammatory cytokines, chemokines 
play an important role in modulating brain function [2]. The system of chemokines and 
their receptors has been described as a major regulating system of the brain and the 
receptor for CCL2, CCR2, is expressed in the brain by astrocytes, microglia and neurons 
[3]. CCL2 (Chemokine (C-C motif ) ligand 2) is an important pro-inflammatory chemokine, 
playing a key role in the recruitment of monocytes to inflammatory foci [4, 5]. Interestingly, 
a genotypic association was found between the A-2518G polymorphism of the CCL2 
gene and resistance to anti-psychotic medication [6] and a predominance of negative 
symptoms over positive symptoms [7]. The A-2518G polymorphism affects the production 
of CCL2 [6]. However, it is unclear if CCL2 serum levels are changed in patients with 
schizophrenia. One study reported a normal level of CCL2 in the serum of a small group 
of institutionalized male patients [8], while another study reported an elevation of CCL2 in 
the cerebrospinal fluid of a small group of patients with psychosis serving as controls for a 
study on neuro-psychiatric lupus [9]. 
Here we present a study on the CCL2 levels in the serum of 145 patients with chronic 
schizophrenia. Patients participated in a study on the prevalence of abnormalities in 
glucose metabolism in patients with schizophrenia or schizo-affective disorder treated 
with anti-psychotics; the demographic data, study design, hyperglycemia measurements, 
diabetes and metabolic syndrome definition and outcomes have been reported in 
detail before [10]. Adult healthy controls (HC, n = 105) were laboratory, medical staff and 
students, with blood collection at the same time as the patients. The medical ethics review 
board METIGG (Utrecht, The Netherlands) approved the study. 
Serum CCL2 levels were measured using the Cytometric Bead Array kit (CBA, BD 
Biosciences, San Diego, USA) according to the manufacturer’s protocol. Serum levels of 
CCL2 were significantly higher in the 145 patients (Fig 1a, median 196.38 pg/ml, range 
up to 958.45 pg/ml) compared to the 105 HC (median 141.41 pg/ml, range up to 310.35 
pg/ml, p < 0.001). Because patients and HC differed in age and had different male/female 
ratios, data were also analyzed as randomly selected nested case-controls of 65 cases with 
schizophrenia and 65 age and gender matched HC. This nested study showed that CCL2 
levels were also significantly higher in patients (Fig 1a, median 184.67 pg/ml, range up to 
673.23 pg/ml) than in HC (median 151.27 pg/ml, range up to 310.35 pg/ml, p < 0.009). 
Increased CCL2 levels were independent of the use of anti-psychotic medication, both 
regarding the class of drug (typical versus atypical) as well as regarding the individual 
drug. Eleven patients did not use any anti-psychotic drug for at least three months. The 
CCL2 level of this “drug-free” chronic schizophrenic population was higher than that of the 
HC (yet numbers were too small to reach significance). To verify whether the raised CCL2 
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level was indeed not due to treatment we retested the 11 drug-free patients together with 
13 newly collected drug-naïve patients (duration of schizophrenia less than 1 year) and 
36 age and gender matched HC for their CCL2 levels in a separate assay. CCL2 levels were 
statistically significantly higher than the HC (patients: median 302.20 pg/ml, range up to 
595.50 pg/ml; HC: median 154.90 pg/ml, range up to 534.30 pg/ml, p < 0.001).
Serum levels of CCL2 correlated positively (r = 0.152, p < 0.05) to the prevalence of the 
metabolic syndrome (MS, prevalence in our study population 51/145), defined according 
to a modified definition of the National Cholesterol Education Program’s Adult Treatment 
panel III. And, also it correlated in particular and negatively (r = -0.108, p < 0.052) to the 
HDL levels. As a consequence, the levels of CCL2 were significantly higher in patients with 
MS (Fig 1a, median 221.91 pg/ml, range up to 955.60 pg/ml) compared to those without 
(median 179.08 pg/ml, range up to 711.82 pg/ml, p < 0.026), though it must be noted that 
those without MS still had higher serum CCL2 levels compared to the HC population (Fig 
1a, median 141.41 pg/ml, range up to 310.35 pg/ml, p < 0.001). It is tempting to speculate 
that the extra increased CCL2 levels in schizophrenia patients with the MS reflect a higher 
load of atherosclerotic plaques in these patients, since CCL2 plays a critical role in fatty 
streak development, e.g. hypercholesterolemic CCL2 deficient mice have less arterial lipid 
deposition [3]. 
The CBA allows the simultaneous quantification of IL-1β, TNF-α and IL-6 in the same test 
and we found all three cytokines elevated in the patients (Fig 1b). These cytokines did not 
correlate to the MS and there was no difference between cytokine levels in patients with 
or without the MS. The levels of CCL2 showed a strong positive correlation to the levels of 
IL-6, IL-1β and TNF-α. 
Limitation of our study is that outcomes are largely based on patients with chronic stable 
schizophrenia with the vast majority of patients on anti-psychotic medication while 
drug-free/naive patients have hardly been studied. Moreover we were not informed on 
the hyperglycemia and the MS in our HC. So, our finding that CCL2 levels are not due to 
medication and correlate at least in part to the presence of MS (and predominantly to a 
low HDL-cholesterol) should be taken cautiously and needs confirmation in a confirmative 
study using patients before and after treatment characterized for the MS and dito HC. 
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Figure 1a:
CCL2 levels are significantly (p < 0.026) higher in patients with schizophrenia with the metabolic 
syndrome (open diamond: n = 52, median 221.91 pg/ml, range up to 955.60 pg/ml) compared to 
patients without the metabolic syndrome (open circle: n = 93, median 179.08 pg/ml, range up to 
711.82 pg/ml), while the CCL2 levels of the latter group are significantly higher (p < 0.001) compared 
to the levels of healthy controls (open quadrangle: n = 105, median 141.41 pg/ml, range up to 
310.35 pg/ml).
CCL2 levels are also significantly (p < 0.02) higher in the nested age and gender matched patients 
with schizophrenia with the metabolic syndrome (closed diamond: n = 23, median 261.61 pg/ml, 
range up to 673.23 pg/ml) compared to patients without the metabolic syndrome (closed circle: n 
= 42, median 156.63 pg/ml, range up to 435.58 pg/ml), while the CCL2 levels of the latter group are 
significantly higher (p < 0.04) compared to the levels of healthy controls (closed quadrangle: n = 65, 
median 151.12 pg/ml, range up to 310.35 pg/ml).
Fig 1b:
a) TNF-α levels are significantly (p < 0.001) higher in patients with schizophrenia (open circle: n = 145, 
median 22.15 pg/ml, range up to 271.06 pg/ml) compared to healthy controls (open quadrangle: n 
= 105, median 0 pg/ml, range up to 98.68 pg/ml). Note that 49 healthy controls have non-detectable 
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TNF-α levels compared to 38 patients with schizophrenia (indicated by 49 = ☐ and 38 = O). 
TNF-α levels are also significantly (p < 0.035) higher in the nested age and gender-matched patients 
with schizophrenia (closed circle: n = 53, median 20.02 pg/ml, range up to 146.69 pg/ml) compared 
to healthy controls (closed quadrangle: n = 58, median 13.93 pg/ml, range up to 72.35 pg/ml) 
Note that 25 healthy controls have non-detectable TNF-α levels compared to 16 patients with 
schizophrenia (indicated by 25 = ■ and 16 = •).
IL-1β levels are significantly (p < 0.001) higher in patients with schizophrenia (open circle: n = 145, 
median 9.09 pg/ml, range up to 43.34 pg/ml) compared to healthy controls (open quadrangle: n = 
105, median 1.37 pg/ml, range up to 25.80 pg/ml). Note that 51 healthy controls have non-detectable 
IL-1β levels compared to 29 patients with schizophrenia (indicated by 51 = ☐ and 29 = O). 
IL-1β levels are also significantly (p < 0.007) higher in the nested age and gender-matched patients 
with schizophrenia (closed circle: n = 57, median 10.61 pg/ml, range up to 43.34 pg/ml) compared to 
healthy controls (closed quadrangle: n = 62, median 6.89 pg/ml, range up to 20.28 pg/ml). Note that 
26 healthy controls have non-detectable IL-1β levels compared to 11 patients with schizophrenia 
(indicated by 26 = ■ and 11 = •). 
IL-6 levels are significantly (p < 0.001) higher in patients with schizophrenia (open circle: n = 145, 
median 31.95 pg/ml, range up to 617.10 pg/ml) compared to healthy controls (open quadrangle: 
n = 105, median 0 pg/ml, range up to 182.46 pg/ml). Note that 50 healthy controls have non-
detectable IL-6 levels compared to 43 patients with schizophrenia (indicated by 50 = ☐ and 43 = O). 
IL-6 levels are also significantly (p < 0.032) higher in the nested age and gender-matched patients 
with schizophrenia (closed circle: n = 52, median 36.49 pg/ml, range up to 208.47 pg/ml) compared 
to healthy controls (closed quadrangle: n = 57, median 26.20 pg/ml, range up to 115.10 pg/ml). Note 
that 28 healthy controls have non-detectable IL-6 levels compared to 18 patients with schizophrenia 
(indicated by 28 = ■ and 18 = •). 
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Abstract
We recently described a pro-inflammatory gene expression signature in the monocytes of 
60% of patients with recent onset schizophrenia (SCZ). We here investigated whether the 
T cell system is also in a pro-inflammatory state. 
A detailed FACS analysis, e.g. of CD3+CD25+ T cells, IFN-γ+, IL-4+, IL-17A+ (CD4+) lymphocytes 
and CD4+CD25highFoxP3+ regulatory T cells, was carried out on peripheral blood of 26 
patients with recent onset schizophrenia (of whom in 19 the monocyte inflammatory 
gene expression signature had been determined) and in age/gender matched healthy 
controls. Various relevant T cell cytokines, e.g. sCD25, IFN-γ, IL-17A and IL-4, were measured 
in serum by a multiplex assay.
We detected:
a) Not only higher percentages of pro-inflammatory prone monocytes, activated 
CD3+CD25+ T cells and pro-inflammatory Th17 cells in patients, but also higher percentages 
of anti-inflammatory CD4+CD25highFoxP3+ regulatory T cells and IL-4+ lymphocytes. 
b) That this activated T cell set point was reflected in a significantly raised serum level of 
sCD25.
c) That the up regulation of IL-4+ containing lymphocytes was predominantly found in 
patients characterized by a monocyte pro-inflammatory set point. 
d) That regulatory T cell and Th17 cell numbers were higher in patients irrespective of the 
monocyte pro-inflammatory state. 
Our data do not support the concept that the T cell system is in a simple pro-inflammatory 
state in recent onset schizophrenia, but do show that the monocyte and T cell networks 
are activated and involve both pro- and anti-inflammatory forces. This suggests control 
within an activated inflammatory system. 
Keywords: Schizophrenia, activated inflammatory response system, Th17, regulatory T 
cells, cytokines
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Introduction
There is accumulating evidence that an activation of the inflammatory response system 
plays an important role in the pathogenesis of schizophrenia. In support of this view we 
recently described an inflammatory gene expression signature, i.e. a coherent aberrant 
expression of a set of 34 pro-inflammatory genes, in the circulating monocytes of around 
60% of patients with recent onset schizophrenia [1]. 
Apart from cells of the monocyte lineage T cells are important contributors to the 
inflammatory response, but literature on T cell numbers and cytokines is scarce and 
conjectural in schizophrenia. Although it has been shown [2] that infusion with IL-2, the 
well-known growth factor for T cells, is capable of inducing psychosis-related symptoms in 
psychiatrically healthy individuals, there are at present inconclusive results on the levels of 
IL-2 or its soluble receptor (sIL-2R, synonymous to sCD25) in the circulation of patients with 
schizophrenia [3]. The same holds true for the blood levels of IFN-γ and IL-4, the hallmark 
cytokines of the CD4+Th1 and Th2cell subsets respectively;  higher [4-5],  lower [6] or 
unaltered levels [7] of these cytokines and T cell subsets have been described in patients 
with schizophrenia.
In recent years a new pro-inflammatory T cell cytokine IL-17, has been discovered 
predominantly produced by so-called CD4+ “Th17 cells” [8]. Th17 cells protect the host 
against bacteria and fungi by activating macrophages via the production of IL-17 (but 
also IL-21 and IL-22). In contrast, they also play a role in the pathogenesis of autoimmune 
diseases such as psoriasis and rheumatoid arthritis [8]. Functions of Th17 cells are thus 
similar to those of Th1 cells.
The inflammation inducing effects of Th17, Th1 cells and of monocytes/macrophages are 
controlled by a special class of T cells, the regulatory CD4+CD25highFoxP3+ T cells [9-10]. 
The main function of these inborn, thymus-derived regulatory T cells is tempering the 
inflammatory response thereby maintaining homeostasis and tolerance to self-antigens. 
Cytokines involved in this anti-inflammatory action are thought to be IL-10 and TGF-β. 
Patients lacking these regulatory T cells due to a genetic mutation in the gene coding 
for FoxP3 suffer from a severe and rapidly lethal auto-immune syndrome (Immune 
dysregulation, Polyendocrinopathy, Enteropathy X-linked syndrome)[11]. 
The aim of this study was to evaluate T cell related inflammatory networks in schizophrenia 
following the hypothesis that not only the monocyte system, but also the T cells system 
would be in a pro-inflammatory state. We therefore determined the percentages of 
IL-2r (CD25+) T cells and of IFN-γ, IL-4 and IL-17A containing blood lymphocytes in the 
circulation of 26 recent onset patients, using intracellular staining and FACS analysis. In 
addition we determined via FACS the percentage of the anti-inflammatory regulatory 
Chapter 5 T cells in schizophrenia
94
CD4+CD25highFoxP3+ T cells. 
Next to these FACS analyses we evaluated the serum levels of the catabolic pro-
inflammatory T cell cytokines IFN-γ, IL-17A, IL-22 (but also of the monocyte/macrophage 
cytokines CCL2, TNF-α, IL-1β and PTX3) and of the anabolic or anti-inflammatory cytokines 
sCD25, TGF-β, IL-10, IL-6, IL-4 and IL-5. 
In 19 of the tested patients the monocyte inflammatory gene profiles had been determined 
in the above mentioned previously reported study [1]. This enabled us to not only relate 
the T cell pro-inflammatory and anti-inflammatory state to various clinical variables which 
we measured in the patients (for example the GAF-score, medication, smoking), but also 
to the pro-inflammatory state of their monocytes. 
Methods 
Patients with schizophrenia: 26 acutely psychotic inpatients with schizophrenia diagnosed 
according to the DSM-IV criteria were recruited at the department of Psychiatry of the 
Erasmus Medical Center in Rotterdam. Schizophrenia was diagnosed according to the 
DSM-IV criteria after a Comprehensive Assessment of Symptoms and History (CASH) 
interview [12] and by consensus between two senior psychiatrists who were blinded to 
the results based on all clinical available evidence. In patients with symptoms for less than 
6 months, a final diagnosis was made after 6 months to comply with the DSM-IV criterium. 
All patients were acutely psychotic on admission. Their level of functioning on admission 
and at discharge was determined by the Global Assessment of Functioning-score on the 
fifth axis of the DSM-IV. 
The patients with schizophrenia were virtually all (except one) recent onset cases and 
had a median duration of illness of only 0.3 yrs (median, range 0-3 yrs). Absence of severe 
medical illness (including infections and allergies) was established by medical history 
assessment, physical examination and routine laboratory testing (Hb, Ht, leukocyte 
count, blood smear and kidney/liver function) on admission. Almost all patients received 
antipsychotic medication at the time of blood collection, however with a low lifetime 
cumulative haloperidol equivalent (median: 42 mg hal.eq.) [13] ; none of the patients were 
drug naïve. 
The demographics of the patients are summarized in Table I.
Healthy Controls:  Age- and gender-matched healthy controls (HC, Table I) were recruited 
from enrolling laboratory staff, medical staff and medical students. The inclusion criteria 
for the HC were an absence of any psychiatric and autoimmune disorder in themselves 
and in first-degree family members. HC had to be in self-proclaimed good health and 
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free of any obvious medical illness for at least two weeks prior to the blood withdrawal, 
including acute infections and allergic reactions.
The Medical Ethical Review Committee of the Erasmus MC Rotterdam had approved 
the study. Written informed consent was obtained from all participants after a complete 
description of the study had been given. 
Table I. Characteristics of patients with schizophrenia and healthy controls.
Schizophrenia Healthy Controls
Group size 26 26
Age (years)1 24 (17-39) 25 (21-39)
Gender Male 23 88% 23 88%
Female 3 12% 3 12%
Smoking 18 69% 9 35%
GAF score1 On admission 21-30 (1-10 – 41-50)
At discharge 51-60 (21-30 – 71-80)
Medication None 1
Typical 
antipsychotics
13
Atypical 
antipsychotics
12
1 Median with range. GAF = global assessment of functioning.  GAF range from 0 to 100, higher 
scores indicate better functioning.
Laboratory methods
Blood collection and preparation
Blood (drawn in the morning hours) was collected in clotting tubes for serum preparation 
(stored at -80°C) and in sodium-heparin tubes for immune cell preparation, on average 
20 ml blood was collected from each patient. From the heparinised blood, peripheral 
blood mononuclear cell (PBMC) suspensions were prepared by low-density gradient 
centrifugation, as described in detail before [14], within 8 hours to avoid activation of the 
monocytes (erythrophagy). PBMCs were frozen in 10% dimethylsulfoxide and stored in 
liquid nitrogen. This enabled us to test patient and control immune cells in the same series 
of experiments later. 
Flow cytometric analyses
FACS (fluorescence-activated cell sorting) analysis was used to measure intracellular 
cytokine content in PBMC of patients and age and gender matched HC. As hallmark 
intracellular cytokines we used: IFN-γ, IL-4 and IL-17A. To enable the enumeration of 
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regulatory T cells we intracellularly stained for FoxP3. Membrane-staining was done for 
CD3, CD4, CD25 and CD45RO. This enabled us to assign the cytokine staining to the 
enigmatic Th1, Th2 and Th17 cells in either the total population of CD4+ cells or the memory 
population. It also enabled us to enumerate the enigmatic regulatory CD4+CD25highFoxP3+ 
T cell population.
For the analysis PBMCs were suspended in complete culture medium. Cell suspensions 
were then stimulated with PMA (Sigma Aldrich, Missouri, USA), ionomycin (Sigma Aldrich, 
Missouri, USA) in the presence of Golgistop (Becton Dickinson, New Jersey, USA) for 4 
hours in 37 C under a 5% CO2 environment for T effector cells, regulatory T cells were not 
stimulated.
Cells were harvested and stained extracellularly with anti-CD4 (PerCP-Cy5.5; Becton 
Dickinson, New Jersey, USA) and anti-CD45RO FITC (DAKO, Glostrup, Denmark). For 
determination of regulatory T cells, non-stimulated PBMC samples were stained with anti-
CD3 (PerCP; BD Biosciences, California, USA), anti-CD4 (APC; BD Biosciences, California, 
USA) and anti-CD25 (FITC; BD Biosciences, California, USA) via standard protocol.
Following extracellular staining, the cells were fixed and permeabilized according to the 
manufacturers instructions (eBioscience, California, USA) and then stained for FoxP3 (PE; 
Becton Dickinson, New Jersey, USA), IL-4 (PE; Becton Dickonson, New Jersey, USA), IFN-γ 
(APC; Becton Dickinson, New Jersey, USA), IL-17A (PE; eBioscience, California, USA). 
Isotype antibody controls were used to confirm antibody specificity for CD25. Stained 
cells were analyzed by four colour flowcytometry (FACSCalibur, BD Biosciences, California, 
USA) as described previously and analyzed using FlowJo (Tree Star Inc. Ashland, Oregon, 
USA) research software. Supplementary Figure 1 gives the dot plots of the stainings and 
definition of cell populations.
mRNA gene expression in monocytes
The definition and determination of the mRNA gene expression fingerprints in monocytes 
has been previously described in detail [1].
Serum cytokine determinations
Serum cytokines (IFN-γ, IL-17, IL-10, IL-6, IL-4, TNF-α, CCL2, IL-5, IL-1β and PTX3) were 
measured using the Cytometric Bead Array kits (BenderMedSystems, California, USA) 
according to the manufacturer’s protocol. Bead flow cytometry allows the simultaneous 
quantification of various proteins in the same test (http://www.bendermedsystems.com/
bm_files/47/BM_Factsheet_3_A4_SCREEN.pdf ). Twenty-five μls of serum per test were 
used. Samples were analyzed in a FACSCanto flow cytometer (BD Biosciences, California, 
USA) using the FlowCytomix Pro 2.3 Software (BenderMedSystems, California, USA). Results 
are expressed as picograms per milliliter.
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For TGF-β (Diaclone, France) and sIL-2r (R & D Systems, Minneapolis, USA) commercially 
available ELISAs were used according to the manufacturer’s protocol. 
Statistics
Statistical analysis was performed using the SPSS 15.0 package for Windows. Data were 
tested for normal distribution using the Kolmogorov-Smirnov test. Parametric tests were 
used when the data had a normal distribution. When normal distribution was not reached, 
data were log-transformed. If the data were still skewed after log-transformation non-
parametric tests were used. In the text, tables and figures the original data have been used. 
Levels of significance were set at p = 0.05 (2-tailed). The specific tests used are mentioned 
under tables and in legends.
Results
Percentages of monocytes and lymphocytes
FACS analysis of the samples showed that the percentage of monocytes was higher in the 
schizophrenia samples as compared to those of the gender and age matched HC (SCZ: 
24.33 +- 7.91, HC: 20.64 +- 4.52, p = 0.049, Mann-Whitney test). Although the percentage 
of lymphocytes was smaller in the schizophrenia samples as compared to the HC, values 
did not reach statistical significance (SCZ: 70.97 +- 7.90, HC: 75.08 +- 5.02, p = 0.077, Mann-
Whitney test). Blood leukocyte counts were within the normal range on admission for all 
patients (routine clinical determination, mean 6.4 +- 1.5 x 10.9/L, reference range for our 
center: 3.5 -10.0 x 10.9/ L).
IFN-γ, IL-4 and IL-17A containing lymphocytes 
We first analyzed via FACS the capability of the total lymphocyte fraction to produce 
IFN-γ, IL-4 and IL-17A. After stimulation with PMA and ionomycin for 4hrs (a procedure to 
re-activate lymphocytes), the percentages of IFN-γ and IL-17A containing lymphocytes 
were not different between schizophrenia samples and HC samples (IFN-γ: SCZ: 24.47 +- 
7.60, HC: 27.63 +- 9.45, p = 0.199; IL-17A: SCZ: 0.39 +- 0.29, HC: 0.27 +- 0.12, p = 0.137). 
However lymphocytes capable of producing IL-4 were more numerous in patients with 
schizophrenia as compared to lymphocytes of HC (Fig 1a). Differences could not be 
detected with regard to the Mean Fluorescence Intensity (MFI, which reflects the actual 
content of the cytokine per lymphocyte).  
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CD3+CD25+ cells
Activation of T cells is classically determined by CD25 (IL-2r) expression, illustrating the 
higher capability of the T cells to react to the growth factor IL-2. Percentages of CD3+CD25+ 
T cells were higher in patients with schizophrenia as compared to HC (Fig 1c). Moreover, 
serum levels of the shed receptor, sCD25 (=sIL-2r), were also higher in patients with 
schizophrenia and correlated positively to CD3+CD25+ T cells (r = 0.394, p = 0.007) and IL-4 
containing lymphocytes (r = 0.462, p = 0.001).
Classical Th1 (CD4+IFN-γ+), Th2 (CD4+IL-4+), Th17 (CD4+IL-17A+) and regulatory 
CD4+CD25highFoxP3+ T cells  
We subsequently studied the percentages of classical Th1 cells (CD4+ T cells capable to 
produce IFN-γ), classical Th2 cells (CD4+ T cells capable to produce IL-4) or classical Th17 
cells (CD4+ T cells capable to produce IL-17A). 
The percentage of classical Th1 cells was not different in patients with schizophrenia (SCZ: 
7.55 +- 4.19, HC: 7.30 +- 3.50, p = 0.905), while that of classical Th2 cells showed a trend to 
be higher in line with the finding that IL-4 producing lymphocytes were higher (Fig 1b). 
Statistically higher percentages of classical Th17 cells were found in the circulation of 
patients with schizophrenia as compared to that of HC (Fig 1d). Virtually all these Th17 
cells were of memory type, i.e. they were CD45RO+. 
Figure 1e also shows that CD4+CD25highFoxP3+ T cell (regulatory T cells) percentages were 
higher in patients with schizophrenia as compared to HC (Fig 1e).  There was a strong 
positive correlation between the percentage of regulatory T cells and the serum levels of 
sIL-2R in the patients (r = 0.447, p = 0.002).
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Fig 1 FACS analysis data of the different subsets tested
Percentages of the different subsets analyzed by 
FACS. Every symbol represents an individual patient, 
the bar represents the median. * = p < 0.05
HC = healthy controls; SCZ = schizophrenia; Sign+ 
= Schizophrenia patients with a positive signature
Sign- = Schizophrenia patients with a negative 
signature ; For the comparison of HC vs. SCZ P values 
were tested by linear regression on log-transformed 
data with age and gender in the model.  For the 
comparison of signature pos vs. neg vs. HC P values 
were tested by linear regression on log transformed 
data. Positive monocyte mRNA gene expression 
inflammatory signature is defined as 9 or more 
genes out of twenty tested genes positive.
Positivity of a gene is defined as more than 1 standard deviation higher expressed than the mean 
expression of the tested gene in healthy controls. 
Percentages expressed as mean +- standard deviation; IL-4 containing lymphocytes: SCZ: 2.27 +- 0.76, HC: 
1.82 +- 0.61, p = 0.015, Sign+: 2.51 +- 0.93, Sign-: 1.91 +- 0.35, p = 0.01; 3Th2: SCZ: 3.65 +- 1.14, HC: 3.23 +- 
0.90, p = 0.124, Sign+: 4.18 +- 1.12, Sign-: 3.29 +- 1.00, p = 0.006
CD3+CD25+ T cells: SCZ: 11.01 +- 3.79, HC: 8.32 +- 2.01, p = 0.002, Sign+: 10.25 +- 4.75, Sign-: 10.95 +- 2.25, p = 0.029
Th17: SCZ: 0.56 +- 0.42, HC: 0.34 +- 0.18, p = 0.042, Sign+: 0.38 +- 0.25, Sign-: 0.56 +- 0.41
CD4+CD25highFoxP3+ T cell: SCZ: 3.01 +- 0.84, HC: 2.57 +- 0.65, p = 0.032, Sign+: 3.01 +- 3.30 +- 0.85, p = 0.043
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Correlations between the different T cell subsets (Table II)
The percentages of CD3+CD25+ cells correlated significantly to the percentages of 
regulatory T cells, classical Th1 cells and Th17 cells, but not to Th2 cells . Percentages of 
Th17 cells correlated with those of Th1 cells, but not to the Th2 cells. The percentages of 
regulatory T cells did not correlate to those of Th17 cells. There was also no correlation for 
regulatory T cells and Th1 or Th2 cells. Although the correlation coefficient was negative 
for the correlation between Th1 and Th2 cells (as could be expected from the reciprocal 
character of the subsets), values did not reach statistical significance. 
Table III Cytokine levels in serum
Schizophrenia Healthy Controls p-value
Monocyte activation CCL2 33.39  (12.46 -60.30) 25.74  (14.10 -60.90) 0.495
IL-1β 0.02 (0 - 0.55) 0.05 (0 - 2.55) 0.447
PTX3 66.50 (7.36 - 381.49) 73.07 (13.90 - 368.80) 0.493
IL-6 nd nd
TNFα nd nd
T cell proliferation activity sIL-2R 1960 +- 593 1496 +- 473 0.009
Th1 IFNγ nd nd
Th2 IL-5 0.05 (0 - 0.41) 0.01 (0 - 2.69) 0.281
IL-4 nd nd
Th17 IL-22 47.43 (41.17 - 94.38) 45.34 (41.17 - 59.98) 0.265
IL17a nd nd
Regulatory T cells TGFβ 13872 (7602 - 68981) 12655 (4761 - 23198) 0.204
IL-10 nd nd
nd = not detected
Levels of cytokines are expressed as median with range. All values are in picograms per milliliter. 
Normal distribution was not obtained after log-transformation. The P values were calculated thus 
by Mann-Whitney tests.
sIL-2r had a normal distribution and the level is thus expressed as mean +- standard deviation in IU/
ml. The P value was calculated by ANOVA with age and gender in the model.
Pro-inflammatory and anti-inflammatory cytokines in serum
Levels of IFN-γ, IL-17, IL-10, IL-6, IL-4 and TNF-α were lower than the detection limit in the 
serum of patients and controls (Table III).
Levels of CCL2, IL-5, IL-1β and PTX3 were detectable, but levels were not different in the 
serum of patients with schizophrenia as compared to those of HC. Levels of the Th17 
related cytokine IL-22 and of the regulatory T cell related cytokine TGF-β were higher in the 
serum of patients with schizophrenia, however levels did not reach statistical significance 
(Table III).
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We were unable to find correlations between the cytokines listed in this section and the 
percentages of the various T cell subsets.
Relation of T cell inflammatory parameters to clinical variables
We were unable to find any correlation between the T cell variables reported here and 
antipsychotic drug, smoking, positive symptoms, negative symptoms or GAF score on 
admission. 
A positive correlation was found between the level of functioning of the patients with 
schizophrenia at discharge and their regulatory T cell percentages on admission (Fig 2): 
Patients with regulatory T cell percentages above 3,25% (n = 16) on admission all had a 
GAF score of 50 or higher at discharge, whereas all patients (n = 7) with regulatory T cell 
percentages lower than 3,25% had a GAF score of 49 or lower at discharge (of 3 patients 
GAF score at discharge were not available). This led to a positive correlation between 
regulatory T cell percentage on admission and GAF-score at discharge (r = 0.442, p = 0.035, 
with Bonferroni correction for 6 tests statistical significance was not reached). 
Figure  2 Relation of regulatory T cell percentage on admission and GAF score at discharge
GAF = global assessment of functioning. 
% Tregs = percentage of CD4+CD25highFoxP3+ cells on admission.
P values were tested by linear regression on log transformed values. p = 0.012 df = 21
Relation of T cell inflammatory parameters to the pro-inflammatory state of patient 
monocytes 
Samples of 19 of the monocyte pro-inflammatory signature-tested patients could also 
be used in the present study and in 11/19 of these patients the signature was present as 
compared to 3/23 of the HC (Legend of supplementary Figure 2 for definition of a positive 
signature). 
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The higher percentages of IL-4 containing lymphocytes and of classical Th2 cells found in 
our patients with schizophrenia were largely confined to patients with schizophrenia with 
a positive monocyte pro-inflammatory signature (Fig 1a-b, Suppl Fig 2). 
The higher percentages of Th17 cells, regulatory T cells and CD3+CD25+ cells were found 
in both monocyte signature positive and negative patients with schizophrenia. In the 
signature negative patients significantly higher percentages of regulatory T cells and 
CD3+CD25+ cells were found (Fig 1c-e).
Discussion
This study shows a strongly activated set point of the T cell and monocyte inflammatory 
network in patients with recent onset schizophrenia. On the one hand an activation of 
pro-inflammatory forces was found, i.e. higher percentages of circulating monocytes 
with a pro-inflammatory gene expression signature, activated (CD3+CD25+) T cells and 
pro-inflammatory Th17 cells, on the other hand there was also an activation of anti-
inflammatory forces, i.e. increases in CD4+CD25highFoxP3+ T cells and IL-4 containing 
lymphocytes. 
The up regulation of IL-4 containing lymphocytes and of classical Th2 cells, i.e. the CD4+ 
population of IL-4 containing lymphocytes, was predominantly found in patients with 
schizophrenia characterized by a monocyte pro-inflammatory gene expression set point. 
This constellation of the co-occurrence of pro-inflammatory prone monocytes with 
higher percentages of IL-4 containing lymphocytes is counterintuitive, since IL-4 dampens 
the inflammatory state of monocytes and macrophages, turning the cells in so-called M2 
cells [15]. We like to interpret our data by hypothesizing that the higher percentage of IL-4 
containing lymphocytes in these monocyte gene expression signature positive patients 
serves as a control mechanism to counteract the monocyte proneness for inflammation 
keeping an actual higher production of inflammatory monocyte cytokines under control. 
This interpretation might then explain the normal serum levels of the pro-inflammatory 
monocyte/macrophage cytokines CCL2, IL-1β and PTX3 we found in our patients. On the 
other hand, preliminary data of our group (to be published) in a cohort of older (on average 
40 yrs) patients with chronic naturalistically treated schizophrenia showed a much lower 
inflammatory monocyte gene expression than reported here for acute schizophrenia, 
while serum levels of inflammatory cytokines were clearly raised in the group of older 
patients, but – apart from disease- also linked to obesity and serum lipid levels. This points 
towards a clear and not congruent role for disease duration, treatment, activity and/
or diet/obesity in the inflammatory profiles of circulating cells and cytokine levels. This 
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impacts further studies for biomarker development needing to control for these variables, 
unfortunately in this study we were not informed on metabolic parameters of patients 
and controls and could not adjust for this.
The increases in both the pro-inflammatory subset of Th17 cells and in the anti-inflammatory 
subset of regulatory T cells in SCZ patients were found irrespective of the monocyte pro-
inflammatory state (be it a little more outspoken in the signature negatives). Increases in 
the regulatory T cells and Th17 cells also correlated to increased numbers of CD3+CD25+ T 
cells and higher levels of serum sCD25. Although we like to interpret these CD25 data as 
reflecting a higher tendency for T cell proliferation, which might then underlie the higher 
percentages of Th17 and regulatory T cells, there are data in the literature which show 
that T cell proliferation is in fact reduced in acute forms of schizophrenia when T cells 
were stimulated with anti-CD3 [16].This study also found a normal expression of CD25 on 
CD4+T cells in patients with schizophrenia. Further studies are needed to clarify this issue.
There is strong evidence that Th17 are inflammation-promoting cells in chronic 
inflammatory conditions such as rheumatoid arthritis, asthma, psoriasis and multiple 
sclerosis and the number of Th17 cells as well as the levels of the Th17 derived cytokines IL-
17, IL-21 and IL-22 are higher in affected tissues [17]. Although patients with schizophrenia 
do have molecular alterations in their brain vasculature [18], it is unknown whether Th17 
cells or the Th17 cytokines pass the blood-brain-barrier to exert an effect. In a mouse 
model of multiple sclerosis Th17 cells do migrate into the brain [19]. Studies on post 
mortem brains of schizophrenia patients and animal models of schizophrenia-like disease 
could be instrumental to solve this question of Th17 influence on behavior. 
There is ample evidence that regulatory T cells are capable of dampening the effect of 
Th17 cells [17] , Th1 cells [10] and pro-inflammatory monocytes [20] in immune reactions. 
It is therefore tempting to hypothesize that the increase in anti-inflammatory regulatory 
T cells is meant (like that proposed of the IL-4 containing lymphocytes) to keep the pro-
inflammatory immune forces in patients with schizophrenia under control.
Another point of interest with regard to both the rise in Th17 and regulatory T cells is that 
the development of regulatory T cells has been reported to be tightly linked to that of 
Th17 cells. Both cell lineages share common developmental pathways [17, 21]. Also Foxp3-
lineage-commited regulatory T cells were directly converted into IL-17-expressing cells by 
CpG treatment and interestingly IDO acts as a pivotal molecular switch in this process: 
Only in the absence of IDO this conversion occurs, whereas this was blocked when IDO 
was active [22]. Although IDO activation and abnormal tryptophan break-down is thought 
to play a role in schizophrenia, we were not able to find in this study a correlation between 
percentages of regulatory T cells and those of Th17 cells. 
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With regard to clinical characteristics we found that a high regulatory T cell percentage on 
admission correlated with a better clinical outcome (GAF score) at discharge. Interestingly 
in this respect is that IL-10, one of the key cytokines produced by regulatory T cells, has 
direct effects on brain function and is able to dampen down sickness behavior [23]. 
However, effects of the regulatory T cells could also be mediated by a direct suppression of 
the pro-inflammatory immune forces in the brain e.g. those exerted by pro-inflammatory 
microglia. 
However and with regard to this clinical effect, a limitation of our study is that it was not 
designed to investigate parameters of prediction and p values did not reach significance 
with Bonferroni correction. Suffice to say that a study on the predictive value of regulatory 
T cells for outcome in psychosis in a larger group of patients is now imperative.
Our study has also other limitations. 
We only used peripheral blood samples and we were not able to investigate the 
cerebrospinal fluid (CSF). Pathologic abnormalities of the brain are probably directly 
reflected in the CSF, and indeed in schizophrenia there are reports on cell aberrancies in 
CSF. A recent paper investigated T cell subsets in CSF and peripheral blood of patients with 
a major psychiatric disorder and found an overlapping low grade inflammation in CSF as 
well as in peripheral blood [24] . Unfortunately, we were unable to obtain CSF samples 
from our patients. 
Furthermore, the study has a small sample size and outcomes should be replicated on 
a larger and independent sample size. The study subjects were the same in which the 
monocyte signature was determined, and it could be that this sample of patients with 
schizophrenia has an extreme activation of the immune system. However, we have found 
a similar strong inflammatory monocyte signature in patients with mania [1, 25] and in 
post partum psychosis (to be published). In the latter conditions the T cell system was not 
activated (to be published). 
Our study is naturalistic and all patients (except one) were on –very recently started- 
antipsychotic medication. As antipsychotic medication exerts anti-inflammatory effects 
[26-28], this effect on the outcome cannot be ruled out [1, 25]. Moreover, there were more 
male participants than female participants in this study. Although healthy controls were 
age and gender matched, we cannot completely rule out a general effect of gender on 
the activation state of monocytes and/or T cells. Moreover, we cannot rule out a general 
effect of smoking in this study sample because there was a difference in the smoking 
status of the patients (69%) versus our healthy controls (35%). We did however not find a 
correlation for smoking with one of the other immune parameters.
A further limitation is that our FACS data represent percentages, not the number, of cells 
within the lymphocyte population. We were unable to give absolute cell numbers, since 
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we had not performed a leukocyte count in the same blood sample as used for FACS, 
although leukocyte counts routinely performed in the patient at the same time did not 
show abnormalities. 
Taken together, our data do not support the concept that the T cell system is in a simple 
pro-inflammatory state (our hypothesis), but do show that the monocyte and T cell 
networks are activated in recent onset schizophrenia and involve both pro- and anti-
inflammatory forces. 
The question remains when and why these activated set points are installed and what 
the consequences are for the pathology of schizophrenia. Here the animal models of 
the disease might become important tools for further study. In rodents chronic immune 
activation in the peri-natal period by reagents mimicking infections with commensal 
bacteria and viruses (such as LPS and GpC) do lead to altered set points of the inflammatory 
system which cause abnormalities in brain development and consequent psychosis-
related behaviour [29-30]. Further studies in these animal models into aberrant set points 
of their macrophage/T cell system are indicated.
Acknowledgements
This study was funded by KP7-HEALTH-2007-B. Acronym: Moodinflame - Grant Agreement 
no222963: “Early diagnosis, treatment and prevention of mood disorders targeting the 
activated inflammatory response system” 
We thank Harm de Wit and Annemarie Wijkhuijs for their excellent technical assistance, 
Caspar Looman for statistical advice and Sandra de Bruin for help with designing the 
figures. 
Financial disclosure: W.A. Nolen has received grants from the Netherlands Organisation 
for Health Research and Development, the European Union, the Stanley Medical Research 
Institute, Astra Zeneca, Eli Lilly, GlaxoSmithKline and Wyeth: has received honoraria/
speaker’s fees from Astra Zeneca, Eli Lilly, Pfizer, Servier and Wyeth; and has served in 
advisory boards for Astra Zeneca, Cyberonics, Pfizer and Servier. D. Cohen has received 
grants from Eli Lilly and Janssen-Cilag; has received honoraria/speaker’s from Astra Zeneca, 
Bristol-Myers Squibb and Eli Lilly; and has served in advisory boards of Bristol-Myers Squibb 
and Eli Lilly.
All other authors declare that they have no conflicts of interest.
T cells in schizophrenia
107
5
References
1. Drexhage, R.C., et al., Inflammatory gene expression in monocytes of patients with schizophrenia: 
overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J 
Neuropsychopharmacol, 2010: p. 1-13.
2. Denicoff, K.D., et al., The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-
activated killer cells. Ann Intern Med, 1987. 107(3): p. 293-300.
3. Drexhage, R.C., et al., The mononuclear phagocyte system and its cytokine inflammatory networks in 
schizophrenia and bipolar disorder. Expert Rev Neurother, 2010. 10(1): p. 59-76.
4. Kaminska, T., et al., Investigation of serum cytokine levels and cytokine production in whole blood cultures 
of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz), 2001. 49(6): p. 439-45.
5. O’Brien, S.M., P. Scully, and T.G. Dinan, Increased tumor necrosis factor-alpha concentrations with 
interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res, 2008. 160(3): p. 256-62.
6. Kim, Y.K., et al., Cytokine changes and tryptophan metabolites in medication-naive and medication-free 
schizophrenic patients. Neuropsychobiology, 2009. 59(2): p. 123-9.
7. Kim, Y.K., et al., Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol 
Psychiatry, 2004. 28(7): p. 1129-34.
8. Bettelli, E., et al., Induction and effector functions of T(H)17 cells. Nature, 2008. 453(7198): p. 1051-7.
9. Hori, S., T. Nomura, and S. Sakaguchi, Control of regulatory T cell development by the transcription factor 
Foxp3. Science, 2003. 299(5609): p. 1057-61.
10. Wing, K. and S. Sakaguchi, Regulatory T cells exert checks and balances on self tolerance and autoimmunity. 
Nat Immunol, 2010. 11(1): p. 7-13.
11. Wildin, R.S., S. Smyk-Pearson, and A.H. Filipovich, Clinical and molecular features of the 
immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet, 2002. 
39(8): p. 537-45.
12. Andreasen, N.C., M. Flaum, and S. Arndt, The Comprehensive Assessment of Symptoms and History 
(CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry, 1992. 49(8): p. 
615-23.
13. Cahn, W., et al., Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen 
Psychiatry, 2002. 59(11): p. 1002-10.
14. Knijff, E.M., et al., A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord, 2006. 
8(6): p. 740-50.
15. Mantovani, A., et al., The chemokine system in diverse forms of macrophage activation and polarization. 
Trends Immunol, 2004. 25(12): p. 677-86.
16. Craddock, R.M., et al., Altered T-cell function in schizophrenia: a cellular model to investigate molecular 
disease mechanisms. PLoS One, 2007. 2(1): p. e692.
17. Crome, S.Q., A.Y. Wang, and M.K. Levings, Translational mini-review series on Th17 cells: function and 
regulation of human T helper 17 cells in health and disease. Clin Exp Immunol, 2010. 159(2): p. 109-19.
18. Harris, L.W., et al., The cerebral microvasculature in schizophrenia: a laser capture microdissection study. 
PLoS ONE, 2008. 3(12): p. e3964.
19. Reboldi, A., et al., C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the 
choroid plexus is required for the initiation of EAE. Nat Immunol, 2009. 10(5): p. 514-23.
20. Tiemessen, M.M., et al., CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human 
monocytes/macrophages. Proc Natl Acad Sci U S A, 2007. 104(49): p. 19446-51.
21. Bettini, M. and D.A. Vignali, Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin 
Immunol, 2009. 21(6): p. 612-8.
Chapter 5
108
22. Baban, B., et al., IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol, 
2009. 183(4): p. 2475-83.
23. Richwine, A.F., et al., Cognitive deficits in interleukin-10-deficient mice after peripheral injection of 
lipopolysaccharide. Brain Behav Immun, 2009. 23(6): p. 794-802.
24. Maxeiner, H.G., et al., Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and 
peripheral blood from patients with neurological and psychiatric disorders. Brain Behav Immun, 2009. 
23(1): p. 134-42.
25. Padmos, R.C., et al., A discriminating messenger RNA signature for bipolar disorder formed by an aberrant 
expression of inflammatory genes in monocytes. Arch Gen Psychiatry, 2008. 65(4): p. 395-407.
26. Drzyzga, L., et al., Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun, 
2006. 20(6): p. 532-45.
27. Pollmacher, T., et al., Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res, 2000. 34(6): p. 
369-82.
28. Rybakowski, J.K., Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry, 2000. 33(5): p. 
159-64.
29. Makinodan, M., et al., Maternal immune activation in mice delays myelination and axonal development 
in the hippocampus of the offspring. J Neurosci Res, 2008. 86(10): p. 2190-200.
30. O’Mahony, S.M., et al., Early life stress alters behavior, immunity, and microbiota in rats: implications for 
irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry, 2009. 65(3): p. 263-7.
Chapter 6
An inflammatory gene-expression fingerprint in 
monocytes of autoimmune thyroid disease patients
Short title: Monocytes in AITD
Leonie van der Heul-Nieuwenhuijsen PhD, Roos C. Padmos MD PhD, Roosmarijn C 
Drexhage MD, H. de Wit, Arie Berghout MD PhD FRCP, Hemmo A. Drexhage MD PhD
J Clin Endocrinol Metab. 2010 Apr;95(4):1962-71 
Chapter 6 An inflammatory gene-expression fingerprint in monocytes of autoimmune thyroid disease patients
110
Abstract
Context: In monocytes of patients with autoimmune diabetes we recently identified a 
gene expression fingerprint of 2 partly overlapping gene clusters, a “PDE4B associated” 
cluster (consisting of 12 core pro-inflammatory cytokine/compound genes), a “FABP5 
associated” cluster (3 core genes) and a set of 9 overlapping chemotaxis, adhesion and cell 
assembly genes correlating to both PDE4B and FABP5.
Objective: To study whether a similar monocyte inflammatory fingerprint as found in 
autoimmune diabetes is present in autoimmune thyroid disease (AITD).
Design and patients: Q-PCR analysis for 28 genes in monocytes of 67 AITD patients 
and 70 healthy controls (HC). The tested 28 genes were the 24 genes previously found 
abnormally expressed in monocytes of autoimmune diabetes patients plus 4 “extra” genes 
found in whole genome analysis of monocytes of AITD patients reported here.
Results: Monocytes of 24% of AITD and 50 % of LADA patients shared an inflammatory 
finger print consisting of the set of 24 genes of the PDE4B, FABP5 and overlapping gene 
sets. This study in addition revealed that FCAR, the gene for the Fcα receptor I and PPBP, 
the gene for CXCL7 were part of this pro-inflammatory monocyte fingerprint. 
Conclusions: Our study provides an important tool to determine a shared, specific pro-
inflammatory state of monocytes in AITD and LADA patients, enabling further research 
into the role of such pro-inflammatory cells in the failure to preserve tolerance in these 
conditions and of key fingerprint genes involved. 
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Introduction
Autoimmune thyroiditis is an autoimmune disease, in which T cells and antibodies specific 
for thyroid antigens target thyrocytes, resulting in the destruction of the gland leading to 
hypothyroidism. 
There is a large body of literature showing that in the animal models for spontaneously 
developing autoimmune thyroiditis (the BB-DP rat and the NOD mouse) cells of the 
monuclear phagocyte series, i.e. monocytes, macrophages (MØ) and dendritic cells (DC), 
are aberrant in function and involved in the induction of autoantigen specific T cells and 
antibodies (1-3). Under normal, steady state conditions DC and MØ take up auto-antigens, 
travel with these to the draining lymph node and activate T regulatory cells specific for 
these autoantigens, inducing a state of tolerance. However, in the BB-DP rat and the NOD 
mouse DC and MØ are in a pro-inflammatory state, resulting in a predominant stimulation 
of autoimmune effector T and B cells. In the BB-DP rat steady state DC are defective in IL-10 
production and have a reduced capability to stimulate a sub-population of T regulatory 
cells in the rat (the ART-2+ T cells, 1), while in the NOD mouse steady state DC express high 
levels of NFκB and IL-12 and have a macrophage-like appearance (2, 3). Correction of the 
aberrant DC in the NOD mouse via transfers of normal DC led to the prevention and/or 
the delay of autoimmunity (4,5), supporting the view that an aberrant pro-inflammatory 
set point of steady state DC is one of the cornerstones in the induction of autoimmunity in 
this model. Not only the DC, but also their immediate pre-cursors in the peripheral blood 
i.e. the monocytes, are in an aberrant pro-inflammatory state in the NOD mouse, which is 
shown by an overrepresentation of the fraction of Ly-6Clow monocytes (6). 
With regard to thyroid autoimmune patients, monocyte integrin- and chemokine-
mediated functions are hampered and we previously hypothesized that – similar to the 
NOD mouse and BB-DP rat - these abnormalities might underlie misbalances in monocyte 
inflammatory set points important for the loss of tolerance (7,8).
Autoimmune thyroiditis has many characteristics in common with autoimmune 
diabetes and the diseases often co-occur in patients and their families (9). Also the BB-
DP rat and NOD mouse are characterized by such co-occurrence (10). In monocytes of 
patients with autoimmune diabetes we (11) recently identified at the molecular, i.e. at 
the gene expression level, a fingerprint of 2 partly overlapping gene expression clusters, 
reflecting the abnormal inflammatory set point of the cells in this disease. One cluster, 
an “inflammatory compound” cluster, consisted of 12 core pro-inflammatory cytokine/
compound genes strongly correlating to the expression of PDE4B (the “PDE4B associated” 
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cluster) and was detected in 60% of adult onset LADA, but in only 10% of juvenile onset 
type 1 diabetic patients. A second cluster consisted of 3 core genes strongly correlating 
to the expression of FABP5 (the “FABP5 associated” cluster), and was detected in 43% of 
juvenile-onset type 1 diabetic and 33% of adult onset LADA patients. Apart from these 15 
core genes there were 9 other overlapping chemotaxis, adhesion and cell assembly genes 
correlating positively but weaker to the expression of PDE4B as well as that of FABP5. 
A gene expression study into an abnormal inflammatory set point of monocytes in 
autoimmune thyroiditis is lacking.
We here report outcomes of a Q-PCR analysis, to investigate whether the in total 24 
genes found aberrantly expressed in monocytes of autoimmune diabetic patients were 
also aberrantly expressed in the monocytes of patients with autoimmune thyroiditis. We 
in addition focused on finding new and discriminating genes abnormally expressed in 
monocytes of autoimmune thyroiditis patients. We used whole genome expression 
profiling (in the same way as we did for the autoimmune diabetes study) to identify 
aberrantly expressed genes in the monocytes of patients with autoimmune thyroiditis 
and found 4 new and extra “thyroid-autoimmune-specific” genes. The extra found 4 genes 
were also validated via Q-PCR analysis in the monocytes of the thyroid autoimmune 
patients.  
Material and Methods
Patients 
Autoimmune hypothyroid and hyperthyroid patients: Newly diagnosed hypothyroid 
Hashimoto’s thyroiditis (HT, n=34) and hyperthyroid Graves’ patients (n=33, together 
indicated as autoimmune thyroid disease (AITD) patients, n=67), who visited the 
outpatient clinic of the Department of Internal Medicine, Maasstad Ziekenhuis, Rotterdam, 
the Netherlands, were recruited. All patients with HT were clinically hypothyroid, had 
a lowered serum free thyroxin level (fT4, cut off levels: 10.0- 24.0 pmol/L) and a raised 
thyroid stimulating hormone level (TSH, cut off levels: 0.4-4.0 mU/L), and were positive 
for thyroid peroxidase antibodies (TPO-abs, cut off level: 35 IU/ml, Immulite, DPC, Breda, 
The Netherlands). TSH-receptor antibodies were negative (cut off level: 1.5 IU/L Brahms 
Diagnostics, Berlin, Germany). The hyperthyroid Graves’ patients all had a raised fT4 level 
and a decreased TSH level.  They also had a diffuse non-nodular appearance of thyroid 
on palpation, scan or ultrasound. In addition, patients were positive for TSH-receptor 
antibodies. None of the newly diagnosed HT and Graves’ patients received medication 
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(also no thyroid medication) at the time of blood collection. 
Healthy Controls:  Age and gender matched healthy controls (HC, n=70) were recruited 
via enrolling laboratory staff, medical staff and medical students. The inclusion criteria for 
the HC were an absence of any thyroid and autoimmune disorder and an absent history 
of these disorders in first-degree family members. HC had to be in self-proclaimed good 
health and free of any obvious medical illness for at least two weeks prior to the blood 
withdrawal, including acute infections and allergic reactions. 
The Medical Ethical Review Committee of the Erasmus MC Rotterdam approved the 
studies. Written informed consent was obtained from all participants after a complete 
description of the study was given. 
Characteristics of both patients and HC are given in Table 1.
Table I. Characteristics of AITD patients amd healthy controls used for RQ-PCR, and IL1β, IL6 
ELISAs.
AITD patients Healthy controls
Group size 34 HT 70
33 GD
Age (years)1 41 (18-88) 40 (21-54)
Gender Male 8 (23%) 5 (18%)
Female 27 (77%) 23 (82%)
1Mean (range)
HT= Hashimoto’s thyroiditis, GD= Graves’ disease, AITD= autoimmune thyroid disease
Laboratory methods
Blood collection and preparation
Blood was collected in clotting tubes for serum preparation (stored at -80°C) and in 
sodium-heparin tubes for immune cell preparation. From the heparinized blood peripheral 
blood mononuclear cell (PBMC) suspensions were prepared by low-density gradient 
centrifugation within 8 hours to avoid activation of the monocytes. PBMCs were frozen in 
10% dimethylsulfoxide and stored in liquid nitrogen. This enabled us to test patient and 
control immune cells in the same series of experiments. 
Isolation of monocytes 
CD14 positive monocytes were isolated from frozen PBMCs from selected subjects 
(Table 1) by magnetic cell sorting system (Miltenyi Biotec) The purity of monocytes was 
> 95% (determined by morphological screening after trypan blue staining and FACS). As 
reported elsewhere positive versus negative selection of immune cells did not influence 
gene expression profiles (11,12).
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ELISAs
The CCL2, CCL7, IL-6 and IL1-β levels in sera of the various patient groups were determined 
via commercially available ELISAs (R&D Systems, Minneapolis MN, USA.) used according to 
the manufacturers protocol.
Affymetrix whole genome gene expression profiling
RNA was isolated from purified monocytes using RNAeasy columns as described by the 
manufacturer (Qiagen, Hilden, Germany). Fragmented cRNA was hybridized to U95Av2 
microarrays (Affymetrix, manufacturers protocol). For all experiments, the 5’ / 3’ ratios of 
GAPDH were 2 or less (usually 0.9 – 1.1). 2 pools of autoimmune thyroiditis (AITD) patients, 
each pool was compared to a monocyte pool of age and gender-matched healthy controls 
(HC), (pools were used for minimizing inter-individual differences in mRNA expression): 
Pool 1 consisted of 2 females with HT (Hashimoto’s thyroiditis) , ages 34 and 40 yrs, pool 2 
consisted of 2 females, ages 49 and 54 yrs with HT, pool 1 and 2 were compared to a pool 
of 4 healthy control females, ages 33-46 yrs.
Quantitative –PCR (Q-PCR)
RNA was isolated from monocytes of the AITD patients and matched healthy controls. To 
obtain cDNA for Q-PCR, we used the extensively described BIOMED-1 protocol (13). One 
mg RNA was reversed transcribed using SuperscriptII (Invitrogen) and random hexamers 
(Amersham Biosciences, Roosendaal, The Netherlands) for 50 min at 42°C.
Q-PCR was performed with Taqman Universal PCR mastermix (Applied Biosystems, Foster 
City, CA). All Taqman probes and consensus primers were pre-formulated and designed 
by Applied Biosystems (Assays on Demand, Appendix 1). PCR conditions were 2 min at 
50°C, 10 min at 95°C, followed by 40 cycles of 15 s at 95°C, and finally 1 min at 60°C. PCR 
amplification of housekeeping gene ABL and RPL32 were performed for each sample to 
allow normalization between the samples. ABL and RPL32 were chosen as housekeeping 
gene because it was previously shown that they were the most consistently expressed 
housekeeping gene in haematopoietic cells (14). The quantitative value obtained from 
Q-PCR is a cycle threshold (CT). The fold change values between different groups were 
determined from normalized CT values (CT gene- CT housekeeping genes (avg)), by the 
ΔΔCT method (2-ΔΔCT, User Bulletin 2, Applied Biosystems, Foster City, California, see Table 
2). To correct for inter-assay variance we set the mean of the studied genes found in the 
healthy control groups in the same assay for each gene to 1 (∑ΔCT HC= 0, 2-0=1). The fold 
change values of the genes in patient monocytes were expressed relative to this set mean 
of 1 (Table 2). 
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Statistics
Scanned microarray images were analyzed using Affymetrix Microarray Suite 4.2 software. 
Further analysis was performed using Rosetta Resolver (www.rosettabio.com) software 
and Ingenuity Systems (www.ingenuity.com) software. Statistical analysis was performed 
using the SPSS 15.0 package for Windows. Data were tested for normal distribution using 
the Kolmogorov-Smirnov test. Depending on the distribution pattern and the total 
number of subjects, parametric (normal distribution and ≥ 50 subjects) or non-parametric 
tests (skewed distribution or <50 subjects) were used. Levels of significance were set at 
p=0.05 (2-tailed). The specific tests used are mentioned under tables and in legends.
Results
Whole genome expression profiling for inflammatory genes in monocytes of 
autoimmune thyroiditis patients
Affymetrix microarray analysis to search for aberrantly expressed genes in monocytes was 
performed on 2 pools of autoimmune thyroiditis (AITD) patients. All raw data obtained 
by Affymetrix are available as MIAMExpress submission E-MEXP- (http://www.ebi.ac.uk/
miamexpress/).
In Rosetta Resolver analysis of the expression data we took only molecules into 
consideration, which were more than 4 fold statistically significantly differentially 
expressed between patients and HC, with the purpose to identify strongly discriminating 
molecules. This resulted in 32 genes for AITD patients (27 over and 5 under expressed). 
These genes were analyzed via Ingenuity pathway analysis software. Major functional 
networks/pathways found to be involved were cell growth/differentiation, cell-to-cell 
interaction, and signaling and cell movement. 
To select for genes which could serve as biomarkers for the monocyte inflammatory 
condition we took the genes in the upper or lower 33 percentile of the list, but with at 
least a 5 fold abnormal expression and of which the function is known and involved 
in inflammation or related processes such as cell movement, cell-to-cell interaction 
or signaling. This selection resulted in 4 genes FCAR, EIF2S3, ADAM17 and PPBP (all up-
regulated, there were no discriminating negative genes fulfilling the criteria). These 4 
up-regulated genes were validated in Q-PCR together (see below) with the 24 genes 
previously found abnormally expressed in autoimmune diabetes patients (11). 
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Q-PCR analysis of monocytes of thyroid autoimmune patients 
Table II shows that in Q-PCR 5 of the in total 28 studied genes were significantly aberrantly 
expressed in the 34 (hypothyroid) Hashimoto’s thyroiditis (HT) patients tested. 
We decided to also include in Q-PCR patients with (hyperthyroid) Graves’ disease (GD), the 
other major autoimmune condition of the thyroid. This enabled us to investigate whether 
the thyroxine/TSH status influenced the pro-inflammatory monocyte gene expression or 
whether the aberrant gene expression was mainly due to the autoimmune condition per 
se. Therefore outcomes in the HT patients were compared to those of 33 GD patients. Table 
II shows that virtually all genes were similarly aberrantly expressed in the monocytes of HT 
and GD patients and it appeared that only EMP1 and EIF2S3 showed a clear correlation 
(Spearman) with fT4 and T3 serum levels (fT4: EMP1 r=0.41, EIF2S3 r=0.27; T3: EMP1 r= 0.35, 
EIF2S3 r=0.41, p<0.05 for all correlations). Thus only these genes were clearly influenced by 
the thyroid hormonal state.
Because of the similar aberrant expression levels of the various genes in monocytes of HT 
and GD patients and the closely related immune-pathology of both autoimmune disorders, 
we analyzed the two clinical conditions together considering them as representing one 
autoimmune condition, i.e. autoimmune thyroid disease (AITD, Table II). Only 6 of the 28 
genes were statistically significant higher expressed in monocytes of the entire group of 
67 AITD patients (Table II). These aberrantly expressed genes were 3 of the 9 chemotaxis/
adhesion/cell assembly set genes and 3 of the 12 PDE4B associated genes. 
Of the new “thyroid-autoimmune-specific” genes none could be verified in Q-PCR as a 
gene significantly abnormally expressed in monocytes of the entire group of 67 AITD 
patients.
It is also of note that we were not able to find a clinical variable (age, gender, age of onset, 
and titer of TPO and TSH-R abs) linked to the expression level of any of the fingerprint 
genes, apart from the genes linked to the thyroid hormonal state (EMP1 and EIF2S3, see 
before). 
Table II. Q-PCR analysis of monocytes of autoimmune thyroid disease (AITD) (n=67) as 
compared to healthy control values (HC AIT: n=70), set at 1 fold. AITD split up in Hashimoto’s 
autoimmune thyroiditis (HT) (n=34) and Graves’disease (GD) (n=33).
      HT      GD AITD    
Genes selected by whole genome screening in this study in autoimmune thyroid disease. 
FCAR 1.85 0.57 1.57 0.84 1.72 0.82
EIF2S3 1.13 0.54 1.44 0.05 1.28 0.15
ADAM17 1.53 0.28 1.75 0.06 1.64 0.09
PPBP 1.31 0.83 2.59 0.16 1.93 0.51
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      HT      GD AITD    
PDE4B correlating set:  genes selected in a previous study on autoimmune diabetes (Padmos et al)
PDE4B 4.62 0.04 4.54 0.22 4.58 0.04
CCL20 26.3 0.64 37.84 0.24 31.98 0.67
DUSP2 4.83 0.22 5.23 0.72 5.02 0.32
IL1B 9.39 0.99 12.47 0.72 10.9 0.82
PTGS2 9.31 0.15 11.61 0.07 10.44 0.05
IL6 38.7 0.17 43.08 <0.01 40.86 0.01
BCL2A1 4.13 0.28 4.67 0.04 4.39 0.06
PTX3 6.47 0.27 4.54 0.21 5.52 0.94
ATF3 4.45 0.08 4.71 0.06 4.58 0.84
TNFAIP3 4.99 0.71 5.09 0.96 3.4 0.37
NAB2 3.11 0.1 4.15 0.42 3.62 0.13
TNF 3.73 0.67 4.04 0.29 3.88 0.36
FABP5 correlating set:  genes selected in a previous study on autoimmune diabetes (Padmos et al)
CD9 3.03 0.55 6.41 0.42 4.69 0.39
HSPA1A 1.21 0.48 1.78 0.1 1.49 0.15
FABP5 2.87 0.21 5.7 0.99 4.26 0.43
Overlapping set of chemotaxis/adhesion/cell assembly genes selected in a previous 
study on autoimmune diabetes (Padmos et al)
PTPN7 1.96 0.04 2.06 0.24 2.01 0.05
MAPK6 1.89 0.52 1.61 0.2 1.75 0.24
DHRS3 2.69 < 0.01 2.68 0.02 2.69 < 0.01
CCL7 21.66 0.83 20.21 0.05 20.95 0.2
STX1A 5.93 0.24 3.98 0.48 4.97 0.24
EMP1 5.13 0.03 2.14 0.98 3.66 0.17
CDC42 4.31 < 0.01 6.26 < 0.01 5.27 < 0.01
CXCL2 10.14 0.79 13.46 0.43 11.78 0.52
CCL2 8.75 0.34 7.65 0.59 8.21 0.36
The quantitative value obtained from Q-PCR is a cycle threshold (CT). The fold change values 
between different groups were determined from normalized CT values (CT gene- CT reference gene 
ABL), by the ∆∆CT methods (2-∆∆CT, user Bulletin 2, Applied Biosystems, Foster City, California). Data 
were standardized to the HC (thus the HC were used as the calibrator). The fold change of the HC is 
therefore 1. Groups were compared using the Mann-Whitney test. HT, Hashimoto’s thyroiditis; GD, 
Graves’disease; AITD, autoimmune thyroid disease
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Cluster analysis of Q-PCR data of monocytes of thyroid autoimmune patients 
In a next step we studied the mutually interdependent state of expression of the 28 
genes and therefore performed a cluster analysis on the Q-PCR data. The heat map of this 
correlation analysis is given in Fig 1. 
In sum, although expression levels of the large majority of the 28 genes correlated to 
each other, two clusters of strongly correlating genes could clearly be identified: One 
cluster (darkest red, Fig 1., correlation coefficient > 0.70) was formed by a large part of 
the previously identified PDE4B associated cluster (genes as PTX3, ATF3, IL-6, IL1B, CCL20, 
PDE4B and PTGS2), the second cluster (also dark red, Fig 1., correlation coefficient > 0.70) 
was formed by a large part of the previously identified chemotaxis/adhesion/cell assembly 
gene set (genes as CXCL2, CCL2, CCL7, MAPK6, PTPN7 and STX1A). 
With regard to the FABP5 correlating set previously identified in autoimmune diabetes 
(FABP5, CD9 and HSPA1A), there was not a clear indication of such strongly correlating set 
in AITD, genes correlated to each other at correlation coefficients of only 0.12 to 0.26.
Special in this study on AITD patients is that the 4 genes newly identified in Affymetrix 
(FCAR, ADAM, PPBP and EIF2S3) also correlated to each other at reasonable level with 
correlation coefficients of  0.21 to 0.48. Special is that of these 4 genes FCAR in particular 
correlated in expression level strongly to both the PDE4B associated genes and the genes 
of the chemotaxis/adhesion/cell assembly set, with correlation coefficients > 0.5 (see Fig. 1). 
A comparison of the prevalences of the monocyte gene expression profiles in 
autoimmune thyroid disease patients with those in autoimmune diabetes patients 
published previously
On the basis of the cluster analysis we decided to express the data as a heat map of the 
individual genes as expressed in monocytes of individual AITD patients (see Figure 2, in 
this figure the various reds mean over expression as compared to the mean expression of 
a particular gene in monocytes of HC, the various greens mean a reduced expression as 
compared to the mean expression of a particular gene in monocytes of HC). 
As can be seen from these heat maps about one quarter of the AITD patients (i.e16/67 
patients, 7 HT patients and 9 GD patients) showed a pro-inflammatory monocyte set point 
of particular the PDE4B associated genes set (gene set B) and the chemotaxis/ adhesion/
cell assembly gene set (gene set C) (both columns for about a quarter strongly red), 
while one third had absolutely no signs of an high pro-inflammatory monocyte set point 
(predominantly strongly green).
Figure 2 also shows the heat maps of the monocyte gene expression levels of the AITD 
patients in comparison to those of LADA patients and childhood onset T1D children 
previously reported (see 11, for the actual raw gene expression data of monocytes of 
LADA and childhood onset type 1 diabetes patients we refer to these previously published 
An inflammatory gene-expression fingerprint in monocytes of autoimmune thyroid disease patients
119
6
Figure 1. Expression levels of monocyte gene clusters in AITD patients
Correlation analysis of expression levels of the 28 genes identified in AITD patients. Data represent 
Spearman’s correlation coefficients illustrated as heatmap by Treeview. Red indicates strong 
correlation, green represents anti-correlation. The 28 genes are divided in 4 groups; Genes selected 
by Affymetrix; PDE4B correlating genes; overlapping set of chemotaxis/adhesion and cell assembly 
genes and FABP5 correlating genes.
data). As can be seen from these heat maps about half of the LADA patients showed a 
pro-inflammatory monocyte set point similar to the pro-inflammatory set point found 
in the one quarter of AITD patients, and again the “negative” LADA cases had no signs of 
an abnormal pro-inflammatory monocyte set point. The childhood onset T1D cases are 
special in that they lack over expression of gene set B, but were positive in about two-third 
of cases for monocyte gene set C (and they also were positive in these cases for gene 
set D, the FABP5 associated cluster, i.e. an over expression of CD9 and FABP5 and a down 
regulation of HSPA1A).
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In an attempt to enumerate more precisely the prevalence’s of the various subsets of 
genes in the patient groups we arbitrarily defined positivity for the PDE4B correlating set 
cluster as positive for at least 6 of the 12 PDE4B genes, positivity for the FABP5 correlating 
set as positive for 2/3 genes and positivity for the chemotaxis/adhesion/cell assembly 
cluster as positive for at least 5 of the 9 genes. Table III gives these prevalence figures. 
As can be seen, 38% of AITD patients share an up regulation of the set of chemotaxis, 
adhesion and cell motility/assembly cluster genes (cluster C in figure 2) in monocytes 
with 60% of childhood onset T1D and 67% of LADA patients. They take an intermediate 
position in positivity for PDE4B correlating gene set (Cluster B in figure 2), i.e. 27% have 
such pro-inflammatory monocytes versus 50% of LADA patients and virtually none (3%) 
of childhood onset T1D patients. With regard to the FABP5 correlating gene sets (Cluster D 
in figure 2) AITD patients were hardly positive.
When we defined “fingerprint“ positivity as a combination of 50% positivity for cluster 
B plus 50% positivity for cluster C (Table III) 24% of AITD, 50% of LADA and none of 
T1D childhood onset cases were positive. Interestingly, when we separated these 24% 
fingerprint positive AITD patients from the 76% fingerprint negative AITD patients (Table 
IV), we observed in the 24% of AITD cases virtually complete over expression of the various 
genes of the different clusters (supporting their mutual correlation, see also Figure 1), and 
also including 2 of the 4 in Affymetrix selected monocyte genes of AITD patients, i.e. FCAR 
and PPBP (i.e. CXCL7). In the 76% fingerprint negative patients significant over expression 
was still reached for some of the genes (IL-6, BCL2A1, NAB2, TNF, FABP5, PTPN7 and CDC42), 
suggesting that at least part of these “negative” cases, which do not have the full-blown 
fingerprint, have some weak expression of the fingerprint genes in their monocytes.
Table III. Prevalence of gene clusters in HC, AITD, T1D childhood onset and LADA patients
legend Table 3.
HC AITD T1D LADA
50% of PDE4B correlating genes
PDE4B, CCL20, DUSP2, IL1B, PTGS2, 
IL6, BCL2A1, PTX3, ATF3, TNFAIP3, 
NAB2 and TNF
19% (13/70) 27% (18/67) 3% (1/30) 50% (15/30)
50% FABP5 correlating genes
FABP5, CD9 and HSPA1A
1% (1/70) 7% (4/67) 50% (15/30) 23% (7/30)
50% chemotaxis, adhesion and cell 
assembly cluster
STX1A, CCL2, CCL7, CDC42, MAPK6, 
EMP1, CXCL2, DHRS3 and PTPN7
14% (10/70) 38% (24/67) 60% (18/30) 67% (20/30)
50% PDE4B + 50% chemotaxis 
associated cluster
6% (4/70) 24% (16/67) 3% (1/30) 50% (15/30)
The presence of a PDE4B-associated, FABP5-associated and chemotaxis, adhesion and cell assembly 
molecular signature in healthy controls HC compared to AITD, T1D childhood onset and LADA patients.
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Table IV. Fold change of individual molecules when comparing the 24% fingerprint positive AITD 
patients to the 76% negative AITD patients. Genes are considered differentially expressed when p< 
0.05, Mann Whitney.
24% fingerprint positive AITD patients vs HC                                       76% negative AITD patients vs HC 
 Fold change p level Fold change p level
Genes selected by whole genome screening in this study in autoimmune thyroid disease
FCAR 4.81 <0.001 0.7 0.904
EIF2S3 1.47 0.076 1.15 0.381
ADAM17 1.81 0.068 1.52 0.753
PPBP 2.42 0.025 1.6 0.344
PDE4B correlating set:  genes selected in a previous study on autoimmune diabetes (11)
PDE4B 11.87 <0.001 2.24 0.395
CCL20 97.21 <0.001 10.72 0.663
DUSP2 7.67 <0.001 4.51 0.817
IL1B 31.41 <0.001 4.55 0.515
PTGS2 26.21 <0.001 4.73 0.109
IL6 119.61 <0.001 13.7 0.027
BCL2A1 8.99 <0.001 3.18 0.001
PTX3 16.96 <0.001 2.33 0.217
ATF3 10.61 <0.001 2.62 0.15
TNFAIP3 5.73 <0.001 2.91 0.971
NAB2 4.72 0.083 3.02 0.017
TNF 6.65 <0.001 3.09 0.002
FABP5 correlating set:  genes selected in a previous study on autoimmune diabetes (11)
CD9 2.77 0.017 5.07 0.512
HSPA1A 3.07 0.008 0.9 0.954
FABP5 2.72 0.003 4.25 0.001
Overlapping set of chemotaxis/adhesion/cell assembly genes selected in a previous 
study on autoimmune diabetes (11)
PTPN7 4.52 <0.001 1.06 0.044
MAPK6 5.84 <0.001 0.4 0.479
DHRS3 5.65 <0.001 1.7 0.381
CCL7 57.92 <0.001 8.86 0.929
STX1A 12.62 <0.001 2.43 0.227
EMP1 6.81 <0.001 2.61 0.529
CDC42 5.63 <0.001 5.39 <0.001
CXCL2 31.65 <0.001 5.19 0.983
CCL2 19.05 <0.001 4.56 0.709
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Expression at the serum protein level
We measured the serum protein expression levels of the gene set molecules IL-1β and 
IL-6 (which are part of the PDE4B associated pro-inflammatory gene set) and CCL2 and 
CCL7 (which are part of the set of chemotaxis, adhesion and cell motility/assembly genes). 
Only the serum CCL2 levels were significantly higher in AITD patients (Figure 3). Thus at 
the serum protein level there were only minor signs of monocyte/macrophage activation 
(since CCL2 is monocyte/macrophage-derived chemokine) and our serum cytokine level 
data again (see also 11) indicate that serum protein levels do correlate with the aberrant 
monocyte gene expression, but are only a weak reflection of it.
Figure 3. The protein expression of IL-1β and CCL2 in serum of thyroid autoimmune patients
Box plots of log transformed Il-1β and CCL2 serum levels of AITD patients. Data were log transformed 
to obtain a normal distribution. Only in case of CCL2 this resulted in a normal distribution, hence an 
ANOVA analysis was used, adjusted for age and gender. For Il-1β the non-parametric Mann-Whitney 
test was used. The boxes indicate the lower and upper quartiles. The lines in the boxes represent the 
median. The whiskers extend to the 2.5 and 97.5 percentiles; the outliers are characterized by the 
filed dots. Il-1β  was tested on the same patients as described in Table 1. CCL2 was tested on more 
patients: HC n=157, 67% females, mean age 36 years, range 19-56 years, and AITD n=59, mean age 
44 years, range 19-87 years.
Discussion
This study shows that monocytes of 24% of AITD patients show an inflammatory set point, 
a “finger print” of a set of 24 genes involved in inflammation, chemotaxis, adhesion and 
cell motility/assembly, similar to that previously described in 50 % of LADA patients: This 
study in addition revealed that two genes which had not been identified before, i.e. FCAR, 
the gene for the Fcα receptor I (FcαRI) and PPBP, the gene for CXCL7 were part of the pro-
inflammatory monocyte fingerprint in these patients. 
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This study has limitations:
Firstly, the study does not include contrast hyper- and hypothyroid cases of non-
autoimmune causes (such as patients with toxic nodular goiters, surgically removed 
thyroid glands or iodine deficient goiters) to formally rule out a clear effect of the thyroid 
hormonal state on the found pro-inflammatory state of monocytes. However, virtually 
the same pro-inflammatory finger print was found in hypothyroid HT and hyperthyroid 
GD cases (this study) and only one fingerprint gene showed a relation with the thyroid 
hormone level (i.e. EMP-1; EIF2S3 also showed a relation with the thyroid hormonal state 
but turned out not to be a significant part of the fingerprint). Also the same fingerprint was 
found in LADA patients in this study and previously in patients with bipolar disorder (15) 
with a normal thyroid function. From this we assume that the here described inflammatory 
state of monocytes is not determined by the thyroid hormonal state.
Secondly, the study does not include cases in follow-up, so we are not informed on the 
fluctuation of the fingerprint expression in monocytes over time during the disease course. 
Such information would tell us whether the 76% fingerprint negative cases represent a 
quiescent phase of the disease or reflect a complete different pathogenic route of thyroid 
autoimmune pathogenesis not involving abnormal monocytes/macrophages. With 
regard to the other patient groups, i.e. autoimmune diabetic patients and bipolar patients, 
showing the same or a similar monocyte pro-inflammatory gene fingerprint we have 
described that such monocyte fingerprints are already present in the pre-clinical stages of 
the disease (15) and are for a large part induced by environmental factors (16), yet detailed 
follow-up studies in AITD patients need to be performed.
It is tempting to speculate that the pro-inflammatory fingerprint of the above described 
sets of inflammatory, adhesion, chemotaxis and cell motility and assembly genes in 
monocytes of AITD and LADA patients leads to a set of functional abnormalities in 
monocyte inflammatory responses, adhesion, chemotaxis and motility. Indeed, we 
previously reported that monocytes and monocyte-derived cells of AITD and autoimmune 
diabetes patients display an array of adhesion and motility disturbances: The cells adhere 
and stretch abnormally on fibronectin (FN) and have a higher expression of the integrin 
CD11b (17). Interestingly, adherence to FN of monocytes of T1D patients induces a 
significantly increased production of MRP8/14 (a pro-inflammatory compound of the 
S100 family) and of the pro-inflammatory chemokine CCL2 (18), which was found at a 
higher level in this study in the serum of AITD patients too. Furthermore, monocytes of 
AITD patients have a reduced potency to form long cellular veiled protrusions (particularly 
after FN adherence) and such veiled cells are less capable to appropriately interact with 
T cells (8), putatively contributing to a faulty tolerance induction (19). Similar adhesion, 
cell motility/assembly and chemotactic abnormalities have been described of monocytes, 
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macrophages and dendritic cells in the NOD mouse. Clearly further functional studies 
with patient monocytes need to be performed particularly in the group of 24% with a 
positive inflammatory gene fingerprint. In particular knock-in and knock-out studies of 
the fingerprint genes will establish their role in the previously found functional adhesion 
and motility disturbances and to establish their role in misbalancing monocyte function 
towards a pro-inflammatory, non-tolerogenic phenotype.
This study also found that in conjunction and in correlation with the other over-expressed 
fingerprint genes, the monocytes of AITD and LADA patients showed a clear up regulation 
of FCAR, the gene for the FcαRI/CD89 and (to a lesser extent) for PPBP, the gene for CXCL7. 
The FcαRI is a bifunctional inhibitory/activating receptor mediating both anti- and pro-
inflammatory functions of IgA (20). Sustained aggregation of the receptor (by e.g. IgA 
immune complexes) results in activation of monocytes, while absence of aggregation 
(monomeric IgA) leads to inhibition. There is a specific polymorphism of the FcαRI, the 
Gly248 allele, which in particular enhances the pro-inflammatory potential of serum IgA 
(21). Enrichment for this allele has been found in SLE, suggesting a pro-inflammatory route 
via this FcαRI allele in autoimmunity and preliminary studies of our team on another group 
of AITD patients also suggest an enrichment for this allele in AITD (to be published). It is 
also of interest to note that an over expression of the FcαRI has been found on white blood 
cells of MS patients (22). Clearly further studies are needed into the mutual involvement 
of mucosal infections, IgA immune complexes, FcαRI polymorphisms and activated 
monocytes/macrophages in AITD patients. 
With regard to CXCL7, little is known about the role of this chemokine in monocytes. 
There are reports on an involvement of CXCL7 in the recruitment of monocytes from 
the circulation (23) and the resistance to mycobacteria (24). Again knock-in or knock-out 
studies in monocytes of AITD patients may unravel its role in the pathogenesis of AITD.
In conclusion monocytes of about a quarter of AITD patients (HT and GD alike) and 
about half of LADA patients share an inflammatory coherent gene-expression fingerprint 
consisting of at least 26 genes with a function in inflammation, chemotaxis, cell adhesion 
and cell motility/assembly, supporting the concept that autoimmune thyroiditis and 
autoimmune diabetes share a common pathogenic route as is indicated by the co-
occurrence of both autoimmune disorders in patients, their families and in animal models 
of the disease. 
But, perhaps the most important progress of this study is that it provides an important 
tool, i.e. the monocyte gene fingerprint, to determine a specific pro-inflammatory state of 
monocytes in patients and their family members. A similar pro-inflammatory state of the 
mononuclear phagocyte series exist in the NOD mouse and BB-DP rat prior to disease and 
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is one of the pillars underlying the pathogenesis of autoimmunity. Our fingerprint thus 
enables research into the presence of pro-inflammatory monocytes in humans in pre-
stages of the disease (as in the animal models) and in addition enables identification of key 
fingerprint genes involved in the failure of mononuclear phagocytes to preserve tolerance 
and which could be targeted by drugs (e.g. PDE4 inhibitors, COX2 inhibitors, anti-TNF and 
N-acetyl cysteine) to correct their aberrant, pro-inflammatory, non-tolerogenic state.
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Abstract
Objectives: We recently described a monocyte pro-inflammatory state in patients with 
bipolar disorder (BD). We hypothesized that the CD4+T cell system is also activated and 
determined percentages of Th1, Th2, Th17 and CD4+CD25highFoxP3+ regulatory T cells. 
Methods: We carried out a detailed FACS analysis to determine the various T cell subsets 
and used frozen stored peripheral blood mononuclear cells (PBMC) of 38 BD patients (of 
whom we previously had tested monocytes for pro-inflammatory gene expression [1, 2]) 
and of 22 age/gender matched healthy controls (HC). In addition the cvtokines CCL2, IL-
1β, IL-6, TNF-α, PTX3, IL-10, IFN-γ, IL-17A, IL-4, IL-5 and IL-22 were measured in serum.
Results:
a) Serum sCD25 levels and percentages of anti-inflammatory CD4+CD25highFoxP3+ 
regulatory T cells were higher, the latter in BD patients < 40 years of age. Percentages of 
Th1, Th2 and Th17 cells were normal.
b) Of the pro-inflammatory monocyte cytokines CCL2 and PTX3 were raised in serum.
c) The monocyte pro-inflammatory state and the raised percentages of CD4+CD25highFoxP3+ 
regulatory T cells occurred independently from each other. 
d) In BD patients positive for thyroid autoimmune disease a significantly reduced 
percentage of CD4+CD25highFoxP3+ regulatory T cells was found as compared to BD 
patients without AITD. 
Conclusion: 
Our data show an enhancement of pro-inflammatory monocyte and anti-inflammatory T 
cell forces in BD patients. A lack of anti-inflammatory T cell forces co-occurred with AITD 
in BD patients.
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Introduction
There is accumulating evidence that activation of the immune system plays an important 
role in the pathogenesis of bipolar disorder (BD). In support of this view we recently 
described a higher expression of a coherent set of 34 inflammatory genes, an inflammatory 
gene expression “signature”, in the circulating monocytes of 60-70% of BD patients [1, 2]. 
Apart from cells of the monocyte lineage, T cells are important contributors to the immune 
response, but literature on T cell numbers and cytokines in BD is scarce and the aim of the 
present study is to evaluate T cell related inflammatory networks in relation to monocyte 
activation state in patients with BD. 
Previously we reported on higher numbers of CD25+ and CD71+ (“activated”) T cells in the 
circulation of BD patients [3], but at present there are no data on the circulating numbers 
of the various CD4+T helper cell subsets in BD, such as CD4+T helper(h)1 and Th2 cells, 
though there are data on the serum levels of IFN-γ and IL-4, the hallmark cytokines of 
these two T cell subsets [4-6]. Both higher and unaltered levels of the cytokines have been 
described.
In recent years a new T helper subset has been discovered, the so-called CD4+ “Th17 cells”, 
which produce the pro-inflammatory cytokine IL-17 [7]. Th17 cells protect the host against 
bacteria and fungi by activating macrophages via the production of IL-17 (but also IL-21 
and IL-22). In addition Th17 cells play a role in the pathogenesis of autoimmune diseases 
such as psoriasis and rheumatoid arthritis [7]. Functions of Th17 cells are thus very similar 
to those of Th1 cells.
The inflammation inducing effects of Th1 cells, Th17 cells and of monocytes and 
macrophages are controlled by a special class of T cells, the regulatory CD4+CD25highFoxP3+ 
T cells [8, 9]. The main function of these natural, inborn, thymus-derived regulatory T cells 
is tempering the inflammatory response thereby maintaining homeostasis and tolerance 
to self-antigens. The cytokines involved in this anti-inflammatory action are thought to be 
TGF-β and IL-10 (though these cytokines are also produced by monocytes/macrophages). 
Patients lacking CD4+CD25highFoxP3+ natural T regulatory (reg) cells due to a genetic 
mutation in the gene coding for FoxP3, suffer from a severe and rapidly lethal poly-
endocrine auto-immune syndrome (IPEX, Immune dysregulation, Polyendocrinopathy, 
Enteropathy X-linked syndrome)[10]. 
Since BD patients have a higher risk to develop endocrine autoimmune diseases, 
including autoimmune thyroid disease (AITD) [11, 12], we had as second aim of this study 
to investigate whether BD patients with AITD have an imbalanced interplay between 
inflammation-prone monocytes and an abnormal tuned T cell system, notably abnormal 
numbers of natural Treg cells.
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For this study we were able to use deep frozen leukocytes of 38 BD patients of the 
previously reported series of 56 BD patients tested for monocyte gene expression [1, 2, 13] 
and 22 age and gender matched healthy controls. This enabled us to relate the T cell state 
to the pro-inflammatory state of the monocytes of the BD patients. TPO-Abs were positive 
in 11 of the 38 cases (29%).
We determined the percentages of IFN-γ+Th1, IL-4+Th2, IL-17A+Th17 and of 
CD4+CD25highFoxP3+ regulatory T cells using FACS analysis. Next to these cellular analyses 
we evaluated the serum levels of the monocyte cytokines PTX3, CCL2, TNF-α, IL-1β IL-6, IL-
8, and IL-10, of the shed sCD25 (the IL-2 Receptor, highly expressed on CD4+CD25highFoxP3+ 
regulatory T cells) and of the T cell cytokines IFN-γ, IL-4, IL-5, IL-17A and IL-22. 
Materials and Methods 
Patients with bipolar disorder and controls: 
The 38 BD subjects tested were the index cases of twin-pairs, which we had used in a 
previous study, aged 18 to 60 years, suffering from bipolar I or bipolar II disorder according 
to DSM-IV criteria [14] (we tested these index BD cases, since we had frozen samples left 
in store of only these individuals). Material of the co-twins was not used in this study. The 
recruitment procedure and inclusion criteria have previously been described in [15]. In 
short the BD diagnosis was confirmed via the Structured Clinical Interview for DSM-IV 
(SCID). The cases had no history of drug or alcohol dependency for the last half year and 
no severe medical illness, verified with a medical history inventory. Current mood state 
was assessed via the Young Mania Rating Scale (YMRS) and the Inventory for Depressive 
Symptomatology (IDS). All patients were euthymic at the time of blood collection, 
euthymia was defined as an YMRS score of ≤ 4 and IDS score ≤ 12. In addition, current and 
previous use of medication was assessed. 
Healthy controls: The BD cases were compared to healthy control twins matched on 
zygosity, gender and age. The controls twins had no history of a major axis I psychiatric 
disorder such as schizophrenia, psychotic disorder, mood disorder, anxiety disorder or 
substance related disorder according to DSM-IV criteria confirmed with a SCID and also 
no history of a severe medical illness. Furthermore, they had no first degree relative with a 
history of a major axis I psychiatric disorder (DSM-IV). 
the Medical Ethical Review Board of the UMC Utrecht had approved the study and all 
participants gave written informed consent after full explanation of the study aims and 
procedures. The demographics of the patients and controls are summarized in Table I.
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Table I. Characteristics of patients with bipolar disorder and healthy controls.
Bipolar Disorder Healthy Controls
Group size 38 22
Age (years)1 41.1  +- 9.6 41.3  +- 9.5
Gender Male 9 24% 3 14%
Female 29 76% 19 86%
Duration of illness (years)1 13.6 +-8.9
TPO-antibodies               Positive 11 29% 7 32%
Negative 27 71% 15 68%
Medication None 1
Lithium 30
Valproate 6
Carbamazepine 3
Lamotrigine 1
Antidepressives 14
Antipsychotics 8
Benzodiazepines 11
1 Mean with standard deviation
Laboratory methods
Blood collection and preparation
Blood (drawn in the morning from 9.00-11.00 hrs) was collected in clotting tubes for serum 
preparation (stored at -80°C) and in sodium-heparin tubes for immune cell preparation. 
From the heparinised blood, peripheral blood mononuclear cell (PBMC) suspensions were 
prepared by low-density gradient centrifugation, as described in detail before [16], within 
8 hours to avoid activation of the monocytes (erythrophagy). PBMCs were frozen in 10% 
dimethylsulfoxide and stored in liquid nitrogen. This enabled us to test patient and control 
immune cells in the same series of experiments later. 
Flow cytometric analyses
FACS (fluorescence-activated cell sorting) analysis was used to measure intracellular 
cytokine content in PBMC of patients and age and gender matched HC. As hallmark 
intracellular cytokines we used: IFN-γ, IL-4 and IL-17A. To enable the enumeration of 
regulatory T cells we intracellular stained for FoxP3. Membrane-staining was done for CD3, 
CD4, CD25 and CD45RO. This enabled us to assign the cytokine staining to the enigmatic 
Th1, Th2 and Th17 cells in either the total population of CD4+ cells or the memory 
population. It also enabled us to enumerate the enigmatic regulatory CD4+CD25highFoxP3+ 
T cell population.
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For the analysis PBMCs were suspended in complete culture medium. Cell suspensions 
were then stimulated with PMA (Sigma Aldrich, Missouri, USA), ionomycin (Sigma Aldrich, 
Missouri, USA) in the presence of Golgistop (Becton Dickinson, New Jersey, USA) for 4 
hours in 37 C under a 5% CO2 environment for T effector cells, regulatory T cells were not 
stimulated. Cells were harvested; membrane staining was done with anti-CD3 (PerCP; BD 
Biosciences, California, USA), anti-CD4 (APC; BD Biosciences, California, USA, PerCP-Cy5.5; 
Becton Dickinson, New Jersey, USA) and CD25 (FITC; BD Biosciences, California, USA) via 
standard protocol. Following membrane staining, the cells were fixed and permeabilized 
according to the manufacturers instructions (eBioscience, California, USA) and then 
stained for FoxP3 (PE; Becton Dickinson, New Jersey, USA), IL-4 (PE; Becton Dickonson, 
New Jersey, USA), IFN-γ (APC; Becton Dickinson, New Jersey, USA), IL-17A (PE; eBioscience, 
California, USA). 
Isotype antibody controls were used to confirm antibody specificity for CD25. Stained cells 
were analyzed by four colour flowcytometry (FACSCalibur, BD Biosciences, California, USA) 
as described previously and analyzed using FlowJo (Tree Star Inc. Ashland, Oregon, USA) 
research software. Supplementary figure 1 gives the gating strategy and the dot plots of 
the stainings and the definition of the cell populations.
mRNA gene expression in monocytes
The definition and determination of the mRNA gene expression fingerprints in monocytes 
has been previously described in detail [1].
Serum cytokine determinations
Serum cytokines (IFN-γ, IL-17A, IL-10, IL-6, IL-4, IL-5, IL-8, TNF-α, CCL2, and IL-1β) were 
measured using the Cytometric Bead Array kits (BenderMedSystems, California, USA) 
according to the manufacturer’s protocol. Bead flow cytometry allows the simultaneous 
quantification of various proteins in the same test (http://www.ebioscience.com/media/
pdf/literature/flowcytomix-multiple-analyte-detection.pdf ). Twenty-five μls of serum per 
test were used. Samples were analyzed in a FACSCanto flow cytometer (BD Biosciences, 
California, USA) using the FlowCytomix Pro 2.3 Software (BenderMedSystems, California, 
USA). Results are expressed as picograms per milliliter.
For sIL-2R (R & D Systems, Minneapolis, USA) a commercially available ELISA was used 
according to the manufacturer’s protocol. For PTX3 an in house ELISA was used.
Statistics
Statistical analysis was performed using the SPSS 15.0 package for Windows. Data were 
tested for normal distribution using the Kolmogorov-Smirnov test. Parametric tests were 
used when the data had a normal distribution. When normal distribution was not reached, 
data were log-transformed. If the data were still skewed after log-transformation non-
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parametric tests were used. In the text, tables and figures the original data have been used. 
Levels of significance were set at p = 0.05 (2-tailed). The specific tests used are mentioned 
under tables and in legends.
Results
Th1 (CD4+IFNγ+), Th2 (CD4+IL4+) and Th17 (CD4+IL17A+) cells in BD patients and HC
We first analyzed by forward and side scatter in FACS (for gating strategy, see Fig 1) the 
percentages of total lymphocytes and monocytes in the PBMC preparations of the BD 
patients and healthy controls (HC). There were no differences in the percentages of 
monocytes and lymphocytes between BD and HC (data not shown).
Subsequently, we quantified after stimulation with PMA and ionomycin for 4 hours (a 
procedure to activate lymphocytes) the percentages of the Th1, Th2 and Th17 cells. There 
were no significant differences in the percentages of Th1 (BD: 10.88 +- 5.65; HC: 9.21 +-4.67, 
p = 0.373), Th2 (BD: 2.42 +- 1.14; HC: 2.25 +- 0.99, p = 0.679) and Th17 cells (BD: 0.55 +- 0.32; 
HC: 0.43 +- 0.24, p = 0.208) between BD patients and controls. 
There was also no statistically significant influence of age and gender on the percentages 
of these T cell subsets.
CD4+CD25highFoxP3+ T cells and serum sCD25 in BD patients and HC
Thereafter we studied the percentages of CD4+CD25highFoxP3+ T cells (natural T reg cells) 
and found these not statistically significantly different in BD patients as compared to 
the controls (BD: 2.36 +- 0.86; HC: 2.08 +- 0.65, p = 0.348). Age however had a positive 
significant influence on the CD4+CD25highFoxP3+ T cells in healthy controls (r = 0.707, p 
= 0.001). Since there was this positive correlation with age, and since there are reports 
showing the same phenomenon [17], we post hoc divided the BD patients and controls 
arbitrarily into a younger age group (< 40 years, BD: n = 19, HC; n = 10) and an almost 
equally large older age group (> 40 years, BD: n = 19, HC: n = 12). After this procedure, 
we found clear differences in the younger BD patients compared to the younger controls 
and percentages of natural T reg cells were significantly higher in the younger BD patients 
compared to the younger HC (Fig. 2, BD < 40: median: 2.49%; min-max: 1.24-4.06%; BD > 
40: median: 2.19%; min-max: 0.50-5.00%; HC < 40: median: 1.58%; min-max: 0.97-2.50%; HC 
> 40: median: 2.38%; min-max: 1.44-3.42%). 
Finally, we measured the shed soluble form of CD25 in the serum and found higher levels 
of sCD25 in BD patients as compared to HC, irrespective of age (Fig. 2b, BD: median: 493IU/
ml; min-max: 190-2223; HC: median: 386 iU/ml; min-max: 225-1040). sCD25 serum levels 
correlated positively to percentages of CD25+ T cells (r = 0.250, p = 0.058),  including the 
natural T reg cells.
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Figure 1.  FACS definition of different subsets and gating-strategy
The gating strategy in flow cytometry to detect the different subsets of CD4+ T cells in a given patient/
control.
1a. Flow cytometric distinction between lymphocytes (lower left gate) and monocytes (upper right gate) 
by forward (FSC: proportional to cell size) and side scatter (SSC: proportional to cellular granularity).
1c+d. Flow cytometric analysis for surface expression of CD25+ on CD3+ lymphocytes in the lymphocyte 
gate of analysis 1a. The gate in 1d represents cells positive for CD25 in the population of CD3+ lymphocytes. 
The isotype IgG1 antibody in 1c was used to specify antibody specificity for CD25. The cells outside the 
gates in 1c and 1d are the CD25 negative CD3+ lymphocytes.
1b. Flow cytometric analysis for intracellular FOXP3 and surface CD25 within gated CD3+CD4+ 
lymphocytes. Pink cells represent FOXP3high and CD25high cells: The natural T regulatory cells. First CD4+ 
were selected in CD3+ lymphocytes, within this subset CD25high cells were selected and in this subset 
FoxP3+ were gated as regulatory T cells.
1e. Flow cytometric analysis for intracellular IFN-γ+ and IL-4+ expression in CD3+CD4+ lymphocytes. The 
upper left quadrant (IFN-γ+ positive cells) represents the Th1 cells. The lower right quadrant (IL-4+ positive 
cells) represents the Th2 cells.
1f. Flow cytometric analysis for intracellular IL-17a expression in CD3+CD4+ lymphocytes. The gated cells 
represent the Th17 cells.
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In 33 (87%) of the BD patients we had determined the gene expression signature in the 
monocytes previously [1, 2]. We correlated the expression levels of the various genes 
with the different T cell parameters studied: We did not find a correlation between the 
expression of the different genes of the pro-inflammatory monocyte gene expression 
signature and the different T cell parameters studied, in particular also not to the raised 
percentages of the natural T reg cells and the raised sCD25 level (data not shown). 
Most patients were using psychotropic medication at the time of blood collection (Table 
I). The use or the class of psychotropic medication did not influence the percentages of 
the different studied T cell subsets and the sCD25 level in serum (data not shown). 
A minority of the BD patients were BD2 patients (20%). Also a subdivision between BD1 
and BD2 patients did not influence the percentages of the different studied T cell subsets 
or the sCD25 level in serum (data not shown). 
Fig 2. Percentages of circulating CD4+CD25highFoxP3+ T regulatory cells and serum sCD25 in 
BD patients
a) Box plots are given of the percentages of CD4+CD25highFoxP3+ cells grouped according to age for 
patients with bipolar disorder and healthy controls. BD < 40 = patients aged under 40 years, BD > 40 
= patients aged over 40 years, HC < 40 = healthy controls aged under 40 years, HC > 40 = healthy 
controls aged over 40 years
b) The serum sCD25 levels in IU/ml
Significant P levels are given between the indicated groups, because of the small groups p values 
were calculated by the non-parametric Mann-Whitney test.
Age had a positive significant influence on the CD4+CD25highFoxP3+ T cells in healthy controls (r 
= 0.707, p = 0.001). Since there was this positive correlation with age, and since there are reports 
showing the same [17], we post hoc divided the BD patients and HC arbitrarily into a younger age 
group (< 40 years, BD: n = 19, HC; n = 10) and an almost equally large older age group (> 40 years, 
BD: n = 19, HC: n = 12). Age did not have a significant influence on the CD4+CD25highFoxP3+ T cells in 
BD patients (r = -0.125, p = 0.475).
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Relation of T cell subsets with the TPO-antibody status in BD patients and HC
TPO-Abs were positive in 11 of the 38 BD cases (29%). Interestingly, patients with BD and 
positive TPO-Abs had significant lower percentages of CD4+CD25highFoxP3+ regulatory 
T cells and higher percentages of Th1 cells (though the latter not significant at p=0.10) 
as compared to BD patients without AITD (Fig. 3). Despite the significant differences in 
natural T reg cell state, the levels of sCD25 were not significantly lower in the TPO-Abs 
positive versus negative BD cases (532 ± 201 and 565 ± 382 IU/ml respectively, p=0.82).
Fig 3.  Th1, Th17 and natural T reg cells in bipolar disorder  patients with and without TPO-Abs
Percentages of Th1, Th17 and regulatory T cells are grouped according to the presence of TPO-
Abs. Positivity for TPO-Abs was defined as values for TPO-Abs higher than 25 pg/ml measured by a 
commercially available ELISA. 
Means ± standard deviations are given. BD with AITD = patients with bipolar disorder positive for 
TPO-abs, BD no AITD = patients with bipolar disorder negative for TPO-Abs, HC = healthy controls 
without TPO-Abs, grey areas are the 95% confidence interval of the healthy controls.
Because of the small groups p values were calculated by the non-parametric Mann-Whitney test. * 
= p < 0.05
Thirty-three BD patients were tested for both T cell and monocyte parameters, 9 of these 
were positive for TPO-Abs. With regard to monocyte gene profiling, the TPO-Abs positive 
BD patients had a weaker inflammatory gene expression in their monocytes as compared 
TPO-Abs negative BD patients (particularly in the cluster 1 genes and not so much in the 
cluster 2 genes) (Table II). 
Of the TPO-Abs positive BD patients there were 3 patients with high TSH levels (“sub-
clinical hypothyroidism”), there were no differences in T cell levels or inflammatory gene 
expression compared to patients with normal TSH levels. All patients had levels of fT4 in 
the normal range.
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Table II. Monocyte gene expression levels in fold change versus the reference gene abl. 
BD with AITD a BD no AITD b HC c
a vs b
p value
a vs c
p value
b vs c
p value
Cluster 1
ATF3 2.42 (9.50) 3.58 (3.92) 2.79 (1.11) 0.380 0.825 0.066
PDE4B 2.62 (16.84) 5.60 (17.37) 3.23 (2.55) 0.357 1.000 0.015
DUSP2 1.86 (9.59) 4.37 (6.04) 2.23 (2.42) 0.428 0.875 0.103
IL1B 29.92 (557.28) 82.16 (1028.66) 11.31 (74.61) 0.273 0.149 0.005
IL6 0.01 (0.01) 0.01 (3.31) 0.01 (0.05) 0.220 0.681 0.212
TNF 5.71 (17.51) 7.57 (34.19) 3.56 (2.63) 0.564 0.325 0.028
PTX3 0.79 (1.92) 0.95 (3.86) 0.54 (0.61) 0.237 0.681 0.016
PTGS2 4.97 (16.28) 8.87 (40.54) 4.29 (5.62) 0.220 0.728 0.026
CCL20 0.03 (1.33) 0.09 (8.22) 0.03 (0.06) 0.220 0.325 0.009
TNFAIP3 2.72 (22.38) 8.45 (30.81) 1.84 (2.76) 0.654 0.076 0.009
Cluster 2
MAPK6 19.67 (564.35) 34.80 (93.67) 2.40 (1.30) 0.848 0.001 0.001
NAB2 0.30 (0.70) 0.27 (0.44) 0.21 (0.65) 0.749 0.875 0.521
PTPN7 0.30 (0.31) 0.41 (0.25) 0.31 (0.38) 0.593 0.825 0.368
EMP1 0.76 (1.62) 0.80 (1.12) 0.54 (1.22) 0.983 0.636 0.484
CDC42 1.27 (0.95) 1.35 (1.30) 0.97 (0.80) 0.380 0.825 0.182
CCL2 0.45 (1.10) 1.25 (2.28) 0.38 (0.90) 0.094 0.636 0.030
CCL7 0.01 (0.15) 0.05 (0.96) 0.01 (0.05) 0.113 0.825 0.420
The determination of the mRNA gene expression fingerprints in monocytes has been 
previously described in detail [1] and the medians (+inter-quartile ranges between 
brackets) of some cluster 1 genes (inflammatory compound cluster) and cluster 2 genes 
(motility, adhesion, chemotaxis cluster) are given for the here tested 38 BD patients in this 
series of experiments. Medians are given for the relative expressions towards the reference 
gene abl, in bold are statistically significant values as indicated. As can be seen the pro-
inflammatory state of monocytes is particularly evident in the BD cases without AITD and 
is in fact hardly present in the BD cases with AITD (except for MAPK6) 
Cytokine measurements in BD patients and controls
Of the cytokines tested only the monocyte/macrophage cytokines CCL2 and PTX3 were 
statistically significantly higher in the serum of BD patients as compared to control serum 
(Table III); levels of the monocyte/macrophage cytokine IL-1β were higher in this series of 
BD patients, but not significant (p=0.10). In a previous study [2] involving 42 BD patients 
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(26 euthymic, 7 mania, 7 depressed and 2 unknown) IL-1β levels were significantly higher, 
while those of CCL2 were near significant. We were not able to find significant correlations 
between the levels of the in this study tested cytokines and the percentages of the various 
T cell subsets, the monocyte gene expression levels or use of psychotropic medication. 
Table III. Cytokine levels in serum of patients with bipolar disorder
Bipolar disorder Healthy Controls
Mean Range Mean Range P-value
Monocyte activation CCL2 1084.31 494.51 867.21 522.85 .009
IL-8 38.95 89.18 33.94 74.50 .678
IL1b 3.43 11.270 0 0 .106
IL-6 0 0 2.65 12.15 .203
TNF-α 1.67 4.120 1.00 3.160 .520
PTX3 166.66 144.380 112.62 187.050 .021
Th1 IFN-γ 0.70 4.07 0 0 .432
Th2 IL-4 1.11 6.50 0 0 .432
IL-5 4.40 20.93 16.93 77.60 .895
Th17 IL17A 6.19 27.87 0 0 .262
IL-22 125.47 217.24 69.46 101.44 .354
Regulatory T cells IL-10 2.37 13.80 15.60 71.49 .708
Levels of cytokines are expressed as mean with range. All values are in pg/ml. Normal 
distribution was not obtained after log-transformation. Therefore P values were calculated 
by Mann-Whitney tests. 
Of the cytokines tested only the monocyte cytokines CCL2 and PTX3 were statistically 
significantly higher in the serum of BD patients as compared to control serum. 
For the other cytokines many of the readings were below the detection level of this 
CBA assay, this was most evident for IL-6, IFN-γ, IL17A and IL-10 (where more than % of 
the readings were below the detection level). Thus although for IL17A and IL-22 (Th17 
cytokines) mean readings were increased and for IL-10 (a monocyte/T reg cell cytokine) 
mean readings were decreased in BD patients, this was not at all statistically significant.
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Discussion
This study shows significantly higher levels of sCD25 and higher percentages of circulating 
CD4+CD25highFoxP3+ regulatory T cells in the circulation of BD patients, the latter only in BD 
patients < than 40 years of age and in BD patients without signs of AITD. 
The BD patients with AITD lacked the increase in CD4+CD25highFoxP3+ regulatory T cells 
and were additionally characterized by high circulating percentages of Th1 cells (though 
the latter not significant). Although in this relatively small series of BD patients the 
presence of AITD was not statistically significantly correlated to a reduced level of sCD25, 
we previously found in a larger series of BD patients that a reduced serum level of sCD25 
was significantly related to AITD: Padmos et al described in a series of 239 BD patients that 
those with AITD had significantly reduced serum levels of CD25 (be it mildly) in accord 
with the here described reduced level of natural T reg cells [12]. 
Our present observation on a relative lack of T regulator cells and our previous observation 
on a reduced sCD25 in BD patients with AITD point to an imbalance within the T cell 
system  as an important determinant for AITD to develop in BD patients. 
Similar T cell imbalances have been found by us 1st) in siblings of AITD patients, who have a 
heightened risk to develop AITD: These at risk individuals exhibited reduced percentages of 
natural T regulator cells as compared to healthy control individuals [18], and 2nd) in a small 
group of patients (n=17, a preliminary not-published study) with recent onset AITD (and 
no BD); in this group we found higher levels of Th1 and Th17 cells as compared to age-and 
gender matched healthy controls with regulatory T cell levels in the range of the healthy 
controls. These findings are in accord that imbalances In the T cell system, i.e. (relative) 
increases of effector Th1 and Th17 cells or (relative) decreases of CD4+CD25highFoxP3+ T 
regulatory cells are of importance in AITD development (be it with or without BD). 
With regard to such imbalances in the T cell system, there is ample evidence that regulatory 
T cells are capable of dampening the effects of pro-inflammatory Th1/Th17 cells [19] and 
of pro-inflammatory monocytes/macrophages [20]. It is thus of note that we found the 
pro-inflammatory state of the monocytes earlier reduced than enhanced in BD patients 
with AITD (see this report) and it is thus likely that in particular the activation state of 
Teffector cells is an important effector driving force in AITD development in BD (and not 
so much the activation state of monocytes/macrophages). 
The here presented study has limitations. First, we had no frozen PBMC left in store of BD 
patients in an active phase of the disease and all tested BD patients were patients in a 
euthymic phase at the time of blood collection. In the previous report of our group we 
found that the monocyte pro-inflammatory activation state was more outspoken when 
blood was collected during a manic or depressive episode [1, 2] and the literature also 
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indicates that pro-inflammatory cytokines are higher when the illness is active such as in 
mania or depression [5]. It might thus be possible that also inflammatory T cell numbers 
are higher during an episode. This being said, the advantage of the present study is that 
the found T cell abnormalities can be regarded as trait rather than state phenomena. 
Second, we have tested for a couple of associations in a relative low number of patients. 
Therefore, the found association between reduced natural T reg cell percentages and TPO-
Abs may be false positive and confirmation is in principle needed in an independent and 
larger series. However in a previous larger series of 239 BD patients significantly reduced 
levels of sCD25 did correlate to the presence of AITD, thus strengthening the present 
observation of weakened T reg cell forces in co-occurrent AITD. 
Third, our study was naturalistic and all BD patients were receiving psychotropic drugs, the 
majority was on lithium. Thus, we cannot rule out that some of the findings are influenced 
by the medications, although we could not establish correlations between the major 
types of medication (lithium, anti-depressants, anti-psychotics and valproate) and the 
various immune parameters in this study. Regarding lithium, this medication is considered 
in general to be anti-inflammatory [21-23]. 
A final limitation is that our FACS data represent percentages, not the number of cells 
within the lymphocyte population. We were unable to give absolute cell numbers of 
circulating cells, since we had not performed a leukocyte count in the same blood sample 
as used for FACS, although leukocyte counts routinely performed in the patient at the 
same time of blood sampling did not show abnormalities.
Despite these limitations our study is the first report on a detailed FACS analysis of 
various CD4+ helper cell subsets and natural T reg cells in BD patients. Previous literature 
concentrated on measuring T cell cytokines in serum and on in vitro production of T cell 
cytokines by isolated blood cells. 
The majority of these previous papers showed, in accord with our data, a tendency for a 
proliferative activation of the IL-2/CD25 system in BD patients: sCD25 higher in 2 reports 
[3, 24], IL2 higher in 1 report [5], IL-2 normal in 2 reports [25, 26]. Our data however extend 
these IL-2/sCD25 data showing that it is mainly the anti-inflammatory regulatory T cell 
force, which is more numerous. This higher activation of the T regulatory cell compartment 
was however not reflected in our study in significantly higher serum cytokine levels of 
the (partly) T reg cell derived anti-inflammatory cytokine IL-10, (though the relative low 
number of patients tested and the relative insensitivity of the used CBA assay may have 
played a role here, Table III).
With regard to literature data on Th1 (IFN-γ) and Th2 (IL-4, IL-5) related cytokines, a higher 
IL-4 level was found in lithium treated patients [26]. We did not find higher or reduced 
levels of typical Th1 or Th2 cytokines in our BD patients, nor did we find abnormal levels 
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of Th1 or Th2 cells, although the majority of our patients were treated with lithium (here 
again the relatively low number of patients and insensitivities of the CBA assay might have 
played a role).
The higher serum levels of CCL2 and PTX3 (this report) and of IL-1β (previous report 
[2]) shown in this cohort of BD patients strongly support the view that the monocyte-
macrophage system is pro-inflammatory activated in BD (a view also expressed in our 
previous reports, [1, 2]). However the altered T cell set point reported here, i.e. an increase 
in circulating CD4+CD25highFoxP3+ regulatory T cells and sCD25, was found independent 
of the pro-inflammatory monocyte gene expression state and did also not correlate to 
the higher levels of CCL2 and PTX3, strengthening a view that T cell and monocyte-
macrophage activation are independent phenomena in BD patients. And thus the question 
arises whether the T cell activation products as described here are capable of inducing 
mood symptoms independent from monocyte-derived pro-inflammatory compounds? 
Infusion of IL-2 in cancer patients has been reported to result in reduced energy, impaired 
confidence, depressed mood and confusion [27], while infusion of the pro-inflammatory 
monocyte-related cytokine IL-1β leads to the so-called sickness behavior [28]. In an animal 
model infusion of IL-2 or IL-1β during the direct post-natal period lead to distinct behaviors 
in adult rats, i.e. active locomotor behavior or increased startle response/decreased 
acoustic prepulse inhibition/increased social interaction respectively [29]. This indicates 
that T cell and monocyte related cytokines might induce distinct behavioral abnormalities. 
Taken together, our observations combined with those in the literature thus suggest that 
both the monocyte-macrophage system and the T cell system are activated in BD patients 
and that both types of activation might play independent roles in the pathophysiology 
of the illness. If this were the case, data from this report would also suggest that in BD 
patients with AITD such monocyte and T cell activation is reduced in comparison to 
BD patients without AITD and it becomes interesting to speculate about differences in 
psychiatric phenotype between BD with and without AITD. In a first report [30] on the 
association between TPO-Ab positivity and psychiatric illness we found that the most 
significant association was between TPO-Ab positivity (in particular of high titer and/or 
with TSH > 4.0 mU/l) and rapid cycling of bipolar disorder. In a later study [11] we could not 
confirm this association with rapid cycling, yet the association of TPO-Ab positivity and 
BD in general was confirmed. Suffice to say that further studies are needed to investigate 
whether differences exist in psychiatric phenotype between BD patients with varying 
involvements of the monocyte/ macrophage and T cell system.
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Abstract  
Objective: Monocytes in childhood-onset type 1 diabetes show distinct gene expression. 
We hypothesize that monocyte activation in monozygotic (MZ) twin pairs discordant 
for childhood-onset type 1 diabetes could reflect distinct stages of the disease process 
including diabetes susceptibility (differences between twins, both diabetic and non-
diabetic, and controls) and/or disease progression (differences between diabetic and non-
diabetic twins). 
Research Design and Methods: We studied patterns of inflammatory gene expression 
in peripheral blood monocytes of MZ twin pairs (n=10 pairs) discordant for childhood-
onset type 1 diabetes, normal control twin pairs (n=10 pairs) and healthy control subjects 
(n=51) using quantitative-PCR (Q-PCR). We tested the 24 genes previously observed by 
whole genome analyses and verified by Q-PCR in autoimmune diabetes and performed a 
hierarchical cluster analysis. 
Results: Of 24 genes abnormally expressed in childhood-onset type 1 diabetes, we re-
validated abnormal expression in 16 of them in diabetic twins, including distinct sets 
of down-regulated (p<0.03) and up-regulated genes (p<0.02). Of these 16 genes: 13 
were abnormally expressed in non-diabetic twins, implicating these genes in diabetes 
susceptibility (p<0.044 for all). Cluster analysis of monocyte gene-expression in non-
diabetic twins identified two distinct, mutually exclusive clusters, while diabetic twins had 
a network of positively correlated genes. 
Conclusions: Patients with childhood-onset type 1 diabetes show abnormal monocyte 
gene-expression levels with an altered gene-expression network due to gene-environment 
interaction. Importantly, perturbed gene-expression clusters were also detected in non-
diabetic twins, implicating monocyte abnormalities in susceptibility to diabetes. 
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Introduction
The destructive autoimmune process associated with type 1 diabetes involves both 
the innate and adaptive immune response represented by monocytes, dendritic cells, 
macrophages and T lymphocytes which infiltrate the islets at disease onset (1). Patients 
with type 1 diabetes show functional abnormalities of monocytes and monocyte-derived 
cells (2-8), which are assumed to promote the immunogenic potential of the cells. 
Recently, we reported that type 1 diabetes patients show abnormal monocyte gene-
expression profiles involving 24 inflammatory-related genes (5). Two distinct sets of 
correlating genes were found. One cluster consisted of down-regulation of 12 core 
“inflammatory cytokine/compound” genes strongly correlated to the expression of PDE4B 
(the “PDE4B-associated” cluster).  A second cluster was most prevalent in childhood-
onset type 1 diabetes and consisted of 10 up-regulated genes strongly correlated to the 
expression of FABP5 (the “FABP5-associated” cluster). 
These aberrant expression profiles in monocytes could be either familial, through shared 
genetic and/or environmental factors, or disease-associated. To resolve this issue we 
studied monocytes of monozygotic (MZ) twin pairs discordant for childhood-onset type 
1 diabetes, that is one twin had type 1 diabetes and the other did not. Gene-expression 
abnormalities associated with type 1 diabetes susceptibility, would be found in both type 
1 diabetes twins and their non-diabetic twins, (such similarities between MZ twins being 
due to shared genes, shared environment, or both), but not in normal healthy individuals 
(twin pair case-control design). Changes associated with type 1 diabetes progression, 
would only be found in the type 1 diabetes twin (co-twin case control design).  
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Research design and methods
Twins and Controls 
Monozygotic twin pairs were selected from the British Diabetic Twin Study (For details 
see reference 10). Of 451 twin pairs we selected MZ pairs discordant for type 1 diabetes 
eligible according to the following criteria: 1) European origin, 2) affected twins had type 
1 diabetes (diagnosed according to American Diabetes Association guidelines), 3) both 
twins of each pair were available for study, 4) neither twin was receiving drugs other than 
human insulin in the index case, 5) the non-diabetic twin had a low disease risk, that is a 
risk less than 2% based on lack of diabetes-associated antibodies (9, 10). Of the selected 
10 MZ pairs discordant for type 1 diabetes (n=10, mean  age 32 years, range 18-50 years, 
3 males), the diabetic twins were treated from the time of diagnosis with insulin and were 
taking highly purified human insulin at least twice daily; mean (Standard Deviation) (SD) 
duration of diabetes 22 (11) years in the diabetic twin. Monozygosity was established 
in twin pairs, using both clinical data and at least 22 blood groups, as described (9, 10). 
Control MZ twin pairs (n=12, mean age 37 (11) years, range 17-53 years, 4 male) were 
recruited from the local population through advertising. Childhood-onset type 1 diabetes 
singletons  (n=30, mean age 24 years, range 5-50 years, 11 males) were identified from our 
previous study (5). Healthy control (HC) singletons (n=51, mean age 39 years, range 21-67 
years, 23 male) were recruited from enrolling laboratory staff, medical staff and medical 
students. The inclusion criteria for the healthy controls were: no family history of diabetes 
or other autoimmune disease, no illness at the time of testing or for at least two weeks 
prior to the blood withdrawal, including acute infections and allergic reactions, taking no 
drugs, and on a normal diet. All the subjects gave informed consent. The ethics committees 
of Bart’s and The London NHS Trust and Royal Hospital Trusts, Heinrich-Heine University, 
Dusseldorf, and Erasmus HC Medical Centre, Rotterdam have approved the study. 
Blood collection and monocyte isolation
Peripheral blood mononuclear cell (PBMC) was isolated from Heparinized blood on 
standard Ficoll procedure (11). Purified PBMCs were then frozen in 10% dimethylsulfoxide 
and stored in liquid nitrogen. This enabled us to store the samples in order to batch samples 
for assays. CD14 positive monocytes were isolated by positive selection as described from 
frozen PBMCs using magnetic cell sorting system (Miltenyi Biotec, UK); monocyte purity 
was > 95% (determined by morphological screening after trypan blue staining and FACS).
 
Quantitative RT–PCR 
In this present study, RNA was isolated from monocytes using RNeasy columns (Qiagen, 
Hilden, Germany) and both this method and quantitative RT-PCR has been described 
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in detail elsewhere (11). Genes under study are the sets of genes previously described 
as aberrantly expressed in type 1 diabetes and type 2 diabetes. All Taqman probes and 
consensus primers were pre-formulated and custom designed by Applied Biosystems (for 
details see 12). PCR amplification of the housekeeping gene ABL was performed for each 
sample to allow normalization between the samples. For details of primers and probes 
used see Supplementary Table 1. The quantitative value obtained from Q-PCR is a cycle 
threshold (CT). The fold change values between different groups were determined from 
the normalized CT values (CT gene - CT housekeeping gene). 
Statistical Analysis
Data were assembled using Microsoft Excel software and are expressed as mean (standard 
deviation)(SD). Data were analyzed using SPSS/the Prism statistical package (SPSS 15.0 
package for Windows/GraphPad Prism, Inc. Version 3). Data were tested for normal 
distribution using the Kolmogorov-Smirnov test. Hierarchical gene analysis and heat 
maps were determined using a Pearson correlation matrix. Depending on the distribution 
pattern and the total number of subjects, parametric (normal distribution and ≥ 50 
subjects) or non-parametric tests (skewed distribution or <50 subjects) were used. Levels 
of significance were set at p< 0.05 (2-tailed).  
Results
Q-PCR analysis A preliminary observation and validation study identified 24 genes 
abnormally expressed in monocytes from type 1 diabetes patients (5). These 24 genes 
were examined in this re-validation study of MZ twins and the gene expression levels of 
16 of these 24 monocyte genes were abnormally expressed in twins with childhood-onset 
type 1 diabetes when compared with 12 normal MZ twin pairs and 51 normal singletons 
(Figure 1, Table I). These 16 abnormally expressed genes were: PDE4B, IL-1B, PTGS2, BCL2A1, 
TNFAIP3, TNF, CXCL2, HSP1A (all down-regulated)(<p0.04 for all) and CCL2, CCL7, STX1A, 
EMP1, PTPN7, CD9, FABP5, DHRS3 (all up-regulated)(<p0.02 for all)(Figure 1, Table 1). 
To determine whether the changes were familial, i.e. due to gene-environment interaction 
independent of diabetes and hyperglycaemia, we examined the non-diabetic MZ twins 
of these patients, selected to be at low disease-risk. Of 16 genes that were altered in 
the validation study in the index twins, 13 were also altered in the non-diabetic twins 
compared with controls: PDE4B, IL-1B, PTGS2, BCL2A1, TNFAIP3, TNF, CXCL2, HSP1A (all 
down-regulated) (p<0.04 for all) and CCL7, EMP1, PTPN7, CD9, FABP5 (all up-regulated) 
(p<0.044 for all)(Figure 1)(Figure 1,Table 1); 2 additional genes were abnormally expressed 
in non-diabetic, but not diabetic, twins i.e. DUSP2 and PTX3 (both down-regulated, p<0.05 
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for each)(Table 1).Only 4 genes (STX1A, CDC42, PTPN7, CD9) were abnormally expressed in 
diabetic compared with both non-diabetic twins and controls (p<0.041 for all), consistent 
with a diabetic effect, these 4 genes are also abnormally expressed in monocytes of type 
2 diabetes patients, consistent with a metabolic effect (5). 
Table I
INDEx DIABETIC TWIN NON-DIABETIC CO-TWIN
fold change p value vs HC fold change
p value vs 
HC
p value vs 
co-twin
PDE4B 0,29 0,001 PDE4B 0,32 0,001 0,741
CCL20 0,45 0,482 CCL20 0,27 0,129 0,425
DUSP2 0,74 0,067 DUSP2 0,44 0,018 0,142
IL-1B 0,16 0,001 IL-1B 0,12 0,001 0,650
PTGS2 0,23 0,014 PTGS2 0,25 0,014 0,899
IL-6 1,99 0,448 IL-6 0,86 0,999 0,216
BCL2A1 0,42 0,021 BCL2A1 0,29 0,001 0,076
PTx3 0,66 0,129 PTx3 0,46 0,027 0,360
ATF3 0,86 0,224 ATF3 1,00 0,697 0,654
TNFAIP3 0,54 0,007 TNFAIP3 0,35 0,001 0,266
NAB2 1,26 0,499 NAB2 1,75 0,601 0,569
TNF 0,35 0,026 TNF 0,48 0,039 0,561
CxCL2 0,41 0,035 CxCL2 0,29 0,016 0,364
CCL7 75,58 0,009 CCL7 43,71 0,033 0,425
STx1A 13,83 0,002 STx1A 9,00 0,081 0,019
CCL2 14,83 0,017 CCL2 8,94 0,074 0,380
EMP1 5,43 0,001 EMP1 4,56 0,007 0,544
CDC42 2,19 0,329 CDC42 1,60 0,754 0,015
PTPN7 3,36 0,004 PTPN7 2,22 0,043 0,023
MAPK6 1,75 0,106 MAPK6 0,77 0,218 0,082
DHRS3 6,11 0,017 DHRS3 7,06 0,203 0,741
CD9 3,94 0,005 CD9 2,81 0,014 0,040
HSP1A 0,28 0,001 HSP1A 0,18 0,001 0,108
FABP5 7,84 0,001 FABP5 2,89 0,002 0,064
Q-PCR analysis of monocytes of MZ twins with and without type 1 diabetes and healthy control (HC) 
MZ twin pairs. The quantitative values are expressed as fold changes: in essence the quantitative value 
obtained from Q-PCR is a cycle threshold (CT). The fold change values between different groups 
were determined from normalized CT values, as previously described (5). Data were standardized to 
51 healthy control singletons (used as the calibrator). Significance was tested by univariate analysis 
of covariance (ANCOVA), so that values >1 (in red) reflect higher expression and <1 (in green) lower 
expression  in twins than in these control singletons. 
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Cluster analysis Diabetic twins had a similar gene-expression profile and gene-order in 
cluster analysis to that found previously in childhood-onset type 1 diabetes singletons 
(Figure 2a,c); strongly positively correlated genes clustered in both diabetic groups, the 
dominant cluster extending from CCL2 to NAB2 (Figure 2a,c). Non-diabetic twins showed 
similar abnormalities of gene-expression (13 of 16) (data not shown) and gene-order to 
their diabetic twins, and a similar positively correlating dominant gene cluster (Figure 2b); 
by contrast, the gene-order differed from control twins (data not shown), and the latter had 
no comparable dominant cluster (Figure 2d). Both diabetic twins and singletons had two 
genes (PTGS2, HSPA1A) strongly negatively correlated with the dominant cluster (Figure 
2a,c); in the non-diabetic twins these negatively correlated genes extended into a cluster 
from PDE4B to CCL20 (Figure 2b). The two gene-expression clusters evident in the non-
diabetic twins broadly corresponded to the PDE4B-associated and FABP5-associated gene 
clusters, this latter previously reported by us as the major gene cluster in childhood-onset 
type 1 diabetes (5). No dominant cluster in diabetic and non-diabetic twins or diabetic 
singletons was found in control twins. Importantly, the disease discordant twin pairs 
showed significant correlations for 12 of 16 abnormally expressed genes (r (range) 0.68-
0.95; for all 12 p<0.05)(data not shown) consistent with a strong shared gene-environment 
interaction.   
Discussion
We previously reported that monocyte gene-expression profiles are abnormal in type 1 
diabetes, and vary according to age at diabetes onset, suggesting heterogeneity in disease 
pathogenesis (5). We re-validated abnormal monocyte gene expression levels for 16 genes 
in twins with childhood-onset type 1 diabetes. Cluster analysis found that the gene order 
was similar in both twins and singletons with childhood-onset type 1 diabetes, but distinct 
from that found in control twins and singletons.  Diabetic twins and singletons showed 
a dominant cluster of 12 abnormally expressed monocytes genes, including FABP5. Our 
failure to re-validate all the abnormally expressed monocyte genes initially reported, could 
be due to the relatively small numbers of highly-selected twin pairs, including selection of 
only childhood-onset type 1 diabetes patients, which will have limited the study power. 
The present observations in type 1 diabetes indicate that much of the altered monocyte 
gene-expression profile is due to shared gene-environment interaction, since similar 
changes were detected in their genetically identical twins who were not diabetic and 
selected to be at low disease risk. Such similarities between MZ twins are not necessarily 
due to shared genes, as shared environmental effects, or shared gene/environment 
interaction, would give the same result. Changes in these non-diabetic twins likely reflect 
monocyte changes associated with disease susceptibility, without necessarily predicting 
type 1 diabetes. Of 16 monocyte genes abnormally expressed in type 1 diabetes twins, 
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Figure 1
This Figure shows monocyte gene-expression levels from diabetic index twins, non-diabetic co-
twins and the index twin of a healthy control (HC) twin pair. Fold changes ( analysed as in table I) are 
presented similarly with increased (red) or decreased (green) expression levels (the colour intensities 
code for the strength of the expression levels). A grey line separates two distinct gene-expression 
profiles (PDE4B- and FABP5-associated clusters). For the majority, diabetic and non-diabetic twins 
show similar increased or decreased gene-expression levels compared with HC twins
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Figure 2
This Figure shows a heat map of correlations between gene-expression levels for 24 genes initially 
observed to be abnormally expressed in type 1 diabetes in: index diabetic twins (A), their non-
diabetic co-twins (B), diabetic singletons (C) and healthy control twins (D). Correlations in gene-
expression level are presented as positive (blue) or negative (red) expression levels (the colour 
intensities code for the strength of the correlations). The hierarchy of gene expression (found in 
cluster analysis) in all figures is ordered according to that in the index diabetic twins; two distinct 
clusters are noted in non-diabetic co-twins. 
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13 were abnormal in their non-diabetic twins and gene-expression levels for the majority 
were strongly correlated between diabetic and non-diabetic twins. Moreover, in contrast 
to controls, the gene order and dominant gene cluster on cluster analysis were broadly 
similar in co-twins. It follows from our observations that most abnormalities in monocyte 
gene-expression in childhood-onset type 1 diabetes are associated with familial 
predisposition to the disease, consistent with a previous study of monocyte responses 
in disease-discordant twins (7). Resolution of the degree of genetic contribution to 
altered monocyte gene-expression must await a classic twin study; but this would require 
substantially more MZ twins discordant for type 1 diabetes, as well as matched dizygotic 
twins, than we studied. 
Cluster analysis showed a striking disparity between non-diabetic twins and other groups, 
in that they had two clear gene-expression clusters, one cluster negatively correlated with 
the other. The dominant monocyte gene-expression cluster, with an up-regulated FABP5, 
included genes involved in adhesion, chemotactic and metabolic factors, while the less 
prominent negatively correlated and down-regulated PDE4B-associated cluster involved 
pro-inflammatory cytokines and chemokines (5).  These two gene clusters were perturbed 
in the diabetic twins into a network of predominantly positively correlated genes, with a 
weaker down-regulation of the PDE4B-associated gene cluster, potentially representing 
a progression marker to clinically overt type 1 diabetes. Longitudinal studies of at-risk 
individuals could clarify if such changes reflect disease progression. 
Our aberrant gene expression data implicates altered monocyte function in the 
pathogenesis of childhood-onset type 1 diabetes through gene-environment interaction. 
The character of the genes and previous studies (6, 7, 12) suggest that these functional 
changes include altered monocyte integrin expression, adhesion to endothelial cells and 
fibronectin, lipid raft and immune synapse formation, cell motility and assembly and 
induction of pro-inflammatory cells.  In-depth functional studies using transfection or 
si-RNA regulating the expression of selected key genes in human monocytes will need 
to be performed to define their exact function in diabetes pathogenesis. A substantially 
expanded classic twin study, also using dizygotic twins, would be required to determine 
to what extent genetic factors alone determine the altered gene expression. Nevertheless, 
identification of key monocyte genes, involved in the perturbed gene-expression 
networks predisposing to type 1 diabetes, suggests possible therapeutic targets to 
prevent progression to clinical disease. 
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Supplementary Table 1. Techniques, primers and probes used in Q-PCR analysis
Public ID Code
(NCBI)
Gene Symbol
Applied Biosystems  gene expression assays (Hs)/
Primer/Probe 5’-FAM-3’
NM_001037339 PDE4B Hs00387320_m1
NM_000600 IL6 Hs00174131_m1
NM_000576 IL1B Hs00174097_m1
NM_002852 PTX3 Hs00173615_m1
NM_000963 PTGS2 Hs00153133_m1
NM_000594 TNF Hs00174128_m1
NM_006290 TNFAIP3 Hs00234712_m1
NM_013448 BAZ1A Hs00203772_m1
NM_006273 CCL7 Hs00171147_m1
NM_004591 CCL20 Hs00355476_m1
NM_002089 CXCL2 Hs00236966_m1
NM_002982 CCL2 Hs00234140_m1
NM_044472 CDC42 Hs00741586_mH
NM_001769 CD9 Hs00233521_m1
NM_004603 STX1A Hs00270282_m1
NM_004049 BCL2A1 Hs00187845_m1
NM_001423 EMP1 Hs00608055_m1
NM_002832 PTPN7 Hs00160732_m1
NM_004418 DUSP2 Hs00358879_m1
NM_001030287 ATF3 Hs00231069_m1
NM_005967 NAB2 Hs00195573_m1
NM_002748 MAPK6 Hs00833126_g1
NM_004753 DHRS3 Hs00191073_m1
NM_001444 FABP5 Hs02339439_m1
NM_005345 HSPA1A
Probe     1.TTCGAGAGTGACTCCCGTTGTCCCA
FPrimer  2.GCTGCGACAGTCCACTACCTT
RPrimer  3.GGTTCGCTCTGGGAAGCC
NM_005157 ABL
Probe    1.TGGAGATAACACTCTAAGCATAACTAAAGGT
FPrimer 2.CCATTTTTGGTTTGGGCTTCACACCATT
RPrimer 3.GATGTAGTTGCTTGGGACCCA
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Discussion
Our data strongly support the presence of an activated immune response involving 
both pro- and anti-inflammatory forces of the monocyte and T cell system in patients 
with bipolar disorder, schizophrenia, autoimmune thyroid disease, juvenile onset type 1 
diabetes (T1D) and individuals genetically at risk to develop juvenile T1D, i.e. monozygotic 
co-twins of a diabetic twin, who however did not develop diabetes. 
Although the set points of the immune system were activated in all patients and at risk 
individuals, set points differed between the various disorders and conditions. Set points 
were in addition modulated by disease activity, disease duration, medication and/or life 
style factors. 
The majority of studies in this thesis focus on the gene expression of circulating monocytes 
to identify a pro-inflammatory state of these cells. In all individuals tested we were able 
to find that monocyte gene activation occurred in real life in two main patterns or gene 
clusters:
1. Cluster 1 with mainly pro-inflammatory cytokines and compounds, with IL-1β, IL-6, 
TNF, PTGS2, PTX3, various pro-inflammatory chemokines and inflammation regulators 
as PDE4B, DUSP2 as eye-catching factors. This sub-cluster is likely driven by the 
transcription factors/regulators ATF3, EGR3, MXD1 and MAFF. 
2. Cluster 2 with mainly adhesion/motility factors and chemokines, such as CDC42, CCL2, 
CCL7, EMP1 and STX1A. PTPN7 and NAB2 are most likely important transcription 
regulators for this sub-cluster.
For T cell activation we tested for the proportions of CD3+ CD25+T cells, Th1 cells, Th2 
cells, Th17 cells and natural CD4+CD25highFOXP3+ Treg cells. 
Cytokine studies in the serum of the patients completed the studies; e.g. serum levels of 
the innate immune cytokines TNF-α, IL-1β, IL-6, IL-10 and PTX3 were measured as well as 
the T cell proliferation indicator sCD25 and the T cell cytokines IFN-γ, IL-4 and IL-17.
Limitations of our studies 
Small study samples 
A strong point of our studies is that we carried out our studies in well-defined psychiatric 
patients. Nevertheless studies involved relative low numbers of patients and healthy 
controls (but never less than 25) and the studies turned out to have enough power to 
detect differences between disease and the healthy state. Although we were able to 
match patients and healthy controls for age and gender, it was not always possible to fully 
correct for confounding factors such as activity of the disease, medication, BMI, smoking, 
and the metabolic syndrome, of which factors we showed that they do influence serum 
cytokine levels and the inflammatory state of the immune cells. Splitting up the groups 
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along these lines, when possible, often resulted in too low numbers of patients with the 
specific characteristic making correlation studies less reliable. 
Therefore our studies should be confirmed in larger study samples of well-defined patients 
and healthy controls, also taking into account the BMI, other variables of the metabolic 
syndrome, disease duration, medication and disease activity making correction for the 
different confounders possible.
Peripheral blood samples 
All our studies were carried out on peripheral blood samples and we are not informed on 
the immune cells in the actual affected organs. We thus do not know whether the same 
aberrant activated set points are present in the immune cells in the brain, the thyroid 
or the pancreas. However in recent onset schizophrenia PET scan studies indicated that 
the microglia were activated in total gray matter [1], and particularly in the hippocampal 
area during acute psychosis [2]. This observation was taken as evidence for a “low grade 
inflammation” of the brain. In addition a recent paper investigated T cell subsets in the 
CSF and the peripheral blood of patients with a major psychiatric disorder and found an 
overlapping “low grade” inflammation in CSF as well as in the peripheral blood [3]. This 
indicates that up to a certain extent studies on immune cells in the peripheral blood 
reflect aberrancies in the target organs, but it is needless to say that our studies should be 
completed with investigations on the cerebrospinal fluid, the brain, the thyroid gland and/
or the pancreas of patients. Such investigations might be feasible via scans or small needle 
biopsies of the target glands (when possible). 
Only percentages have been given for CD4+ T cell subsets
In our studies only percentages for CD4+ T cells subsets were given, since we were not 
informed on the actual blood cell counts in the same sample (all of the samples had been 
frozen as PBMC). However there was in routine screening at intake of the patients (tested 
for a limited number of samples) no leukocytosis or abnormal differentiation. Another 
weak point of our way of enumeration is that functional studies on the CD4+T cell subsets 
are lacking; this is particular relevant for the natural T regulator cells, which might be 
normal or even increased in number, yet functional defective.
Influence of medication. 
Most patients in our studies were using medication and – as discussed above - medication 
has an effect on the immune system.
With regard to the effects of psychiatric medication it must be noted that effects of 
lithium and anti-psychotics are generally anti-inflammatory in character [4-6] and the data 
presented in this thesis, as well as previous data from our group, support such an immune 
suppressive action of lithium and anti-psychotics and show that, if any, these medications 
do not induce but correct the described high inflammatory set point of patient monocytes 
and T cells. 
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For patients with T1D it is in general more difficult to rule out an effect of medication, 
because all patients need insulin to survive. However, we were able to test individuals at 
risk to develop T1D (without having the disease or being on insulin). In both groups of 
tested individuals (patients with juvenile onset T1D and their non-affected monozygotic 
co-twin) a good correlation could be established between patients and healthy co-twin 
regarding the core-signature of autoimmune diabetes (cluster 2), which rules out an 
effect of medication on the induction of this cluster in monocytes by insulin. Insulin might 
however have an effect on cluster 1 expression and future studies should address this.
With regard to the disease state of patients with autoimmune thyroid disease we showed 
that there were only minimal differences in monocyte and T cell aberrancies between 
patients with hyper- or hypothyroidism and we interpreted the findings as indicating that 
there exists an immune aberrancy in monocytes and T cells that is shared between GD and 
HT and that too low or too high thyroid hormone levels did not influence the detected 
immune activation. Patients with AITD were very recent onset patients with hardly any 
drug treatment.
Summary of data in the endocrine autoimmune diseases
Taken the limitations into account, we established for autoimmune thyroid disease:
• That only a minority (24%) of AITD patients (mean age 41 yrs, ranging from 18-88 yrs, 
females 76%) had an activated monocyte set point, i.e. a monocyte pro-inflammatory 
gene expression signature (this thesis), which was however very similar to that found 
in about 50-60% of patients with LADA (this thesis) [7]. When splitting the signature 
in “presence of cluster 2 genes” 38% of AITD patients were positive, when splitting 
the signature in “presence of cluster 1 genes” 27% of AITD patients were positive (this 
thesis).
• That the serum levels of IL-1β, IL-6 and TNF-α were not raised, which is in accord with 
the in general low inflammatory gene cluster 1 state of the monocytes. However 
the serum levels of CCL2 were higher in patients suggesting an adhesion/infiltration 
activity of monocytes and in accord with the higher prevalence of gene cluster 2 
genes in monocytes. 
We established for juvenile onset type 1 diabetes mellitus (T1D):
• That activation of cluster 2 genes was present in 5/10 juvenile onset T1D index twin 
cases and also in a paired fashion in the monocytes of their monozygotic, discordant 
co-twins (this thesis). This shows that activation of cluster 2 genes is a familial trait and 
probably linked to a higher risk to develop T1D. These findings are in accord with our 
previous findings that around 40% (13/30) of T1D patients had a monocyte activation 
set point formed by cluster 2 genes only [7].
 Activation of cluster 1 genes was not present in the monocytes of the index juvenile 
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T1D cases; there was even a downregulation of some of the cluster 1 genes. This 
downregulation of cluster 1 genes was in particular prominent in the monocytes of 
monozygotic, discordant co-twins of T1D index twins (this thesis). This suggests that an 
anti-inflammatory set point of monocytes for cluster 1 genes might be a mechanism 
to prevent islet autoimmunity in the discordant co-twins. 
We conclude for endocrine autoimmune diseases: 
A. That it is unlikely that a pro-inflammatory state of circulating monocytes via cluster 
1 genes is an important causal factor for the development of AITD and juvenile onset 
T1D disease. If any, downregulation of these genes in monocytes might be a factor in the 
prevention of the disease. Preliminary data of our group also show a strong downregulation 
of cluster 1 genes in monocytes of recent onset cases of juvenile T1D, again showing that 
this type of monocyte activation cannot play a positive causal role in the outbreak of 
endocrine autoimmune disease.
B. That, however, monocytes activated via cluster 2 genes (the adhesion, motility and 
chemotaxis genes) might be causally important in the development of at least a proportion 
of juvenile onset T1D and AITD cases. This gene expression pattern probably points to an 
abnormal adhesion, motility and chemotaxis of monocytes and this view is congruent with 
the observations on abnormal monocyte adhesive and motility function in AITD patients, 
T1D patients and in the NOD mouse model of these diseases (see Introduction):In patients 
with AITD and T1D monocytes show a higher adhesion to endothelial cells and fibronectin 
(FN). After such adhesion the monocytes become less motile and more pro-inflammatory 
activated producing more of CCL2 and the inflammatory compound S100A [8, 9]. The 
monocytes also show a reduced migration towards the chemokines CCL2 and CCL3.
In the NOD mouse model monocytes also show an increased adhesion to fibronectin, in 
particular the expanded mature (Ly6C low) population of circulating monocytes, while 
recruitment of monocytes, macrophages and dendritic cells into inflammatory sites is 
hampered pointing to an abnormal chemotactic response, which can indeed be shown 
by a reduced migration towards CCL2. Interestingly more of FN is present in the vascular 
pole of the dysmorhogenic pre-diabetic islets of the NOD mouse [10]. Monocytes and 
macrophages adhere in particular to these spots [10] and would thus be strongly pro-
inflammatory activated. Indeed Wildenberg et al from our group [106] were able to show 
that such tissue DC lacked the expression of CCR5 and that this reduced CCR5 expression 
leads to an over production of IL-12, a cytokine capable of skewing the T cell response in 
a damaging Th1 direction.  
It remains to be seen whether also in AITD and T1D patients disease-pre-existing 
abnormalities exist in the ECM of islets and the thyroid, similar to those of the NOD mouse. 
Such abnormalities would aggravate the induced higher local pro-inflammatory state of 
abnormally adhesive monocytes and their descendent cells (the macrophages and DC) in 
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individuals at risk to develop endocrine autoimmunity. 
C. However, it must be noted that not only adhesive monocyte-macrophage abnormalities 
dictate the autoimmune process in humans and that – similar to the animal models of 
endocrine autoimmunity – concurrent T cell abnormalities probably play a prominent role 
in the pathogenesis. It is therefore relevant to note that we detected clear abnormal set 
points of the T cell system both in recent onset AITD and in recent onset childhood T1D. 
Figure 1. Preliminary data on CD4+ T cell subsets in patients with autoimmune thyroid disease.
Percentages (mean and standard deviation) of circulating IFN-γ+Th1, IL17+Th17 and 
CD4+CD25highFoxP3+ T regulatory cells in patients with recent onset autoimmune thyroid disease 
(n=15, including 8 autoimmune hypothyroidism and 9 Graves’ disease patients) are shown. For FACS 
techniques see Chapters 5 and 7. Patients samples were from the group of AITD patient studied in 
Chapter 6.
Significant P levels are given between the indicated groups, because of the small groups p values 
were calculated by the non-parametric Mann-Whitney test. * = p<0.05.
 
For AITD we found that the percentages of Th1 and Th17 cells were higher in the circulation 
of the cohort of recent onset AITD patients studied in Chapter 6, while the percentages of 
activated T cells (CD3+CD25+ cells) and in particular of CD4+CD25highFOXP3+ regulatory 
T cells were normal (Figure 1). We have to recall here that we also reported a reduced 
number of T cells with a T regulator phenotype in a study on individuals at risk to develop 
AITD (family members of AITD patients) and we took these data as suggestive for a 
reduction in T cell tolerance mechanism in these at risk individuals [11].
We also tested very recently a small series of recent onset Dutch T1D children the first 
week after diagnosis (n=5) and 6 months after diagnosis (n=10) and compared data to 
those of healthy control children (n=6). Patients were recruited from the diabetes clinic 
DIABETER in Rotterdam (courtesy Dr H.J. Aanstoot). In this series of recent onset Dutch T1D 
children we also found the percentages of Th1 and Th17 cells raised in the first half year 
after onset of the disease, however here percentages of CD4+CD25highFOXP3+ regulatory 
T cells were raised too in the circulation (though there are data in the literature that such 
cells are functionally defective, see introduction).
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These T cell data suggest that at the time of clinical outbreak of thyroid and islet 
autoimmunity the destructive process is probably driven, besides by an abnormal 
inflammatory state of the monocytes/macrophages and DC in the target-gland-to-be - by 
Th1 and Th17 effector cells, which are apparently out of control of T cell regulator forces, 
though we found these only numerically decreased in at risk individuals and not in recent 
onset cases. 
Table I. Summary of monocyte and T cell data for the endocrine autoimmune diseases under 
study
AITD At risk AITD T1D At risk T1D LADA
Monocyte gene cluster  1 ↑ nd ↓ ↓ ↑
Monocyte gene cluster 2 ↑ nd ↑ ↑ ↑
T effector cells ↑ nd ↑ nd nd
T regulator cells = ↓ = nd nd
(AITD=Autoimmune thyroid diseases, T1D=type 1 diabetes, LADA= Latent autoimmune diabetes 
of the adults). Higher (↑), lower (↓), or the same (=) expression or percentage as in healthy controls. 
nd=not determined
Table I summarizes the monocyte and T cell data and figure 2 illustrates a hypothetical 
scheme for the development of human endocrine autoimmune disease (present state of 
the art) integrating the data presented in this thesis with our previous animal and human 
data and the previous data from the literature. In the Introduction we summarized the 
data found in endocrine autoimmune diseases in figure 5, and showed that they were 
very similar to those found in the NOD mouse and BB-DP rat. These data are depicted here 
again under “old” in figure 2. In summary these data at the start of my studies show that 
there were signs of
1. An abnormal adhesive state of circulating monocytes (gene cluster 2 upregulated, 
more adhesiveness to FN and endothelial cells) leading to an over production of pro-
inflammatory factors (CCL2 and S100A)
2. A defective generation of veiled cells and dendritic antigen presenting cells (APC) from 
monocytes resulting in APC with a poor capability of stimulating tolerogenic T cells or 
to induce AITCD
3. A resistance of T cells to undergo apoptosis in AITCD
4. A defective function of natural regulatory T cells, and
5. A reduced number of regulatory T cells in individuals at risk for endocrine autoimmunity.
The new findings presented in this thesis include (figure 2 “new”):
6. That the abnormal state of the circulating monocytes hardly includes an upregulation 
of cluster 1 inflammatory genes and often includes even a downregulation of the 
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cluster 1 genes. This was described in chapter 6 for AITD, where there was only a limited 
expression of this gene cluster in patients as compared to the expression of cluster 2 
genes in monocytes. For childhood onset T1D (chapter 8) we also found a slightly 
downregulation of cluster 1 genes in index cases of T1D twins and the expression 
level of these cluster 1 genes was positively correlated to the expression level of 
cluster 2 genes. Interestingly in the non-diabetic co-twins there was even a stronger 
downregulation of cluster 1 genes that was tightly negatively correlated to the 
expression level of cluster 2 genes in the monocytes, suggesting an anti-inflammatory 
counter regulatory mechanism in monocytes of at risk individuals who do not develop 
autoimmunity.
7. That T effector cells are often increased in number in recent onset cases of T1D and 
AITD (preliminary data described above in the discussion section and see figure 1)
8. That even regulatory T cells may be increased in recent onset cases (preliminary data 
in T1D).
Figure 2. An update on the suggested immune mechanism playing a role in endocrine 
autoimmunity.
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Summary of data in the psychiatric disorders
We established for schizophrenia:
• That the majority of patients with a recent onset acute schizophrenia (mean age 27, 
range 17-59 yrs, 81% male, Chapter 3) had an activated monocyte set point, i.e. a pro-
inflammatory gene expression signature 
o With a high expression of cluster 1 genes, but 
o Lacking cluster 2 genes.
• That the serum levels of pro-inflammatory monocyte cytokines and chemokines were 
not higher in this cohort of relatively young acute patients. 
• That the percentages of monocytes, activated T cells (CD3+CD25+ cells), 
CD4+CD25highFOXP3+ regulatory T cells and (memory) Th17 were higher in the 
circulation of this cohort of relatively young acute patients, as well as the serum level 
of sCD25 (Chapter 5);
• That there was no correlation between the monocyte and T cell activation parameters;
• That the levels of IL-1β, IL-6, TNF-α and CCL2 were higher in a cohort of older patients with 
chronic schizophrenia (mean age 40 yrs, range 18 to 65 yrs, Chapter 4) of whom 51/145 
(35%) suffered from the metabolic syndrome (visceral obesity, hypercholesterolemia, 
and diabetes). 
Interestingly preliminary data on 11 patients of this cohort of older chronic schizophrenic 
patients show a rather limited monocyte pro-inflammatory gene expression, in which 
only ATF3, MAFF, MXD1, PTGS2, EREG and THBD were over expressed (data not shown).
• That in this older cohort of patients with chronic schizophrenia and the higher 
prevalence of the metabolic syndrome the serum level of raised CCL2 was negatively 
correlated with reduced HDL levels, one of the traits of the metabolic syndrome.
We established for bipolar disorder:
• That the majority of patients (mean age 42, range 26-61 yrs, 61% female, of whom one 
third had active disease) had an activated monocyte set point involving both cluster 1 
and cluster 2 genes.
• That the serum levels of IL-1β, PTX3 and CCL2 were raised in these patients 
• That the overexpression of the monocyte gene expression signature was particularly 
evident in active cases, i.e. in patients with mania or with an active depression. 
• That the percentages of activated T cells (CD3+CD25+ cells) and CD4+CD25highFOXP3+ 
regulatory T cells as well as the sCD25 in serum were higher in the circulation of patients 
under 40 yrs of age. The numbers of (memory) Th1 and Th17 cells tended to be higher 
(but differences did not reach statistical significance).
• That the serum levels of the innate immune cytokines TNF-α, IL-10 and TGFβ and the T 
cell cytokines IFN-γ, IL-4 and IL-17 were not different between patients and controls.
• That there was no correlation between the monocyte and T cell activation parameters, 
indicating separate activation mechanisms.
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Table II. Summary of monocyte and T cell data for schizophrenia (SCZ) and bipolar disorder (BD)
SCZ BD
Monocyte gene cluster 1 ↑ (B) ↑ (A)
Monocyte gene cluster 2 ↓ ↑
T effector cells ↑ =
T regulator cells ↑ ↑
Higher (↑), lower (↓), or the same (=) expression or percentage as in healthy controls. nd=not 
determined
We conclude for schizophrenia and bipolar disorder (Table II) that our monocyte gene 
expression studies, our T cell FACS analysis and cytokine studies suggest that 
1. An upregulation of subset 1A and 1B monocyte genes and products of both T effector 
and T regulator cells are involved in the activation of the MPS and microglia perturbing 
brain development and function in SCZ.
2. An upregulation of subset 1A monocyte genes, but in particular also of subset 2 
monocyte genes, is involved in the activation of the MPS and microglia perturbing brain 
development and function in BD. In addition products of T regulator cells may play a role 
in the elicitation of psychiatric symptoms in BD. 
Figure 3 represents a hypothetical scheme of the different immune set points relevant for 
the development of both disorders.
Monocytes in circulation are ‘angry’, that is to say, they have a pro-inflammatory 
transcriptome, which differs between bipolar disorder (both gene cluster 1 and 2) 
and schizophrenia (only cluster 1). There is indication from twin studies that cluster 1 
overexpression is determined by environmental factors, whereas genes determine for a 
part gene cluster 2 overexpression [12]. 
It can be envisaged that inflammatory monocytes, upon arrival in the limbic system (the 
“emotional brain”) as inflammatory microglia, will display an abnormal interaction with 
neurons and deregulate synaptic function and neuronal sprouting, and are perhaps even 
cytotoxic to these cells. This will lead to vulnerability for psychiatric behavior.
A higher level of pro-inflammatory cytokines in the circulation reflects the inflammatory 
state of the MPS, at least in bipolar disorder and chronic schizophrenia. These cytokines 
may penetrate the brain and aggravate the neuronal deregulations of the brain.
It can also be envisaged that inflammatory monocytes, when differentiated to dendritic 
cells in the tissues and after having traveled to the draining lymph nodes will abnormally 
stimulate the T cells in the lymph nodes. Indeed there are signs of an abnormal 
differentiation of monocytes of bipolar patients to dendritic cells, these dendritic cells 
have a reduced T cell stimulatory capacity [35].
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With regard to the expansion of the T cells: In the circulation of schizophrenia patients 
both Th17 cells and T regulator cells are over represented, in the circulation of bipolar 
patients only T regulator cells are more numerous. As a sign of higher T cell proliferation 
sCD25 is higher in the serum of both recent onset schizophrenia and bipolar disorder 
patients. Since there is both a stimulation of the anti- and pro-inflammatory T cell forces 
autoimmunity does not develop yet.
Differences between the immune status in young patients with acute and older 
patients with chronic schizophrenia.
Despite the clear overexpression of genes for the inflammatory cytokines in the circulating 
monocytes of young schizophrenic patients we found the level of the inflammatory 
cytokines not raised in the serum of these patients. Previously we also noted in our BD 
patients that serum pro-inflammatory cytokine levels were only mild reflections of the 
expression levels of their respective genes in the circulating monocytes of the patients 
[12], and over the last decade it has become clear that there is a whole level of complex 
regulation from gene expression to protein expression, a.o. by microRNA’s.  
In contrast to the young patients we did find many pro-inflammatory cytokines elevated 
in the serum of our cohort of older SCZ patients (mean age 40 yrs, range 18 to 65 yrs, 
Chapter 4), while there was only a limited expression of the pro-inflammatory gene 
expression signature in their circulating monocytes (see before, preliminary data). Recent 
data (Beumer at all, to be published) show that although the higher serum levels of these 
cytokines in older SCZ patients are clearly linked to the disease state that they are in 
addition strongly determined by the BMI of the patients and other components of the 
metabolic syndrome, such as the lipid profile. 
It is tempting to speculate that the higher serum levels of the pro-inflammatory cytokines 
in older SCZ individuals is mainly due to a higher production of these cytokines by tissue 
macrophages (such as in the adipose tissue, the microglia and/or –atherosclerotic- 
endothelial cells) and not by circulating monocytes. It is known that older SCZ patients 
are in particular at risk for morbid obesity and atherosclerosis and perhaps the medication 
(inducing obesity) might play a role as well in switching the pro-inflammatory cytokine 
production from circulating immune cells to the sessile macrophages in fat (though we 
found anti-psychotics to be mainly anti-inflammatory). 
Immune system to brain communication in psychiatric illnesses: A key role for 
microglia. 
In this thesis we clearly showed an activation of the immune system in patients with 
psychiatric disorders. But how does this impact the brain?
There is clear evidence from animal models that an activation of the immune system 
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influences the brain causing an altered behavior. The nicest model in this respect is in our 
vision the “maternally induced inflammation model”, which highlights several aspects of 
the immune to brain communication. Several studies have shown that intra-peritoneal 
injection of a pregnant rodent at late gestational age with LPS gives the pups a long lasting 
activation of the immune system together with behavioral changes [13]. These behavioral 
changes include learning disabilities and reduced social behavioral performances and 
are often referred to as schizophrenia-like behavior. The LPS treatment of the pregnant 
rodents is known to elevate levels of various pro-inflammatory cytokines in the serum, 
fetal liver and amniotic fluid of the pregnant rodent, but also TNF-α and IL-10 have been 
found higher in the fetal brain, which are thought to be involved in the abnormal brain 
development and behavior of the pup. Blocking antibodies against IL-6 given to the 
pregnant rodents prevent the later altered behavior in the pups [13]. 
Interestingly there is a human correlate: The relation between prenatal infections and 
the development of schizophrenia has been described for a long time. Mothers suffering 
from influenza in the first trimester of pregnancy have a 7 times higher chance for the 
development of schizophrenia in their offspring, this was 3 times higher for an infection in 
the second trimester. Another study shows that mothers sero-positive for herpes simplex 
virus (HSV)-2 in pregnancy have a 2 times higher chance of schizophrenia development 
in their offspring. Moreover in a cohort study IgG antibodies to Toxoplasma were 2 times 
higher in mothers who gave birth to a child with schizophrenia [14]. These data are in 
general interpreted that the microbial pathogens are crossing the placenta and cause 
congenital brain anomalies and this has been proven for Toxoplasma, HSV, rubella and 
cytomegalovirus. However a role for inflammation and immune activation in general 
should not be neglected, it has also been shown that levels of pro-inflammatory cytokines 
were higher in the serum of mothers during the pregnancy from which a child was born 
who later developed a psychiatric disorder [14]. 
Via which routes does a peripherally activated immune system influence brain 
development and function? Two main pathways have been described:
1. An altered inflammatory set point of the brain milieu and in particular of the microglia.
Pro-inflammatory cytokines can enter the brain via the circumventricular organs and the 
choroid plexus via an active transport mechanism. Although infiltrated cytokines may 
influence neuronal networks directly, there are no histological reports on the expression of 
pro-inflammatory cytokine networks in the brain of BD and SCZ patients. There is a report 
on an increased ICAM-1 expression in gray and white matter of the anterior cingulated 
cortex in post mortem brains of BD patients (this overexpression was absent in that of 
SCZ patients), suggesting a low grade inflammation of the anterior cingulated cortex of 
patients with bipolar disorder [15].
We however like to suggest that the microglia, the “macrophage/dendritic cell of the brain” 
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is the important intermediate in the process of immune system to brain communication. 
A direct role of microglia was recently shown by Chen et al [16]  where compulsive-like 
behavior in a mouse model had a hematopoietic origin: The Hoxb8 mutant mouse showed 
excessive grooming and hair removal and this is originated from mutant microglia of bone 
marrow origin [16].
Also the “maternally induced mouse inflammation model” is very instructive for a key role 
of microglia in peripheral immune system-brain communication: In recent experiments 
carried out in our group via the EU-consortium MOODINFLAME Beumer et al and Bessis et 
al (to be published) showed that LPS injection of pregnant mice induces a monocyte gene 
expression profile very similar to the monocyte gene expression profile reported here in 
psychiatric patients. In the mouse model this resulted in an identical pro-inflammatory 
gene expression profile in the fetal microglia, which clearly impacted the growth and 
development of neurons in the hippocampal area. At an earlier occasion Bessis et al [17] 
had already shown that pro-inflammatory activated microglia alter glutamatergic synaptic 
function in the brain. 
Is microglia activated in the brain of psychiatric patients? 
With regard to the number of microglial cells and their activation, histological post 
mortem reports are limited and controversial. A post-mortem study on the brains of 
SCZ patients, who had committed suicide, revealed increased densities of microglia [2]; 
two other studies also reported on increased microglial activation in SCZ patients [18, 
19]. However, 3 studies refuted an activation state of microglia [20-22].  A drawback of 
these post mortem studies is their character, since they are normally performed on old 
to very old individuals (after a process of dying) and studies on brain material collected 
in these individual might not reflect the acute disease stages happening years before the 
post mortem examination. Currently one does not need to rely on post mortem studies, 
developments in the field of positron emission tomography (PET) allow researchers to 
study microglia activation in real-time in live patients. A PET-tracer ([11C]-PK11195) 
binds to the peripheral benzodiazepine receptor (PBR), which expression is increased 
in activated microglia and interestingly also on pro-inflammatory activated monocytes 
(to be published), thereby visualizing microglia and microglia activation. This technique 
has already successfully been applied in several patient and animal studies on Parkinson’s 
disease and recent-onset schizophrenia [1, 23]. 
2. Depletion of tryptophan and its metabolite serotonin and the production of neurotoxic 
metabolites from an altered tryptophan break down pathway.
Tryptophan can be broken down via 2 metabolic pathways 
1. The Methoxyindole pathway leading to the formation of the important neurotransmitter 
5-HT or serotonin
2. The Kynurenine pathway leading to kynurenic acid and quinolonic acid via the 
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production of kynurenine. Quinolonic acid has neurotoxic effects, kynurenic acid has a 
neuroprotective effect. Plasma kynurenic acid is lower in patients with MDD, as well as 
the ratio kynurenic acid/kynurenine.
The rate-limiting enzyme for the second tryptophan-kynurenine pathway is IDO (99%). 
IDO activity is particularly induced at sites of inflammation in immune cells. The IDO 
pathway is a key regulatory element responsible for induction and maintenance of 
peripheral immune tolerance in normal physiological situations [24].  Pro-inflammatory 
cytokines, e.g. produced by macrophages, induce IDO in a variety of immune cells [25]. 
Inflammation (and probably pro-inflammatory monocytes and microglia) promotes 
the second pathway, thereby depriving the first pathway of fuel leading to a decrease 
in serotonin synthesis [26]. Serotonin deprivation is an important determinant for the 
development of depression. Serotonin reuptake inhibitors are commonly used in patients 
with depression. Also a meta-analysis shows that acute tryptophan depletion decreases 
mood in healthy controls with a family history of MDD and patients with MDD in remission 
but not in population healthy controls [27]. 
Not only there is a deprivation of fuel for the serotonin pathway, but there is also a 
shift towards formation of kynurenines, which have an apoptotic, neurotoxic, and pro-
oxidative effect. Interestingly a higher expression of quinolate has been seen in activated 
microglia in the brains of suicide victims [2]. Moreover the second pathway may lead to 
an upregulation of inducible nitric oxide synthase (iNOS), phospholipase A2, arachidonic 
acid, prostaglandin, 5-lipoxygenase, and the leukotriene cascade which may lead to the 
development of metabolic syndrome [25]. 
The origin of the activated immune system: Genes or environment?
The effect of the environment on the immune activation 
A couple of years ago Padmos et al [28] from our group carried out a case-control study 
using the monocytes of bipolar twins to determine the contribution of genetic and 
environmental influences on the expression of the monocyte pro-inflammatory gene 
signature. It was found that the association of the pro-inflammatory monocytes gene 
signature with bipolar disorder was primarily the result of common shared environmental 
factors, apart however for some of the cluster 2 genes, which were also genetically 
determined. In her thesis Roos Padmos extensively described the various environmental 
factors, which could play a role in this influence and highlighted the role of the microbiome, 
acute and chronic stress and dietary factors. Also for endocrine autoimmunity these 
environmental factors have been described as important determinants.
Our data on the relation between high CCL2 levels and a reduced HDL in older patients 
with chronic SCZ illustrate the role of a western style diet with too much unsaturated fat 
in the higher set point of the immune system in psychiatric disease.
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The effect of genes on the immune activation.
Genome wide association studies (GWAS) have been performed in the last decade in 
large cohorts of patients with BD and SCZ with overall disappointing results. It turned out 
to be virtually impossible to consistently find specific genes linked to the disorders and 
to replicate findings for individual studies. The problem is that psychiatric diseases are 
probably from a pathogenesis point of view very heterogeneous and certainly in general 
not the result of a mutation in a single or a few genes. Large meta-analyses were needed 
to complete the GWAS studies and presently a few genetic markers with a limited risk 
have been identified. Amongst these markers is the MHC complex in SCZ [29] and the TNF 
gene in major depression [30]. A new approach is to find in these large studies molecular 
pathways, which are affected in psychiatric disease. This approach is somewhat more 
successful and found for SCZ for instance an involvement of the glutamate metabolism 
pathway and the TNFR1 pathway [31]. These data point indeed towards a role for an 
activated mononuclear phagocyte system (MPS, including circulating monocytes and 
brain microglia) in interaction with neurons in psychiatric disease, as discussed above, yet 
also show that the contribution of genetic polymorphisms to the activation of the MPS is 
limited.
This might be different for the activation of the T cell system in psychiatric disease. An 
extension of our twin studies involving Treg cell enumeration (to be published) shows 
that Treg cell numbers are under the influence of genes (see Figure 4). These studies need 
now to be extended for the other T cell populations, but at least show for an important T 
cell population in autoimmunity that genes are involved. The genes consistently found to 
be involved in endocrine autoimmunity are the MHC-complex, CTLA4 and PTPN22 and 
point to an important contribution of disturbances in T cell activation and downregulation 
in endocrine autoimmunity [32]. It is of interest to note that the gene molecular pathway 
studies mentioned above also delivered the TGF-β signaling pathway in SCZ; TGF-β is an 
important Treg cell cytokine and T regs are elevated in SCZ (see this thesis).
The role of epigenetic imprinting in the immune activation
Epigenetic imprinting can certainly be a mechanism via which the above-described 
environmental factors create long lasting pro-inflammatory set points in the MPS of 
psychiatric patients and via which even fetal/childhood influences impact cellular 
functions later in life. Of chronic severe stress (child abuse) it has been reported that it 
induces epigenetic changes in the glucocorticoid receptor in the brain [33]. Glucocorticoid 
resistance is an important phenomenon in at least the T cell activation of psychiatric 
patients [34]. Epigenetic modulations of important cluster 1 and 2 signature genes 
therefore deserve further study. 
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Figure 4. Preliminary data on the percentages of natural T regulator cells in monozygotic 
and dizygotic twins, either with an index twin with bipolar disorder or a healthy index twin 
of matched age and gender.
Twins were from a study previously published by Vonk et al [41]. As can be seen from the 
figure monozygosity strongly determines the correlation between the percentages of 
CD4+CD25highFoxP3+ regulatory T cells in index twin and co-twin, while the presence or absence 
of bipolar disorder is of limited influence. This suggests that in particular genes play a role in the 
numbers of circulating natural regulatory T cells. Clearly further studies are needed. 
A relation of a partial immune deficiency, the commensal microbial environment 
and a pro-inflammatory set point of the immune system in severe psychiatric 
disease?
A previous study of our group showed that the dendritic cells of patients with bipolar 
disorder are poor T cell stimulatory antigen presenting cells [35]. Theodoropoulou et al 
made a similar observation in medicated and not medicated patients with schizophrenia 
and showed that patients had a diminished autologous mixed lymphocyte reaction [36]. 
These poor presentation and T cell stimulatory skills of patient antigen presenting cells may 
lead to difficulties in immunization towards commensal microbes such as streptococci, 
staphylococci and yeasts like candida. Indeed patients with schizophrenia have diminished 
delayed type hypersensitivity skin reactions to such commensals, showing a partial T cell 
immune deficiency towards these commensal microbes [37]. Perhaps this partial T cell 
deficiency is also linked to the MHC gene linkage of SCZ and BD (see before), since the 
MHC complex determines the host’s capability to optimally respond to the commensal 
bacterial flora. It is thus tempting to speculate that patients with BD and SCZ have a 
reduced T cell immunity to commensal (and non-commensal) bacteria, making patients 
more vulnerable to infections with commensal micro-organisms (perhaps even from birth 
onwards). 
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There is indeed circumstantial evidence for this view in studies measuring antibodies 
against various common bacteria and viruses. Many of these studies do find higher titers to 
commensal microbes in patients with SCZ or BD compared to healthy controls, suggesting 
a higher exposition level to these microbes [38]. This would allow factors produced by 
these microbes, such as LPS, peptidoglycan and viral DNA/RNA, to continuously stimulate 
the immune system through pattern recognition receptors, such as the Toll-Like Receptors 
(TLRs), leading to a pro-inflammatory set point as described in this thesis.
The Poly-endocrine Glandular Syndrome (PGS) extended to the Poly-Neuro-
Endocrine Syndrome (PNES): The association of bipolar disorder with thyroid 
autoimmunity/T1D. 
AITD and T1D occur more frequently together than normal within patients and families. The 
co-occurrence of these two organ specific autoimmune diseases is described as subtype 
3A of a syndrome called Poly-endocrine Glandular Syndrome [39]. This syndrome was 
initially defined as a multiple endocrine gland insufficiency associated to an autoimmune 
disease in a patient, involving AITD, T1D, atrophic gastritis and Addison ’s disease (adrenal 
cortex insufficiency). These associations were noted not to be at random but to occur in 
particular combinations. 
However not only autoimmune endocrine gland insufficiencies cluster mutually together 
in patients and their families, but also together with mood disorders.
First, hypothyroidism is commonly accompanied by depressive symptoms. Second, 
subjects positive for TPO-antibodies were shown to have a higher risk to develop mood 
disorders. And, finally, bipolar patients are more prone to develop thyroid autoimmunity 
(see for references the Introduction).
Also children of bipolar patients are at higher risk to develop endocrine autoimmunity as 
was demonstrated by a study conducted in our group [40]. In this research, there was a 
higher prevalence of TPO-antibody positivity than in healthy controls especially in female 
bipolar offspring (16% vs. 4%). Furthermore, three children had developed T1D (i.e. 2% 
versus 0.4% in the general population). In addition, a twin study of our group showed that 
healthy co-twins of bipolar index twins show a similar high prevalence in TPO-antibody 
positivity, irrespective of mood symptoms [41]. Thus family members of BD patients 
are more vulnerable to develop thyroid and islet autoimmunity, but these endocrine 
autoimmune diseases do develop independently from the vulnerability to develop 
aberrancies of the mood state. These findings refute the concept that mood disorders 
and thyroid/islet autoimmunity are cause or consequence of each other. This is further 
strengthened by our observation in pregnant and postpartum women where postpartum 
depression was related to TPO-antibody positivity rather than to thyroid dysfunction [42] 
and by the observation that the depression seen in TPO-antibody positive post-partum 
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women was not corrected by thyroid hormone treatment [43]. 
Collectively these data imply the presence of a shared common vulnerability factor for 
mood disorders, thyroid autoimmunity and possibly also T1D.  
We hypothesized that in particular the immune activation state is important as shared 
vulnerability factor and asked ourselves the question what the key immune abnormality 
is which runs in the patients and their family members and which raises the chance 
for acquiring a psychiatric disorder and/or an endocrine autoimmune disease. Table III 
summarizes the monocyte and T cell findings in BD with and without AITD.
We like to discuss two possibilities:
1. Both psychiatric and endocrine autoimmune disorders are driven by pro-inflammatory 
set point of circulating monocytes.  
In BD and SCZ cluster-1-activated pro-inflammatory monocytes are present in 50-60% 
of patients, particularly in those with active disease (Chapter 3). However in AITD only 
24% of circulating monocytes show this pro-inflammatory profile (Chapter 6). Moreover 
in BD patients with AITD monocytes are, if any, less cluster-1-pro-inflammatory activated 
as in BD patients without AITD (Chapter 7). This makes it less likely that the cluster 1 gene 
activation state of circulating monocytes is the factor for the higher co-occurrence of both 
psychiatric and endocrine autoimmune disorders (see also Table III). 
2. Both psychiatric and endocrine autoimmune disorders are driven by a pro-inflammatory 
set point of monocyte-descendent cells in the tissues, respectively in the brain and the 
thyroid.
The serum level of CCL2 is raised in BD and AITD, indicating a migratory activity of 
monocytes and their descendant cells in the tissues (Chapters 4 and 6). PET indicates 
a pro-inflammatory state of microglia in SCZ (see before), but we are not informed on 
the pro-inflammatory activation state of microglia in BD and AITD, let alone on the pro-
inflammatory activation state of monocytes and DC infiltrating the thyroid or the islets in 
BD patients or individuals at risk for or with an endocrine autoimmune disease. 
However, if analogies exist with the animal models of autoimmune thyroiditis and insulitis 
(see Introduction) a role of an enhanced adherence of abnormally sticky monocytes/
dendritic cells to an abnormal ECM with a high FN content might play a role in an enhanced 
pro-inflammatory set point of both the microglia in the brain (in such view activated by 
an abnormal ECM compartment in the brain) and DC in the thyroid/islets of patients. This 
stickiness and resulting local inflammatory state of monocytes/macrophages and DC 
would then be the shared vulnerability mechanism between BD and AITD and indeed 
Table III shows that cluster-2 activation in monocytes is the shared vulnerability factor 
between BD and AITD.
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Table III. Summary of monocyte and T cell data for the bipolar disorder (BD) with and without 
autoimmune thyroid disease (AITD)
BD without AITD BD with AITD
Monocyte gene cluster  1 ↑ (A) =
Monocyte gene cluster 2 ↑ ↑
T effector cells = ↑
T regulator cells ↑ ↓
Higher (↑), lower (↓), or the same (=) expression or percentage as in healthy controls. nd=not 
determined
It would also mean that there are in fact two immune mechanisms that may lead to BD 
(see Figure 5): 
a) One primarily based on a pro-inflammatory activation of peripheral mononuclear 
phagocytes, including monocytes via subset 1 genes. These genes are predominantly 
induced by environmental factors [28], and 
b) The other based on a stickiness of mononuclear phagocytes, including monocytes, to 
extracellular matrix components (as indicated by the upregulation of subset 2 genes), 
which would render the cells in the tissues pro-inflammatory. The latter would be also 
genetically determined [28], and the one linked to thyroid autoimmunity.
Five-year view
Various issues will be addressed in the coming 5 years regarding the activated immune 
system in schizophrenia, bipolar disorder and endocrine autoimmunity.
1. The development of array systems other than those described in this thesis both 
on the transcriptomic and proteomic level to more reliably detect the activated state of 
monocytes and T cells in schizophrenia, bipolar disorder and endocrine autoimmunity. 
At present also other research groups perform transcriptomic arrays on T cells and various 
proteomic arrays on the cytosol of circulating blood cells and on serum/plasma (Sabine 
Bahn, personal communication). The first indications are that with arrays of limited 
numbers of 10-20 analytes (many comprising growth and immuno-neuro-endorine 
factors) on serum assays may be developed that are able to make distinctions between 
the disease states and healthy controls.
2. The potential of the above described transcriptomic and proteomic array systems 
to objectively identify and subdivide major psychiatric illnesses, such as schizophrenia, 
bipolar disorder and major depressive disorder. 
Here it must also be noted that only part of the patients (about 50-60%) in the different 
psychiatric categories are positive for pro-inflammatory (“angry”) monocytes in the RQ-
PCR arrays. The question must be addressed whether this indicates heterogeneity in 
disease pathogenesis, as we suggest in Figure 5. 
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Figure 5. The hypothetical mechanisms for two types of immune pathogenesis of bipolar 
disorder. 
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Mechanism A is as described for bipolar disorder in Figure 3.
Mechanism B is more of an “autoimmune type” and is associated with thyroid autoimmunity.  We 
like to suggest that in fact the pathogenic mechanism is followed for endocrine autoimmunity as 
illustrated in endocrine autoimmune patients and the animal models of endocrine autoimmunity. 
That is to say that the myeloid precursors of the bone marrow show a deviant maturation. This 
deviant maturation results in 
1) An abnormal adhesive state of circulating monocytes (gene cluster 2 upregulated, more 
adhesiveness to FN and endothelial cells) leading to an over production of pro-inflammatory 
factors (CCL2 and S100A). This abnormal adhesive state would be more determined by genes 
than environment.
2) An abnormal maturation of microglia from these sticky monocytes resulting in microglia with 
an intrinsic high inflammatory set point. This microglia will display an abnormal interaction 
with neurons and deregulate synaptic function and neuronal sprouting, and is perhaps even 
cytotoxic to these cells. This will lead to vulnerability for psychiatric behavior.
3) With regard to the thyroid DC developing from sticky monocytes see Figure 2.
4) In bipolar patients with autoimmune thyroid disease there is a clear imbalance between Th1 and 
regulatory T cells (in favor of the Th1 cells) as compared to those without autoimmune thyroid 
disease. Interferon-γ produced by these Th1 cells might also play a role in the deregulation of 
brain function by inducing IDO and interfering in the tryptophan metabolism.
If autoantibodies play a role in the induction of psychiatric symptoms Mechanism B would be the 
pathogenic mechanism in which they are the most likely produced.
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3. The power of the transcriptomic and proteomic arrays to identify psychiatric 
patients, who will benefit from adjunctive anti-inflammatory therapy targeting important 
fingerprint genes. 
Adjunctive therapy with anti-inflammatory agents, such as COX-2 inhibitors, can alleviate 
symptoms in mood disorders and schizophrenia (44). Also patients treated with TNF 
antagonists for immune diseases such as psoriasis, Crohn’s disease or rheumatoid arthritis 
not only describe improvements in somatic symptoms but also in depression scores and 
quality of life (45). Drugs inhibiting the activity of PDE4 have anti-depressive and anti-
inflammatory potential (46-47), as do have strong anti-oxidants, such as N-acetylcysteine 
(NAC) (48). It is to be expected that in particular the psychiatric patients with “ angry” 
monocytes showing strong elevations of pro-inflammatory genes (about 50% of the 
patients) will benefit from these treatments.
4. The prognostic potential of the transcriptomic and proteomic array systems to 
identify at risk individuals for schizophrenia, bipolar disorder and endocrine autoimmunity. 
In particular family and twin studies will be instrumental here. At the same time 
environmental influences (stress, infections) inducing the abnormal inflammatory 
state of the immune cells and preceding the psychiatric illnesses can be studied via 
epidemiological approaches in these individuals at risk.
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Although there were already reports of an involvement of the immune system in major 
mental illnesses in the first decade of the 20th century, it took until the last decade of the 
20th century before detailed studies on an immune involvement became more numerous. 
These studies reported aberrant levels of pro-inflammatory cytokines in the serum, plasma 
and cerebrospinal fluid of patients with schizophrenia and major mood disorders. On the 
basis of these reports, it was hypothesized that a pro-inflammatory state of the cytokine 
network induces psychopathologic symptoms, and is involved in the pathogenesis and 
pathophysiology of these major mental illnesses.
Activated cells of the immune system, such as activated endothelial cells, cells of the 
mononuclear phagocyte system (MPS; e.g., monocytes, monocyte-derived dendritic 
cells and macrophages) and T cells primarily produce these pro-inflammatory cytokines. 
The realization that such cells must be involved led to the ‘macrophage–T-cell theory 
of depression and schizophrenia’, which was proposed in 1992 and adapted in 1995. 
In this theory, chronically activated macrophages (and their related cells in the brain, 
i.e., the microglia) and T cells produce cytokines and inflammatory compounds, which 
destabilize the brain in such a way that other genetic and environmental influences are 
able to precipitate the signs and symptoms of schizophrenia and mania/depression. 
Indeed, receptors for inflammatory cytokines are present in various brain nuclei and, via 
their triggering, deregulations of important neurotransmitter and neurodevelopmental 
systems are introduced, facilitating the development of psychiatric signs and symptoms. 
Microglia is particularly important for synaptogenesis, synaptic functioning and neuronal 
sprouting. Under steady state conditions, microglia promotes neurogenesis by the 
production of neurotrophic factors such as nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) that support the survival of neurons. However when microglia 
switches from a steady state to a pro-inflammatory set point, it impacts the growth of 
neurons in the hippocampus and synaptic function.
The major mental illnesses studied in this thesis are bipolar disorder (BD) and schizophrenia 
(SCZ). According to the DSM-IV classification BD is a chronic, episodic illness of the mood 
with usually a full recovery between episodes. Patients have to suffer from at least one 
manic episode to be diagnosed with bipolar disorder, with or without having had a 
depressed episode. In this aspect bipolar disorder differs from unipolar depression since 
in that disorder patients do not experience episodes of elevated mood but only episodes 
of a depressed mood. According to the DSM IV SCZ is a mixture of positive and negative 
psychiatric signs and symptoms. Positive symptoms reflect an excess or distortion of 
normal perceptive function such as delusions and hallucinations. Negative symptoms 
reflect a diminution or loss of normal function such as affective flattening and lack of 
initiative.
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In a previous study on a large sample of outpatients with BD we found the prevalence of 
autoimmune thyroiditis (as evidenced by a higher prevalence of antithyroid antibodies) 
and of thyroid failure (as evidenced by a raised serum TSH) higher than in the general 
population and disease controls. Autoimmune thyroiditis is a major cause of thyroid failure, 
and is marked by the presence of antibodies to the thyroid, in particular TPO-antibodies. 
Mild forms of autoimmune thyroiditis with a clinically euthyroid state are not uncommon: 
Antithyroid antibodies occur in 5–15% of the normal population, predominantly in women 
and older people. 
Since autoimmune thyroiditis was not associated with lithium exposure in the BD cases 
and since there were also no differences in the prevalence rates of autoimmune thyroiditis 
between euthymic bipolar patients and bipolar patients in a manic or depressive episode, 
we considered thyroid autoimmunity more likely to be a “trait marker” of BD than a 
“state marker” of an episode and these findings raised the question whether thyroid 
autoimmunity is related to the disease itself or to the vulnerability for BD. For that reason 
we studied co-twins of a bipolar index case and offspring of a bipolar parent for the 
presence of autoimmune thyroiditis. Both studies revealed that co-twins and offspring 
were not only vulnerable to develop mood disorders but also more vulnerable to develop 
autoimmune thyroiditis independently from the mood disorders. These findings refute 
the concept that mood disorders and thyroid autoimmunity are cause or consequence 
of each other, but that they are more likely part of a larger neuro-immuno-endocrine 
syndrome and are rooted in the same, shared immune abnormality. 
In later studies BD patients not only appeared to have a higher prevalence of TPO-
antibodies, but also a higher prevalence of antibodies to glutamic acid decarboxylase-65 
(GAD-65). Antibodies to GAD-65 are frequently present in Type 1 diabetes (T1D), another 
typical organ specific endocrine autoimmune disease. In T1D an autoimmune process 
destroys the insulin producing β cells of the islets of Langerhans in the pancreas. Because 
of this β cell destruction, the production of insulin diminishes and finally comes to an 
end. This will lead to well-known hyperglycemia of T1D.  Apparently also T1D is part of the 
extended neuro-immuno-endocrine syndrome.
This thesis deals with the immune aspects of bipolar disorder, schizophrenia, autoimmune 
thyroid disease (AITD) and T1D and also tries to find the shared immune abnormality 
underlying these disorders in the extended neuro-immuno-endocrine syndrome.
Chapter 1 firstly gives an introduction to the immune system and some of its important 
cells. In particular the cells of the mononuclear phagocyte system are addressed, how 
these cells traffic and behave under steady state conditions, how they are involved in 
the inflammatory immune response under ‘danger’ conditions, and which are the most 
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important adhesion molecules, cytokines and chemokines the cells produce in these 
processes. 
Thereafter the various aberrancies in monocyte, macrophage, DC, T cell and endocrine 
cell functions in the three animal models of spontaneous endocrine autoimmunity are 
summarized. Collectively these aberrancies are highly suggestive for a basic underlying 
inborn defect in growth and development of myeloid, lymphoid, epithelial and 
mesenchymal cell precursors. This defect is characterized by a reduced proliferation and a 
reduced apoptosis resistance, but an accelerated and deviant maturation. 
For myeloid cells these growth and developmental defects result in a mature (partly 
inflammatory) set point of circulating monocytes with an enhanced adhesiveness to ECM 
and to monocyte-derived macrophages and DC with an intrinsic high inflammatory set 
point skewing T cell responses away from tolerogenic to effector immunogenic responses.
For lymphoid cells the growth and developmental defects result in imbalances between 
the various T cell tolerogenic and autoimmunization differentiation routes, again leading 
to a skewing towards effector immunogenic T cell responses.
The experimental questions (Chapter 2) concentrate 
a) On the pro-inflammatory aspects of circulating monocytes in BD, SCZ, autoimmune 
thyroid disease (AITD) and T1D, and
b) On the presence of effector and suppressor T cell populations in BD, SCZ, AITD and T1D
to establish a putative pro-inflammatory state of the monocyte and T cell system in these 
disorders as well as trying to find the shared vulnerability factor between these disorders.
The questions addressed are:
Q1. Do patients with schizophrenia and AITD have a pro-inflammatory monocyte 
gene expression signature and is there a difference or overlap with the previously 
found monocyte pro-inflammatory gene expression signature in patients with 
bipolar disorder?
In a previous study Padmos et al found a pro-inflammatory gene expression signature in 
the monocytes of patients with bipolar disorder and in the monocytes of LADA patients. 
The gene expression fingerprint consisted of 2 partly overlapping gene clusters, a PDE4B 
associated cluster (consisting of 12 core pro-inflammatory cytokine/compound genes), a 
“FABP5 associated” cluster (3 core genes) and a set of 9 overlapping chemotaxis, adhesion 
and cell assembly genes (the “overlapping cluster”) correlating to both PDE4B and FABP5. 
In Chapter 3 we extended these studies to patients with recent-onset schizophrenia and 
aimed at detecting a specific inflammatory monocyte gene expression signature in SCZ 
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and compare such signature with the inflammatory monocyte gene signature in BD and 
relate it to the use of medication. We first searched for “schizophrenia-related monocyte 
genes” via Affymetrix whole genome analysis on pools of monocytes of patients with 
schizophrenia and thereafter carried out a quantitative-PCR case-control gene expression 
study on monocytes of 27 SCZ patients and compared to outcomes collected in 56 BD 
patients (most patients were drug-treated). For Q-PCR we used 9 “SCZ specific genes” 
(found in Affymetrix whole genome analysis) and the 24 genes described above. 
Monocytes of recent onset SCZ patients had (similar to those of BD patients) a high 
inflammatory set point. This set point was composed of three sub-sets of strongly 
correlating genes characterized by different sets of transcription and MAPK regulating 
factors: 
1) Sub-set 1A, characterized by ATF3 and DUSP2. This sub-set was previously identified 
as the PDE4B associated cluster. It was upregulated in the monocytes of 67 % of SCZ 
patients and 34 % of BD patients.
2) Sub-set 1B, characterized by EGR3 and MXD1. This sub-set was de novo identified in 
Affymetrix analysis of the pooled monocytes of SCZ. This sub-set was upregulated in 
41% of SCZ patients and only 34% of BD patients.
3) Sub-set 2, characterized by PTPN7 and NAB2. This sub-set was previously identified as 
the “overlapping cluster” Sub-set 2 was upregulated in the monocytes of 62% of BD, but 
downregulated in the monocytes of 48% of SCZ patients.
With regard to mood state: Only during depression (and not in the manic phase) there was 
a significant upregulation of the gene expression signature and only of sub-set 2 genes.
With regard to medication: Both lithium and anti-psychotics downregulated many of the 
signature genes, but only one of the genes significantly, i.e. PDE4B, a cluster 1A gene. 
Our approach shows that monocytes of SCZ and BD patients overlap in inflammatory 
gene expression (regarding sub-sets 1), but also differ in inflammatory gene expression 
(regarding sub-set 2). The Q-PCR assay system to detect the fingerprints was shown to 
be robust and the different fingerprint patterns detected with this system will open new 
avenues for the possibility for a nosological distinction between schizophrenia and bipolar 
disorder based on a biochemical blood test.
In Chapter 6 we studied whether the monocyte inflammatory fingerprint as found by 
Padmos et al in BD and LADA is also present in autoimmune thyroid disease (AITD). We 
again first searched for “AITD-related monocyte genes” in Affymetrix analysis on pools of 
monocytes of patients with AITD and thereafter carried out a Q-PCR analysis for 28 genes 
in monocytes of 35 AITD patients and 38 healthy controls (HC). The tested 28 genes were 
the 24 genes previously found abnormally expressed in monocytes of BD and LADA plus 
4 “extra” genes found in the Affymetrix whole genome analysis of monocytes of AITD 
patients.
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Monocytes of a considerable proportion of AITD patients showed an abnormal 
inflammatory fingerprint: 
a) In 57% of the patients characterized by the expression of subset 2 genes (the set of 
genes involved in chemotaxis, adhesion and cell motility/assembly (i.e. by CCL7, EMP-
1, CDC42, STX1A, PTPN7, MAPK6, DHRS3), but
b) In only 34% of the patients characterized by some of the cluster 1A genes (the PDE4B 
associated inflammatory compound genes, i.e. by PDE4B, IL-6, ATF3 and NAB2). 
c) Of the 4 in Affymetrix identified genes only FCAR was found to be significantly over 
expressed in Q-PCR in the 35 AITD patients. FCAR expression correlated as strongly to 
the expression of sub-set 2 as sub-set 1A genes.
We concluded in the discussion section that the monocytes of 50-60% of AITD patients 
show an inflammatory gene expression fingerprint with an over representation of cluster 
2 genes similar to that previously described by us in the monocytes of 60% of childhood 
onset T1D cases and 67% of LADA patients, the latter in addition characterized by a strong 
overexpression of sub-set 1A genes.
Q2. Do monozygotic discordant co-twins of an index twin with juvenile-onset T1D 
have the same pro-inflammatory monocyte gene expression signature?
Padmos et al previously described that monocytes of patients with juvenile onset T1D 
have monocytes with a comparable gene expression fingerprint as LADA patients, but 
importantly lacking cluster 1 (which contains most of the pro-inflammatory cytokines and 
compounds) while cluster 2 (containing predominantly adhesion and motility factors and 
chemokines, like CCL2 and CCL7) was present in 60%.
In Chapter 8 we investigated the presence of the pro-inflammatory mRNA gene expression 
signature in the monocytes in monozygotic co-twins of index twins with a juvenile onset 
T1D, who were discordant for T1D for already for many years. We hypothesized that 
monocyte activation in monozygotic (MZ) twin pairs discordant for childhood-onset 
type 1 diabetes could reflect distinct stages of the disease process including diabetes 
susceptibility (differences between twins, both diabetic and non-diabetic, and controls) 
and/or disease progression (differences between diabetic and non-diabetic twins). 
We therefore studied patterns of inflammatory gene expression in peripheral blood 
monocytes of MZ twin pairs (n=10 pairs) discordant for childhood-onset type 1 diabetes, 
normal control twin pairs (n=10 pairs) and healthy control subjects (n=51) using 
quantitative-PCR (Q-PCR). We tested the 24 genes previously observed by whole genome 
analyses and verified by Q-PCR in LADA and childhood onset T1D and performed a 
hierarchical cluster analysis. 
Of the 24 genes abnormally expressed in childhood-onset type 1 diabetes, we re-
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validated abnormal expression in 16 of them in diabetic twins, including distinct sets of 
downregulated sub-set 1A genes (p<0.03) and up regulated sub-set 2 genes (p<0.02). Of 
these 16 genes: 13 were abnormally expressed in non-diabetic twins, implicating these 
genes in diabetes susceptibility (p<0.044 for all). Cluster analysis of monocyte gene-
expression in non-diabetic twins identified that the two distinct sub-sets 1A and 2 were 
mutually exclusive clusters (i.e. there was a strong correlation between the upregulation 
of sub-set 2 genes and the downregulation of sub-set 1A genes), while diabetic twins 
had a network of positively correlated genes (i.e. sub-set 2 genes were up regulated and 
although sub-set 1A genes were not significantly up regulated the mutual exclusiveness 
was lost). 
We concluded that patients with childhood-onset T1D show abnormal monocyte gene-
expression levels with an altered gene-expression network due to gene-environment 
interaction. Importantly, perturbed gene-expression clusters were also detected in 
non-diabetic twins, implicating monocyte abnormalities in susceptibility to diabetes, 
particularly sub-set 2 genes.  
Q3. Do patients with bipolar disorder and schizophrenia have aberrancies in their 
Th1, Th2, Th17 and natural T regulator cell compartment?
Since there is evidence for the involvement of the T cell system in the pathogenesis of 
schizophrenia and bipolar disorder, we investigated the frequency of CD3+CD25+T cells, 
IFN-γ+Th1, IL-4+Th2, IL-17A+Th17 CD4+ lymphocytes and CD4+CD25highFoxP3+ natural 
regulatory T cells in the circulation of patients with schizophrenia and bipolar disorder 
using detailed FACS analysis. 
We related T cell outcomes to the pro-inflammatory state of the monocytes in the same 
patients, i.e. to the presence of the pro-inflammatory mRNA gene expression signature 
described above.
None of our SCZ patients was positive for thyroid autoimmune disease, i.e. TPO-antibodies. 
The prevalence of TPO-antibodies in our BD cohort was however 29%, thus about 3X 
higher than the general population. Thus only in the BD patients we were able to correlate 
the presence of TPO-antibodies to the T cell (and monocyte pro-inflammatory) state. 
We detected for schizophrenia (Chapter 5): 
(a) Higher percentages of pro-inflammatory-prone monocytes, activated CD3+CD25+ T 
cells and pro-inflammatory Th17 cells in patients, but also higher percentages of anti-
inflammatory CD4+CD25highFoxP3+ regulatory T cells and IL-4+ lymphocytes; 
(b) That this activated T-cell set point was reflected in significantly raised serum levels of 
sCD25; 
(c) That the upregulation of IL-4+-containing lymphocytes was predominantly found in 
patients characterized by a monocyte pro-inflammatory set point; and 
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(d) That regulatory T-cell and Th17-cell numbers were higher in patients irrespective of 
the pro-inflammatory state of the monocytes. 
We detected for bipolar disorder (Chapter 7):
a) That percentages of anti-inflammatory CD4+CD25highFoxP3+ regulatory T cells were 
higher, the latter only in BD patients < 40 years of age. Percentages of Th1, Th2 and 
Th17 cells were normal.
b) The monocyte pro-inflammatory state and the raised percentages of 
CD4+CD25highFoxP3+ regulatory T cells occurred independently from each other.
c) In BD patients positive for thyroid autoimmune disease a significantly reduced 
percentage of CD4+CD25highFoxP3+ regulatory T cells was found as compared to BD 
patients without AITD, as well as a near significant rise in the percentages of Th1 cells. 
d) Curiously in the BD patients positive for TPO-antibodies the pro-inflammatory 
monocyte signature was different from those without TPO-antibodies: There was a 
clear and significant decrease of sub-set 1 expression.
We overall conclude in the discussion section that our data do not support the concept 
that the T-cell system is in a simple pro-inflammatory state in recent-onset SCZ and 
euthymic BD patients, but do show that the monocyte and T-cell networks are activated 
independently from each other and that the T cell networks involve both pro- and 
anti-inflammatory forces. Our data suggest T regulatory cell control over an activated 
inflammatory system in SCZ and BD patients. 
In BD patients with AITD there was a lack of anti-inflammatory regulatory T cell forces, 
suggesting that these cells are important to prevent AITD from developing in BD patients.
Q4. Is an altered inflammatory set point of the monocytes and T cells in patients 
with bipolar disorder, schizophrenia and AITD reflected in higher serum levels of 
pro-inflammatory and T cell cytokines/chemokines and how are these levels related 
in patients with chronic forms of schizophrenia to the presence of the metabolic 
syndrome, a common co-morbidity of chronic schizophrenia?
Levels of monocyte and T cell cytokines were investigated in the serum of the patients 
with AITD, the group of patients with euthymic bipolar disorder (used for T cell analysis) 
and the patients with recent-onset acute schizophrenia using a cytometric bead array 
(CBA). Serum levels of the cytokines were correlated with the monocyte gene expression 
signatures and the T cell state in the same patients. Various relevant T-cell cytokines/
shedding products, e.g. sCD25, IFN-γ, IL-17A and IL-4 were measured in serum by the 
multiplex CBA. In addition the monocyte/macrophage cvtokines CCL2, IL-1β, IL-6, TNF-α, 
PTX3 and IL-10 were measured in the CBA.
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We found that: 
a) In AITD cases only the pro-inflammatory monocyte cytokine CCL2 was raised. In 
previous studies we found the T cell shedding product sCD25 downregulated in cases 
at risk to develop AITD.
b) In euthymic bipolar disorder cases the pro-inflammatory monocyte cytokines CCL2 
and PTX3 and the T cell shedding product sCD25 were raised.
c) In recent onset schizophrenia none of the pro-inflammatory monocyte cytokines 
were raised, but the T cell shedding product sCD25 was raised.
For chronic schizophrenia pro-inflammatory monocyte cytokines have been described 
in literature as raised in serum. The serum level of the chemokine CCL2 had however 
not been studied in such patients, despite a reported polymorphism of its gene being 
over represented in psychiatric patients. CCL2 has also been implicated in diabetes (DM), 
obesity (OS) and the metabolic syndrome (MS), co-morbidities of chronic schizophrenia. 
We therefore investigated (Chapter 4) the serum CCL2 level in chronic schizophrenic 
patients (145 patients and 105 healthy controls, HC) and related the level with the use 
of anti-psychotics, with the presence of DM, OB and MS and with the level of typical 
monocyte pro-inflammatory cytokines and sCD25. 
We found: 
a) That the serum level of CCL2 was increased in patients as compared to HC 
b) That CCL2 levels were not related to the use of anti-psychotics, the presence of 
diabetes or obesity, but were dependent on the presence of chronic schizophrenia 
and to the presence of the metabolic syndrome, and within the syndrome primarily to 
HDL-cholesterol. 
c) That the levels of IL-1β, IL-6, TNF-α and sCD25 were also raised in patient serum. The 
levels of CCL2 correlated with these pro-inflammatory cytokine levels, but not with the 
sCD25 level. 
We overall conclude for the cytokines: 
1) That serum sCD25 is invariably raised in both recent onset and chronic psychiatric 
disease in fact reflecting the raised numbers of circulating CD3+CD25+ T cells, but in 
particular of anti-inflammatory CD4+CD25highFoxP3+ regulatory T cells.
2) That pro-inflammatory monocyte cytokines are not raised in recent onset cases of 
psychiatric disease (despite clear signs of pro-inflammatory monocyte activation at the 
gene level), but are raised in chronic cases of psychiatric disease and that levels of these 
cytokines are in these chronic cases co-determined by the presence of the metabolic 
syndrome. We hypothesize that intrinsically inflammation prone macrophages (due to 
the psychiatric disease) when accumulated in the vasculature or in the adipose tissue 
in these chronic cases are the source of these raised serum cytokines in these chronic 
SCZ cases. 
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3) That serum CCL2 is raised in endocrine autoimmune disease, but that sCD25 tends to 
be reduced, the latter reflecting a T cell tolerance defect.
With regard to the actual protein levels in serum of the inflammatory compounds and 
cytokines of the transcriptomic monocyte fingerprint and of the T cell activation state, 
we found the data from serum protein assays less robust and inconsistent, apart from 
the sCD25, which was a robust reflection of the CD25 expression on T cells, most notably 
in regard to the CD25 expression on T regulator cells. For the other pro-inflammatory 
monocyte and T cell cytokines, protein levels did not reach the same high levels as the 
genes in cells or the products in cells; e.g. in our studies on BD patients the approximately 
six fold raised expression of IL1B at the monocyte mRNA level was only reflected in a 
twofold raised IL-1β protein level in the serum of bipolar patients, while CCL2, CCL7 and IL-6 
serum levels were not significantly higher. Clearly a regulation at the protein transcription 
level is operating in the pro-inflammatory ‘angry’ monocytes of psychiatric patients to 
ensure a close-to-normal (but still somewhat raised) protein production, and the question 
rises as to what is the role of epigenetic imprinting for these ‘angry’ monocytes and which 
environmental or endogenous conditions will create a failure of these angry monocytes 
to keep control over their aberrant gene transcript expressions, avoiding a high actual 
production of the pro-inflammatory compounds. 
Our collective data suggest that an overexpression of sub-set 2 monocyte genes and 
a high T effector cell/T regulator cell ratio are mechanisms involved in (the proneness) 
for endocrine autoimmunity. In contrast: A raised number of T regulator cells and a 
downregulation of sub-set 1 monocyte inflammatory genes might protect from endocrine 
autoimmunity to develop.
For BD the data suggest that an upregulation of sub-set 1A monocyte genes, but in 
particular also of subset 2 genes, is involved in the activation of the MPS and microglia 
perturbing brain development and function in BD, while also products of T regulator cells 
may play a role in the elicitation of psychiatric symptoms.
For SCZ the data suggest that in particular an upregulation of sub-set 1B monocyte genes 
and products of both T effector and T regulator cells are involved in the activation of the 
MPS and microglia perturbing brain development and function in SCZ.
Figures 2 and 3 in the discussion section represent cartoons of these suggested immune 
mechanisms crucial for the development of endocrine autoimmunity and psychiatric 
disease. 
Table III of the discussion section finally addresses the question what the shared vulnerability 
factor might be of BD and AITD. The most likely shared vulnerability factor is formed 
according to this table by the monocyte cluster 2 gene overexpression in monocytes of 
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both BD and AITD patients. This would mean that the chemotactic, motility and adhesion 
behaviour of circulating monocytes might be a crucial factor for both diseases developing 
in the same patient and that the local higher adhesiveness to endothelial cells and extra-
cellular matrix proteins after infiltration of the monocytes to the thyroid or the brain and 
the consequent higher local inflammatory set point of local thyroid DC and microglia 
created by this adhesive interaction would constitute a general mechanism by which 
thyroid autoimmunity and “low grade inflammation” of the brain leading to BD would be 
linked. It would also mean that there are in fact two immune mechanisms that may lead 
to BD (see Figure 4 of the discussion section): 
a) One primarily based on a pro-inflammatory activation of peripheral mononuclear 
phagocytes, including monocytes. This activation would predominantly be induced 
by environmental factors and 
b) The other based on a (in part genetically-determined) stickiness of mononuclear 
phagocytes, including monocytes, to extracellular matrix components, which would 
render the cells in the tissues pro-inflammatory. The latter would be the one linked to 
thyroid autoimmunity.
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Abbreviations
Abs  Antibodies
AITCD  Activated immune T cell death
AITD  Autoimmune thyroid disease 
ANOVA  Analysis of variance
APC  Antigen presenting cells
APS  Autoimmune Polyendocrine Syndrome
ATF3  Activating transcription factor 3
BB-DP  Biobreeding diabetes prone
BB-DR  Biobreeding diabetes resistant
BCL2A1  BCL2- related protein A1
BD  Bipolar disorder
BDNF  Brain derived neurotrophic factor
BMI  Body mass index
CBA  Cytometric bead array
CCL2  Chemokine (C-C motif ) ligand 2
CCR2  Chemokine (C-C motif ) receptor
CD  Cluster of differentiation
CDC42  Cell division control protein 42
CI  Confidence interval
CMV  Cytomegalovirus
COX2  Cyclo-oxygenase 2
CSF  Cerebrospinal fluid
CTLA4  Cytotoxic T-lymphocyte antigen 4
CXCL  Chemokine (C-X-C) ligand
DC  Dendritic cells
DSM  Diagnostic and statistical manual of mental disorders
DUSP2  Dual specificity phosphatase 2
DZ  Dizygotic
EAE  Experimental allergic encephalitis
EAT  Experimental allergic thyroiditis
ECM  Extra cellular matrix
EGR3  Early growth response 3
EIF2S3  Eukaryotic translation initiation factor 2, subunit 3
ELISA  Enzyme-linked immunosorbent assay
EMP1  Epithelial membrane protein 1
EREG  High epiregulin gene
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FABP  Fatty acid binding protein
FACS  Fluorescence activated cell sorting
FcαR  Fc fragment of IgA receptor
FN  Fibronectin
FOXP3  Forkhead box P3
FSH  Follicle-stimulating hormone
GAD65   65 kDA glutamic acid decarboxylase
GD  Graves’ disease
GH  Growth hormone
GITR  Glucocorticoid-induced tumor necrosis factor receptor
GM-CSF  Granulocyte monocyte colony stimulating factor
GWAS  Genome wide association studies
HDL  High density lipoprotein
HLA  Human leukocyte antigen
HSV  Herpes simplex virus
HT  Hashimoto’s thyroiditis 
IA2  Insulinoma-associated protein 2
ICA 69  69 kDa islet cell antigen
ICAM  Intercellular adhesion molecule
ICD  International Statistical Classification of Diseases 
IDO  Indoleamine 2,3-dioxygenase
IFN  Interferon 
IGF  Insulin like growth fractor
IL  Interleukin
IRS  Inflammatory response system
LADA   Latent autoimmune diabetes of the adults
LDL  Low density lipoprotein
LFA-1  Lymphocyte function associated-antigen 1
LH  Luteinizing hormone
LPS  Lipopolysaccharide
LTA  Lipotichoic acid
MACS  Magnetic cell sorting system
MAFF  V-maf musculoaponeurotic fibrosarcoma oncogene family
MAPK  Mitogen-activated protein kinase
MDD  Major depressive disorder
MHC  Major histocompatibility complex
MLR  Mixed lymphocyte reactions
MPS  Mononuclear phagocyte system
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MXD  MAX dimerization protein
MZ  Monozygotic
NAB2  NGFI-A-binding 2
NAC  N-acetyl cysteine
NFκB   Nuclear factor kappa-light-chain-enhancer of activated B cells
NGF  Nerve growth factor
NK cell  Natural killer cell
NOD  Non obese diabetic
NOS  Not otherwise specified
OS  Obese strain
PBMC  Peripheral blood mononuclear cell
PCR  Polymerase chain reaction
PDE4B  Phosphodiesterase 4B
PET  Positron emission topography
PTGS2  Prostaglandin-endoperoxide synthase 2
PTPN7  Protein tyrosine phosphatase, non-receptor type 7
PTPN22  Protein tyrosine phosphatase, non-receptor type 22
PTX  Pentraxin
ROS  Reactive oxygen species
RTE  Recent thymic emigrants
SCID  Structured clinical interview for DSM-IV axis I
SCZ  Schizophrenia
SDR  Short chain dehydrogenase/reductase 1
SFBN  Stanley foundation bipolar network
sIL-2R  soluble IL-2 receptor
STX  Syntaxin
T1D  Type 1 diabetes
T2D  Type 2 diabetes
Tg  Thyroglobulin
TGF  Tumor growth factor
THBD  Thrombomodulin
THBS  Thrombospondin
Th  T helper cells
TLR  Toll like receptors
TNF  Tumor necrosis factor
TNFAIP3  Tumor necrosis factor, alpha-induced protein 3
TPO  Thyroid peroxidase
Treg  regulatory T cells
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TSH  Thyroid stimulating hormone
TSHR  Thyroid stimulating hormone receptor
VNTR  Variable number tandem repeats
YMRS  Young mania rating scale
ZFAT  Zinc finger gene in autoimmune thyroid disease
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Depressie of psychose door een ontstoken brein?
Ontsteking is nuttig. Het afweersysteem komt in actie tegen een probleem in het 
lijf en ruimt het op. Helaas is het in het echt niet zo eenvoudig. We weten al lang dat 
ons immuunsysteem soms ook zelf problemen veroorzaakt. Denk aan jeugd-diabetes, 
schildklieraandoeningen en andere auto-immuunziekten. In deze gevallen is de 
ontstekingsreactie volkomen onnuttig en schadelijk voor het lichaam. Toch wordt bij 
psychische problemen nog niet zo snel aan ontsteking gedacht.
 
Misschien komt daar nu verandering in. In de nog altijd voortdurende zoektocht naar 
oorzaken van psychiatrische ziektebeelden zijn wij nu iets interessants en belangwekkends 
op het spoor: problemen in het immuunsysteem als oorzaak van ernstige psychiatrie zoals 
schizofrenie, manisch-depressiviteit (bipolaire stoornis) en ernstige depressie.
Het idee van een mogelijke relatie tussen ontsteking en hersenaandoeningen is niet 
helemaal nieuw. Er wordt al een tijdje naar gezocht: 
Een opmerkelijke link werd gevonden in het feit dat psychiatrische aandoeningen vaak 
samengaan met afweerstoornissen. Schizofrenen hebben in verhoogde mate last van hart- 
en vaatproblemen die door een ontsteking worden veroorzaakt. Ook auto-immuunziektes 
zoals diabetes en de ziekte van Crohn komen vaker voor bij mensen met depressie. En 
bipolairen hebben drie keer zo vaak een chronische auto-immuunschildklierontsteking 
als gezonde mensen.
Gevalletje kip of ei werpen sceptici tegen. Van de gevolgen van een chronische ziekte kun 
je behoorlijk depressief raken. Bovendien zijn medicijnen tegen schizofrenie slecht voor 
het hart. En lithium, dat bij bipolaire stoornis geslikt wordt, werkt ook op de schildklier. 
Dit klopt maar voor een deel. Toch hebben wij in dit proefschrift bewijs gevonden dat 
psychiatrische aandoeningen onderdeel zijn van chronische ontstekingsziekten. De 
chronische ontstekingsziekten kwamen namelijk ook meer voor bij niet-psychiatrische 
familieleden of wanneer er geen of andere medicijnen geslikt werden. 
Hoe kan het immuunsysteem dan het functioneren van de hersenen verstoren? 
Dit proefschrift beschrijft dat. De witte bloedcellen regelen onze afweer. We hebben 
er verschillende van, waarvan voor dit verhaal de monocyten het belangrijkst zijn. 
Monocyten komen via de bloedbaan in alle weefsels terecht. Daar specialiseren ze zich tot 
macrofagen. En macrofagen zijn de stofzuigers van het afweersysteem. Zij zuigen storende 
elementen op en vernietigen ze. Ze hebben echter nog een belangrijke rol: zorgen dat het 
immuunsysteem niet op hol slaat en de eigen lichaamscellen gaat aanvallen. Ook in het 
brein zitten deze macrofagen en daar heten ze microglia. Naast het opruimen van indringers 
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zorgen deze microglia ook voor het goed functioneren van de neuronen (zenuwcellen). 
Ze helpen onder andere bij het vormen van nieuwe synapsen (verbindingen) en nieuwe 
neuronen. Zo spelen ze ook een rol bij de vorming van de belangrijke neurotransmitter 
serotonine. Het is dus niet zo gek dat een afwijking in deze microglia een verstoring van 
de hersenen kan veroorzaken (RC Drexhage et al, Expert Reviews Neurotherapy 10(1) 2010).   
Naast de microglia zijn de voorlopers, de cellen van het immuunsysteem in het bloed, 
de monocyten, dus heel belangrijk en veel gemakkelijker te bestuderen, omdat een 
beetje bloed snel en veilig kan worden afgenomen. In de witte bloedcellen begint het 
probleem en mogelijk kunnen zij gebruikt worden bij het diagnosticeren en hopelijk ook 
voorkomen van ziekte. Naar deze cellen hebben wij voor dit proefschrift vooral onderzoek 
gedaan en wij hebben gevonden dat bij patiënten met schizofrenie en met bipolaire 
stoornis (manisch-depressiviteit) veranderingen te zien zijn in het bloed, onder andere in 
de monocyten. 
Bij deze patiënten zijn de monocyten anders dan bij gezonde mensen. Dit is heel 
interessant, omdat deze cellen daardoor gebruikt kunnen worden in de diagnostiek. De 
monocyten hebben een zogenaamde genetische handtekening. En deze blijkt bij mensen 
met schizofrenie net een beetje anders dan bij mensen met bipolaire stoornis. Zo kan je 
dus een onderscheid maken dat gebaseerd is op een biologische test in plaats van alleen 
af te gaan op de symptomen. De DSM-4, die nu nog wordt gebruikt om patiënten in te 
delen in de psychiatrie, is nog gebaseerd op symptomen. Hopelijk kan in de toekomst de 
biologische etiologie meer een rol gaan spelen (artikel hierover in International Journal of 
neuropsychopharmacology juni 2010).
Daarnaast zijn in het bloed zowel de pro-ontstekingslymfocyten als de anti-
ontstekingslymfocyten (andere soorten van witte bloedcellen) verhoogd. ‘Het eerste 
betekent dat er al sprake is van ontsteking. Het tweede betekent dat er ook sprake is van 
regulatie van het immuunsysteem. En dit is voor ons belangrijk. Bij deze mensen is het 
immuunsysteem als het ware anders afgesteld dan bij een gezond persoon. Er is sprake 
van een ander setpoint.’ (artikel hierover in Expert Reviews Neurotherapy 10(1), 2010). 
Zo’n ander setpoint van het afweersysteem is al eerder gezien. Namelijk bij kinderen van 
ouders met een bipolaire stoornis. In 2007 onderzochten wij samen met Manon Hillegers 
en Willem Nolen 140 van deze kinderen en wij doen nu nog verder onderzoek aan 
deze kinderen. Zij hebben een verhoogde kans op bipolaire stoornis. En ook zij bleken 
afwijkende cellen in hun bloed te hebben, al voordat ze überhaupt een ziektebeeld 
ontwikkelden. In een aantal gevallen veroorzaakten deze cellen uiteindelijk auto-immuun 
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schildklierproblemen, in een aantal gevallen stemmingsstoornissen, soms beide en soms 
helemaal niks (European Neuropsychopharmacology juni 2007).
Dit onderzoek is van groot belang. Hierdoor weten we dat het afwijkende immuunsysteem 
zeer waarschijnlijk oorzaak is van de psychische problemen en niet andersom. Daarnaast 
kan bij deze kinderen onderzocht worden of preventief ingrijpen werkt. We kunnen het 
systeem bij hen als het ware weer terug zetten. Dat kan hopelijk met sterke anti-oxidanten 
zoals n-acetyl cysteïne. De verwachting/hoop is dat er dan geen klachten zullen ontstaan.
Belangrijk ondersteunend voor dit werk in het proefschrift is dat andere onderzoekers 
onlangs ook een direct verband hebben gevonden tussen een ontspoord immuunsysteem 
en een afwijking in de hersenen dat leidde tot een veranderd ziekelijk gedrag. 
Een onderzoeksteam uit Utah ontdekte dat muizen met een bepaald gendefect zo erg 
bezig waren met het verwijderen van lichaamshaar dat ze kale plekken en diepe wonden 
bij zichzelf veroorzaakten. Dit gedrag is vergelijkbaar met een vorm van dwangneurose 
(obsessief-compulsieve stoornis) bij de mens, namelijk trichotillomanie, het uittrekken 
van eigen haar. Bij nader onderzoek bleek dit gendefect een verandering te geven in de 
vorming van monocyten, de voorlopers van de microglia in de hersenen. Deze muizen 
bleken dan ook afwijkingen te hebben in hun microglia. 
Het opvallendste deel van dit onderzoek is dat de muizen vervolgens een 
beenmergtransplantatie kregen. Daardoor maakten ze weer gezonde bloedcellen 
aan, de microglia werden weer normaal en wat bleek: binnen vier maanden stopte het 
dwangmatige gedrag en huid en haar herstelden (Cell, mei 2010). 
Waarom is deze ontdekking nou zo belangrijk? Wel, dit is de eerste keer dat er een direct 
verband is gelegd tussen microglia en gedrag. En daarbij door in te grijpen in de microglia 
was het gedrag bij een muis te veranderen. Nu willen we natuurlijk weten of dat ook bij 
mensen lukt. 
Overigens is het niet zo dat iedere psychiatrische aandoening dus altijd door een soort 
chronische ontsteking wordt veroorzaakt. Onderzoek in dit proefschrift suggereert de 
kans op vijftig tot zestig procent. Dit betekent wel dat veel psychiatrische patiënten 
nu een niet-optimale behandeling krijgen. Als ons afweersysteem de veroorzaker 
is, hebben psychiatrische middelen en psychoanalyses maar een beperkte werking. 
Ontstekingsremmende behandelingen zouden dan een goede aanvulling zijn.
Om terug te komen op de chronische ontstekingziekten die vaak voorkomen samen met 
stemmingsstoornissen, in dit proefschrift is ook onderzoek gedaan naar het setpoint van 
de monocyten en de lymfocyten bij jeugd-diabetes en schildklieraandoeningen. Dit gaf 
ons de mogelijkheid om overeenkomsten en verschillen te bestuderen met de setpoints bij 
psychiatrische ziekten en om er achter te komen waarom de aandoeningen zo frequent bij 
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elkaar voorkomen. Dit proefschrift beschrijft experimenten die aantonen dat de setpoints 
bij jeugd-diabetes en autoimmuun schildklierziekten vergelijkbaar en overlappend zijn 
met de setpoints gevonden bij stemmingsstoornissen, maar niet identiek zijn. Juist het 
overlappende gedeelte en de afwijkingen die daarbij horen geven ons meer inzicht in het 
ontstaan van deze autoimmuunziekten. 
Om nu voor een grote groep psychiatrische patiënten precies op een rijtje te krijgen 
wat er gebeurt in het immuunsysteem, hoe de overlap is met auto-immuun ziekten en 
andere chronische ontstekingsziekten en of er immuuntherapie mogelijk is, loopt er een 
onderzoek bij 400-600 patiënten in Europa gefinancierd door de EU: MoodInflame. 
Wij willen samen met de andere Europese onderzoekers verder onderbouwen dat 
patiënten met een ernstige stemmingsstoornis (dat zijn bijvoorbeeld de bipolaire stoornis, 
ernstige depressie en postpartum psychose) een afwijking hebben in hun afweersysteem 
en daardoor een lichte chronische ontsteking in de hersenen en ook chronische 
ontstekingsprocessen elders in het lichaam. De bedoeling is om van deze patiënten een 
uitgebreid profiel te maken met de genetische handtekening van de monocyten, de 
vorming van andere witte bloedcellen en van de cytokinen. Hiervoor moeten verdere 
bloedtests en hersenscans ontwikkeld worden. Daarnaast worden er dierproeven gedaan 
en ook zullen er clinical trials gedaan worden, waarbij patiënten naast hun gewone 
medicatie behandeld worden met ontstekingsremmers (Cox-2-remmers). De verwachting 
is dat zij sneller van hun klachten af zijn dan zonder (http://moodinflame.eu). De planning 
is om vóór 2013 definitieve resultaten te hebben. Interessant detail: Antidepressiva en 
antipsychotica werken sowieso al ontstekingsremmend. 
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Dit proefschrift had ik nooit kunnen maken zonder de hulp van velen.
Graag noem ik een paar mensen specifiek die dit mede mogelijk hebben gemaakt.
Beste prof. dr. Rob Benner,
Ik ben binnengekomen op de afdeling immunologie als keuze-onderzoekstudent. 
Als “ dochter-van” ben ik altijd welkom geweest op uw afdeling. Toen ik graag wilde 
blijven, bleken daar ook mogelijkheden voor te zijn. Ik wil u van harte danken voor deze 
mogelijkheid en uw ondersteuning, ik heb het erg naar mijn zin gehad op de afdeling.
Beste Herbert,
Als mijn officiele promoter stond jouw deur altijd voor mij open. De laatste tijd was ik daar 
ook steeds meer te vinden. De gesprekken gingen niet altijd over het onderzoek, maar 
waren altijd leuk en leerzaam. Bedankt dat ik deze unieke kans heb gekregen om zo mijn 
promotie-onderzoek uit te kunnen voeren.
Beste Marjan,
Ook voor jou was dit een unieke situatie. Ik heb heel veel aan alle gesprekken gehad tijdens 
mijn project. Altijd hield jij de tijdlijn scherp in de gaten en hierdoor had ik een strakke 
planning en kon ik het onderzoek goed combineren met de kliniek. Jouw deur stond altijd 
open, of het over het onderzoek ging of iets anders. Bedankt voor al je adviezen.
Beste Wendy , Sandra, Nikki en Simone, bedankt voor de hulp met mijn proefschrift, zonder 
jullie had ik nooit zo’n mooi boekje gehad!
Beste Harm, Annemarie, Angelique en Thomas, jullie ben ik heel veel dank verschuldigd, 
zonder jullie zou er zeker geen proefschrift zijn. Als team hebben jullie ontzettend veel 
werk verricht.
Ook hebben jullie mij de basisprincipes van het labwerk bijgebracht. Het samenwerken 
was altijd ontzettend prettig. De experimenten die ik met Harm en Thomas heb gedaan 
waren de leukste dagen op het lab!
Thomas bedankt dat je mijn paranimf wil zijn, met jou naast me zie ik mijn verdediging 
wel zitten!
Beste Wouter, Zana en Karin W,
Wij waren zonder twijfel de leukste AIO-kamer van de hele toren! Er werd niet altijd even 
hard gewerkt, maar het was altijd reuze-gezellig. Bedankt ook voor jullie hulp in de laatste 
maanden met het afronden van mijn proefschrift!
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Ook alle andere AIO’s  en collega’s wil ik graag bedanken voor de leuke tijd op het lab, 
tijdens labdagen en AIO-weekenden. Het was een ontzettend leuke en leerzame periode. 
Het karten als afscheidsfeestje was erg leuk (wat minder leerzaam).
Beste Dr. Bakker, Dr. Berghout en Dr. Van de Dorpel en overige collega’s uit het Maasstad 
Ziekenhuis. Mijn klinische carriere ben ik begonnen bij jullie. Ik heb het ontzettend 
naar mijn zin gehad en jullie hebben mij de klinische basis geleerd. Bedankt voor jullie 
professionele ondersteuning.
Beste collega’s van het Ikazia ziekenhuis. Ik ben er nog niet zo heel erg lang, maar werk al 
met veel plezier met jullie samen. Ik heb erg veel zin in de komende drie jaar! 
Beste Willem Nolen,
Erg bedankt voor uw (altijd snelle) commentaar op mijn manuscripten. Het was fijn om 
met u samen te werken. Ik stel het erg op prijs dat u in mijn commissie wil plaatsnemen. 
Beste Ralph Kupka, 
Na u veelvuldig geciteerd te hebben vind ik het erg bijzonder dat u in mijn commissie wilt 
plaatsnemen.
Dear Sabine Bahn and Steven Kushner, 
Thank you for the lively discussions during the various meetings on the biological psychiatry, 
it gave me new insights. Thank you for attending my defence as real  ‘Rotterdammers’.
Dear Olivia Dean, 
Thank you for coming all the way from down under for attending my defence. 
Beste Prof. Wiersinga, 
Bedankt dat u als autoriteit op het gebied van schildklierziekten in mijn commissie wilt 
plaatsnemen.
Beste Elisabeth van Rossum, 
Bedankt dat je in mijn commissie wil zitten, ik hoop dat we in de toekomst samen kunnen 
werken in de kliniek.
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Dear David Leslie and Huriya Beyan,
Thank you for the wonderful time in London in your lab and in the clinic. David, thank you 
for  attending my defence. Thank you for the pleasant and constructive cooperation in the 
twin study.
Beste Nico van Beveren, 
Bedankt voor de samenwerking aan de verschillende manuscripten. Erg bedankt dat ik 
materiaal van uw patiënten mocht gebruiken voor mijn studies.
Beste Dan Cohen, 
Mijn eerste artikel had ik niet kunnen schrijven zonder uw hulp. Ook uw verdere hulp en 
commentaar bij mijn andere artikelen vond ik erg waardevol. 
Beste Veerle en Karin B, 
Het was erg leuk samenwerken met jullie. Bedankt voor de introductie in de psychiatrie en 
dat ik altijd bij jullie terecht kon voor mijn psychiatrische vragen.
Beste Manon en Esther, 
Bedankt dat ik met jullie data aan de slag heb mogen gaan. Ik vind het een ontzettend 
mooi project. Veel succes met tijdstip 4! 
Dear collaborators of MoodInflame, 
I have good memories of the meetings and inspiring discussions in the last 3 years, I think 
it is an amazing project and I am looking forward to all the publications!
Ook wil ik de volgende mensen bedanken voor het meeschrijven, meedenken of het 
helpen met het verzamelen van de patiënten: Ronald Vonk, Nannette Schloot, Leonie van 
der Heul-Nieuwenhuijsen, Roel de Rijk en Remco Boerman.
Studiegroep geneeskunde 2001:
Lieve Nath, collega maar vooral vriendin (en mijn grote voorbeeld ;) ). Super dat je naast 
me wil staan tijdens mijn verdediging. We hebben er een paar jaar naartoe kunnen werken 
met veel werkoverleg in het DE cafe. Over een paar maanden ben jij aan de beurt!
Lieve Ka en Jen, bijna 10 jaar verder en nog steeds vriendinnen. We zijn allemaal wat 
anders gaan doen. De koffie tussen de colleges door hebben we inmiddels verruild voor 
borrels na het werk! 
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Lieve Nien, samen naar hockey, middelbare school, op de Meent wonen, tegelijkertijd 
afgestudeerd, aan promotie-onderzoek begonnen, samen gaan wonen, specialisatie 
begonnen. En we zijn nog steeds niet uitgepraat ;). Super dat je weer in de buurt komt 
wonen!
Lieve Suus, al bijna 30 jaar vriendinnen! We zijn samen opgegroeid en altijd beste 
vriendinnen gebleven. Het is uiteindelijk toch nog goed gekomen met de ‘roze heksjes’. 
Lieve Macha-meiden, we zijn 10 jaar geleden begonnen met pasta op dinsdag op een 
studentenkamertje, sindsdien is er veel veranderd (behalve mijn kookkunst…), maar zien 
we elkaar nog steeds. Van hip in de hooizolder tot paardrijden in de bergen tot op je 
slippers in de Pacha. Super dat we nog steeds zoveel leuke dingen doen!
Lieve Jan en Carla, Pieter en Janine, bedankt voor jullie interesse en voor de kritische 
vragen die mij weer aan het denken zetten. Het is gebleken dat het wel handig is om een 
dokter in de familie te hebben, vooral als ze de weg weet in het Sophia…
Lieve Lotte, wat ben ik blij dat het zo goed gaat!
Lieve Pap,
Wat was het leuk om samen te werken en wat heb ik enorm veel geleerd! Het was en is 
een unieke en waardevolle ervaring. Ook nu ik weer in de kliniek ben gaat het gewoon 
soepel weer verder. Wat mij betreft zijn we ook zeker nog niet klaar!
Lieve Mam, 
Bedankt voor al je gezelligheid en steun. Er is altijd tijd voor een bakkie en om even bij te 
kletsen en weer even bij te komen zodat ik weer verder kan. Fijn dat jullie zo dicht in de 
buurt wonen zodat we altijd even kunnen komen aanwaaien. 
Lieve Joost en Karien, Mark en Fleur, bedankt voor jullie interesse in jullie kleine zusje. 
Fleur: van de 5 naar de 10 en verder… Kleine verrassing: ik heb ons ingeschreven voor de 
marathon in New York voor 2012! En dan bedoel ik niet de winkelmarathon…  
Lieve Thijmen, Kathelijn, Jart en Eva, jullie krijgen een hele dikke knuffel van een trotse 
tante!
Lieve Thijs, zonder jou was mijn proefschrift misschien wel sneller afgeweest ;) Bedankt dat 
je me altijd stimuleert om het beste uit mezelf te halen. En nu lekker op vakantie!
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